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Abstract 
Dendritic cells (DC) are unique antigen presenting cells which playa 
major role in antigen presentation and initiation of the immune response 
by regulating B- and T- cell activation. Antigen targeting to DC receptors 
is an effective, safe and specific method for vaccine development. The 
mannose receptor (MR) is an endocytic receptor expressed by 
subpopulations of DC and antigen targeting through MR leads to 
enhanced antigen uptake and presentation to T -cells. This makes MR a 
favourite receptor for the development of vaccines against diseases that 
require T-cell immunity such as cancer and viral infections. This project 
sought to develop tools to target antigens through MR and investigate 
their ability to induce T-cells activation in vitro and in vivo. 
We have used three approaches to deliver antigen through MR; (i) MR-
specific mAbs: 503 and 6C3, have been chemically linked to the 
melanoma epitope TRP-2, (ii) MR-specific chimeric antibodies carrying 
several model antigens have been generated by using genetic 
engineering and (iii) Glycopolymers and the suitable antigens such as a 
shorter version of model antigen ovalbumin (OVA), with and without N-
glycosylation sites have been generated and characterised. 
Glycopolymer-OVA conjugates were prepared by chemical coupling but 
it requires further optimization. The binding efficiency of anti-MR 
antibodies has been assessed using ELISA and BIACORE and the 
glycopolymers have been tested for their interaction with MR. 
Immunisations were performed with anti-MR mAb-TRP2 conjugates 
which induced TRP-2 specific COS+ T-cells activation and improved 
humoral response. Due to limitations in this approach in terms of 
chemical coupling being an inefficient method and the potential 
involvement of Fc recetors (FcRs), chimeric Abs fused to model 
antigens and bearing mutated Fc were generated. These chimeric Abs, 
have been tested for their ability to induce T-cell activation in vitro and 
in vivo. But the progress has been hampered due to the labile nature of 
these reagents. 
In future, anti-MR chimeric Abs will be used to generate anti-MR single 
chain antibodies carrying OVA (ScFv-OVA) and the glycopolymer 
project will be taken up Dr. Manovani Giuseppe (School of Pharmacy, 
University of Nottingham). It will involve further optimization of chemical 
coupling of glycopolymers to a-glycosylated OVA-mini protein, and the 
in vitro Ag presentation assay to investigate whether glycopolymers 
mediated Ag targeting of APe enhance T-cells activation. These further 
studies would greatly benefit the understanding of the mechanisms 
associated with the elicitation of immune resposes as a result of Ag 
targeting through MR. Anti-MR reagents generated in this study along 
with appropriate adjuvant could be exploited to target malarial, 
cancerous and viral Ags for robust T-cell activation against these 
infectious diseases. On the other hand, the role of MR in homeostasis 
and allergy has been already established, and the anti-MR reagents 
generated in this study can be used to target allergens and self-Ags to 
APes in an attempt to induce tolerance. 
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1 General Introduction 
Chapter I General introduction 
1.1 Vaccines 
Diseases caused by infections are a major cause of death in humans and 
vaccination has been an important medical intervention to treat infections for 
last 200 years (Pashine et aI., 2005). Vaccines are biological preparations used 
to establish or improve immunity to a particular disease. The term 'vaccine' 
derived from Edwar Jenner's use of cow pox: Latin variolre vaccinre. adapted 
from the Latin vaccinus, from vacca cow (Peter J. Delves, 2011). 
The earliest vaccines were developed in China based on the concept of 
variolation in which a person is infected with the weak virus obtained from 
variola scabs as a form of inoculation to immunise against small pox (Plotkin, 
2004). Later, Jenner observed that deliberate infection with cow pox virus; 
which is nonvirulent in humans, induced mild disease and consequent 
elicitation of immunity against smallpox (Plotkin, 2004). Though variolation 
was banned for sometime due to some fatal reactions of small pox, this idea of 
deliberate infection to protect against infectious disease led to the eradication 
of smallpox in the twentieth century (Pardoll, 2002). 
Jenner's works eventually lead to Louis Pasteur's attenuated vaccines. Pasteur 
came upon this idea when he was working on chicken cholera caused by 
Pastellrilla mliiticoda (Plotkin, 2005). He infected chickens with an old 
culture which did not cause disease. These pre-infected chickens showed 
resistance when intected with a new culture of P. multicoda. On the basis of 
this observation Pasteur hypothesised that pathogens could be attenuated by 
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environmental stress such as high temperature and chemicals, which was 
confirmed by his work on rabies and anthrax (Plotkin, 2005). 
1.2 Immunotherapy 
Immunotherapy is wider term defined as the treatment of diseases by 
manipulating the immune system. It is of two types: active and passive 
immunotherapy. Self-limiting infectious diseases are easily controlled by 
traditional active vaccination strategies. Treatment of chronic infectious 
diseases or cancer is currently the main objective of immunotherapy, and it 
requires better understanding of the immune systems in terms of its regulatory 
mechanisms, identification of appropriate antigen and optimization of the 
interaction between antigen presenting cells (APC) and T-cells (Waldmann, 
2003) (see section 1.5.6). 
Passive immunotherapy refers to the transfer of pre-made immunological 
molecules, mostly antibodies after to naive patients. The concept of passive 
immunity was introduced by Koch's laboratory, where they injected animals 
with a small dose of diphtheria toxin. The serum containing anti-toxin 
antibodies was collected from the immunised animals to be administered to 
diphtheria patients providing passive immunity (Waldmann, 2003). 
The discovery of monoclonal antibodies (Kohler and Milstein, 1975) 
revolutionised passive immunotherapy; Muronomab-CD3 was the first 
monoclonal antibody approved by FDA to prevent organ allograft rejection 
(Group, 1985). In order to reduce immunogenicity monoclonal antibodies have 
been modified into chimeric and humanized antibodies and are being used to 
3 
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cure vari ous di fferent diseases. Some m Abs such as Gemtuzumab ozogamicin 
(Kreitman, 1999) and Ibritumomab tiuxetan (Witzig et ai. , 2002) li nked with 
tox in and radionuclide have been used to treat leukaemia and lymphoma 
respectively. 
Active immunotherapy involves long lasting changes in the immune system 
that lead to the induction of acquired immune response against the vaccine and 
establishment of memory. Active immunotherapy is the most desirable and 
widely used form of immunotherapy which, as mentioned above, started from 
Edward Jenner s discovery of the protective effect of deliberate infection with 
cow pox virus (Plotkin, 2005). This strategy of active immunotherapy led to 
the development of vaccines against many infectious diseases as described in 
Table.l.l. 
Tillie scule Developmellt ill vtlcL'illatioll 
1796 Jenner introduces vaccinia (cowpox) immunisation to prevent 
s u b s ~ q u e n t t small pox infection. 
1879-1886 Louis Pasteur introduces first laboratory-weakened infectious agent 
(chicken cholera bacterium) and shortly there after develops weakened 
rabies for active immunisation. 
1888 Emile Roux and Alexander Yersin isolate toxin from Diphthea. 
1890 Emil Von Behring and Shibasabo Kitasato in Koch ' s laboratory find 
that injecting diphtheria toxin into animal produces a serum containing 
an antitoxin that provides passive anti-diQhtheria immunity to people. 
1900 Paul Ehrlich suggests that molecules that react with tumours could 
playa key role in cancer therapy, presaging antibody - mediated 
passive immunotherapy. 
1954-1955 Jonas Salk and Albert Sabin introduce killed and live attenuated polio 
vaccines that soon lead to the elimination of poliomyelitis. 
1965 [gG anti-O (anti-RH) is administered to prevent ofRH immunisation 
and thus prevents erythryblastosis fetalis ; this is a transiation of the 
basic insight that passive administration of a specific IgG antibody 
inhibits the active production of that antibody. 
1975 George Kohler and Cesar Milstein develop hybridoma technology for 
monoclonal antibody generation. 
1977 SmallQox is declared eradicated through vaccination. 
1982 The first report of a successful use of a monoclonal antibody to treat a 
human neoplasm (patient specific anti-idiotype antibody to treat B-cell 
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ItInphoma) is r e ~ ~ r t e e . .
1986 The first monoclonal antibody, muromonab -CD3 (orthoclone OKT3), 
is approved by the FDA. 
1986 The first humanized antibody is produced by replacing the 
c o m p l e m e n t a r i ~ ~ r ~ i o n s s in a human antibody with those of a mouse. 
1986-2000 IL-2, [FN-a, IFN-p and rFN-y are proved for usse in the treatment of 
neoplasia, h ~ E a t i t t s s and multiple sc lerosis. 
1988-1991 The methodology for isolating tumour antigens recognized by CTLs is 
introduced; the first human antigen from melanoma patients identified 
by CTLs is isolated. 
1997 The first humanized monoclonal antibody (daclizumab, zenapax) is 
approved by the FDA. 
1997 The first monoclonal antibody (rituximab, rituxan) for the treatment of 
malignancy is ~ r o v e d . .
1998 An antibody to TNF-a (infliximab, remicade), and p75 TNF receptor 
linked to the Fe of IgG 1 (etanercept, Enbrel) are approved for use in 
the treatment of rheumatoid arthritis and Crohn disease. 
2000 The first toxin-linked monoclonal Ab (Gemtuzumab ozogamicin 
Mylotarg) is approved b b , _ _ the FDA. 
2002 The first radinuelide-linked monoclonal Ab (ibritumomab tiuxetan, 
Zevalin) is a2Qfoved ~ _ _ the FDA. 
2007 Tositumomab is a IgG2a anti-CD20 monoclonal antibody 
derived from immortalized mouse cells used for the treatment of 
fo llicular lymphoma (Jacene et aI. , 2007). 
2008 Cetuximab is a chimeric mAb, an epidennal growth factor 
receptor (EGFR) inhibitor, for treatment of metastatic colorectal 
cancer and head and neck cancer (Yonesaka et aI., 20 II) . 
2009 Palivizumab is a humanized monoclonal antibody directed 
against an epitope in the A antigenic site of the F protein of 
respiratory syncytial virus (RSV), u ed in the prevention of RSV 
infections in infants (Wang et aI., 2008). 
2009 Alemtuzumab is a monoclonal antibody used in the treatment of 
chronic lymphocytic leukemia (CLL), cutaneous T-cell 
lymphoma (CTCL) and T-cell lymphoma (Schnitzler et aI., 
2009). 
2010 Catumaxoma is a bispecific rat-mouse hybrid monoclonal 
antibody which is used to treat malignant ascites, a condition 
occurring in patients with metastasizing cancer (Linke et al., 
20 10). 
Table 1.1: Key developments in vaccination along with the time scale. 
(Waldmann, 2003). 
Classic vaCC1l1es which are based on the principal of active immunisation 
contain either the live, attenuated or a portion of disease causing agent 
(bacteria, virus or toxin) along with an adjuvant. Vaccines are nonnally 
administered with a priming dose in order to initate the immune response 
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followed by the two to three booster doses which induces not only the effector 
cells but al 0 memory immune cells . The general classification of vacci nes IS 
shown in tlgure 1.1 . 
Subunit 
Protein Bene 
live attenuated 
vaccine 
Cloning 
(e.g. subunit) 
~ ~
ONAVaccine 
Sub cloning 1 
Live vector vaccine 
000 
000 
00 
Recombinant 
subunit vaccine 
Killed vaccine 
000 
000 
00 
Subunit vaccine 
Figure 1.1: Classical approaches to develope killed, attenuated, inactivated and 
recombinant subunit vaccines from pathogens. (Peter J. Delves, 2011). 
l.2.1.1 Killed vaccines 
These vaccines are composed of pathogens killed by either chemicals or heat 
and induce effective humoral immune response as they include all the epitopes 
and virulence factor of the pathogen, however during deactvation it should be 
ensured that important antigenic parts of the organi m are not destroyed. As 
they are composed of dead organisms they do not cause the side reactions 
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associated with live vaccines such as replication and reacquisition of virulence 
within the host. As compared to bacteria and viruses parasitic worms and 
protozoa are extremely difficult to grow in order to produce killed vaccines. 
Examples of killed vaccines are influenza, cholera and inactivated 
poliomyelitis (Salk) vaccines (Peter J. Delves, 2011). Moreover these vaccines 
have longer shelf life and are easier to handle and store. Killed vaccines also 
cause side reactions such as in the case of pertussis vaccine which causes 
inflammation at the site of injection and leads to fever due to the presences of 
endotoxins in the vaccine preparation (Sidey et ai., 1989). 
1.2.1.2 Live / attenuated vaccines 
Natural infection or the infection with the modified live organism leads to the 
induction of most etTective and long lasting cellular and humoral immunity 
without using adjuvants. Live vaccines are administered through the natural 
route of infection i.e. where the natural infection occurs, and needs fewer no of 
re-inoculations (Roberts, 2004). Live vaccines are attenuated or their virulence 
capacity is reduced either by repeated passages (l0-1000 times) in vitro or by 
genetic manipulation as in the case of the sabin oral polio and flu mist vaccines 
(Roberts, 2004). On the other hand a non-pathogenic partner of the organism 
which shares immunoprotective epitopes can be used to induce immunity 
against natural pathogens. For example Bacillus Calmette-Guerin (BCG) 
vaccine in which attenuated Mycobacterium bovis is used to protect against 
natural infection caused by M tuberculosis (Peter J. Delves, 2011). 
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Although live vaccines are very etTective to induce immunity, they can also 
cause severe side reactions such as inflammation at the site of inoculation and 
as they replicate inside the host can revert back to a virulent strain by genetic 
recombination. Moreover, live vaccines are difficult to store as their half life is 
short which makes it difficult to keep organisms alive for long periods of time 
(Wilson-Welder et aI., 2009). 
1.2.1.3 Subunit vaccines 
Subunit vaccines are composed of only a portion of pathogen and could be 
either an immunogenic peptide or DNA encoding the peptide. As compared to 
other types of vaccines it is safer and does not lead to side reactions associated 
with live or killed vaccines as it does not include virulence factors such as 
endotoxins and other TLR agonists (see section 1.4) which induce innate 
immune responses. On the other hand subunit vaccines are not very 
immunogenic and need multiple doses of the vaccines along with the 
appropriate adjuvant to trigger the immunity. Even with the adjuvant subunit 
vaccines leads to the induction of humoral responses but fail to induce cell 
mediated immunity (Wilson-Welder et aI., 2009). Subunit vaccines can be 
improved to induce cell mediated immunity by using different antigen targeting 
approaches in combination with different adjuvants, to induce cell mediated 
immunity (Singh and O'Hagan, 2003). 
Recombinant viruses such as modified vaccinia Ankara strain can be used as a 
vector to deliver antigens associated with pathogens and to induce immunity. 
These recombinant viral vectors include constructs which are replication 
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defi cient, non-integrating, stable and easy to prepare. Examples incl ude 
Hepatitis B surface antigen (HBsAg) and influenza hemagglutinin when 
expressed using recombinant vaccinia virus result in the induction of immunity 
and protection against hepatiti s B virus and influenza infection in chimpanzee 
and mice, respectively as shown in figure 1.2. (Peter 1. Delves, 20 11). 
HBsAg 
Peptide 
MHC 
Vaccinia 
Ant igen 
processing 
DNA 
"'- .. 
Protein syn thesis 
Vacdnla 
promoter gene 
H H ' A g g
patlcle 
Folding 
glycosylation 
Infected cell 
Figure 1.2: Hepatitis B surface antigen (fmsAg) vaccine using vaccinia virus as a 
vector to deliver antigen (Peter J. Delves, 2011). 
Antibody-mediated targeting of Ag or subunit vaCC1l1e, to APC is another 
approach to develop T-cell immunity. Different receptors expressed by APC 
such as DEC205 (CD205) dendritic cell-Specific intercellular adhesion 
molecule-3 -grabbing non-integrin (DC-SIGN), DC NK lectin group receptor- l 
(DNGR1) and mannose recptor (MR) have been tested in order to deliver 
antigen to APC and to elicit antigen-spefi cic immunity (see section 1.6.2). 
9 
Chapter 1 General introduction 
1.3 Routes of vaccine administration 
As described in section 1.2 different vaccines are associated with different 
adverse reactions at the site of injection. In order to reduce the side reaction 
and maximize immunogenicity of the vaccines, selection of an appropriate 
route of vaccine administration is needed. Normally vaccines are administered 
through subcutaneous, intramuscular and mucosal routes (Cook, 2008, Denis et 
aI., 2007). Conventionally, all vaccines other than BCG and typhoid were 
given subcutaneously until vaccination led to an extra inflammation at the site 
of injection(Volk et aI., 1954). 
LF Cook showed that for all vaccme categories such as live attenuated, 
inactivated whole cell, toxoid and subunit vaccines, intramuscular 
administration leads to better immune outcome and reduced side reaction as 
compared to subcutaneous injection (Cook, 2008). Increased reaction at the site 
of reaction associated with subcutaneous route of vaccine can be explained by 
two theories: (i) according to first theory numerous sensory neurons are present 
in subcutaneous as compared to muscles (Lindblad, 2004) and (ii) 
inflammatory cells present in the skin might be involved in the inflammation at 
the site of injection (Laurichesse et ai., 2007). 
Administration of vaccines through the mucosa is performed either through 
nose or mouth and induces protective immune response in both mucosal level 
and systemically. Vaccines against the microbes causing cholera, diarrhea and 
typhoid or pathogens which infect in the gastric tract are given through the oral 
or rectal route and vaccines against respiratory pathogens may be be 
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administered though the nose. Mucosal vaccines which are currently being 
used are the sabin oral polio vaccine (OPV) (Dowdle et aI., 2003), rota virus 
vaccine and cold-adapted influenza vaccine (Belshe et aI., 2000). Currently 
with a few exceptions most of the vaccines are administered either through the 
subcutaneous or intramuscular routes as Ag dose and its deposition can be 
controlled at the site of injection. Ag deposition continuosly supply Ag to 
APes which is difficult to achieve by the intradermal route. Other than the 
route of vaccine administration other factors such as the type of Ag, type of 
adjuvant and time of vaccination are also important to achieve an appropriate 
immune response. 
1.4 Role of adjuvants in the development of vaccines 
The word adjuvant is derived from Latin verb adjuvare which means to help or 
aid and it may be deiined as compoment of vaccine formulation which 
stimulates prolonged specific immune response to a vaccine without having 
any antigenic effect (Lindblad et aI., 1997). 
Only antigen which is transported into secondary lymphoid organ in sufficient 
amount and for sufficient time leads to the induction of effective immunity. On 
the other hand if the Ag persists in the secondary lymphoid organ or 
transported there in excess for long periods of time it leads to antigen specific 
T -cell anergy (Zinkemagel, 2000). Subcutaneous injection of bovine serum 
albumin, hen egg lysozyme and fowl gamma globulin does not lead to the 
induction ofT-cell or antibody response due to rapid degradation of the foreign 
antigenic protein as their half life is very short (Weigle, 1961). Adjuvants 
11 
Chapter I General introduction 
entrap the antigen in poorly metabolized or slowly degradable materials and 
protect antigen from degradation. Morover, adjuvants provides an Ag depot 
which facilitate its transport to secondary lymphoid organs for long time and in 
sufficient quantity as to induce an effective immune response. Aluminium 
phosphate and aluminium hydroxide known as alum are commonly used in 
human vaccines (Wilson-Welder et ai. , 2009). Freund' s complete adjuvant 
(FCA) is one of the most effective adjuvants. [t is composed of water in oil 
emulsion containing killed mycobacteria and it is highly reactogenic. It is used 
as an adjuvants in animal vaccines but not in humans as it induces granuloma 
formation at the site of injection. Freund's incomplete adjuvant contains only 
water oil emulsion and is recommended to be employed in influenza and H[V 
vaccine (Vogel, 2000). The adjuvants which are currently used along with the 
licensed vaccines are given in Table 1.2. 
Hilma" ... US HlIIlltlll ... U"ited Killgdom Lil'e .\'t(}('k worldwitie 
Aluminum hydroxide, 
Alumillum phosphate, 
Potassium aluminum 
sulfate(a/um) 
allti Ellropetlll U"ioll (gelleral categories) 
Aluminum hydroxide, 
Aluminum phosphate, 
Potassium aluminum 
sui fate(alum) 
Calcium phosphate 
MF-59 (squalene in Fluad) 
AS04 (liposome 
fonnulation containing 
MPLA and QS-21) 
(FENDrix, servaix) 
Aluminum hydroxide, 
Aluminum phosphate, 
Potassium aluminum 
sulfate(alum) 
Saponin QS-21 
Oil emulsions paraffins, 
Mineral oil, lanolin, 
Squalene, ISA-70, 
Montanide (IMS) 
Glycerin 
Table 1.2: Vaccine adjuvants currently used along with the licensed vaccines 
(Adapted from Wilson-Welder ct al., 2009). 
Other than depot effect, adjuvants also interact with pattern-recognition 
receptors (PRR) expressed on APC and provide danger signal as as it occours 
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during an active infection. These adjuvants could be derived by pathogens that 
express conserved structures such as pathogen associated molecular patterns 
(PAMPs) (Wilson-Welder et aI., 2009, O'Hagan and Valiante, 2003). PRR 
recognizies P AMPs and induce innate immune response by activating the 
complement pathways and intracellular signalling leading to inflammatory 
reponses required to clear pathogens (Janeway and Medzhitov, 2002, 
Pulendran and Ahmed, 2006). PRR are found in three different compartments 
such as body t1uids, cell membrane and cytoplasm. PRR found in body t1uids 
are involved in the the activation of complement pathway (Gasque, 2004). PRR 
associated with cell membrane include toll like receptor (TLR), scavenger 
receptors, MR and other C-type lectins which help microbial uptake by 
phagocytosis and activation of intracellular signalling pathways (Lee and Kim, 
2007). 
TLRs are best to generate intracellular signalling and shape the acquired 
immunity. In mammals all TLRs are type-I transmembrane glycoproteins 
containing an extracllular domain for ligand recognition and a cytoplasmic 
Toll/IL-l R homology (TIR) domains to initiate intracellular signalling (Akira 
and Takeda, 2004). Four different TIR domain containing adaptor molecules 
such as MyD88, TIRAP, TRIF and TRAM are recruited in different 
combinations to initiate signalling pathways (Akira and Takeda, 2004) as 
shown in tigure 1.3. Toll-like receptors (TLR) recognise pathogen-associated 
molecular patterns (PAMPS) that act as warning signs of infection. 
Consequently TLR are considered pattern recognition receptors (PRR) (Pasare 
and Medzhitov, 2004). Engagement of the TLR with the PAMPS results in the 
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DC maturation due to the increased cytokines production on its urface which 
is very important for the development of the imm unity (Hemmi and Akira, 
2005). Cross presentation (Burgdorf et aI. , 2008) and the antigen presentation 
through MHC-II pathway by the DCs increased in the presence of endotoxins 
(Blander and Medzhitov, 2006). So, PRR on the DCs play an important role in 
the Ag presentation are critical for the development of the immunity. 
LPS Triacylated ilpopeptides 
TLR2 
TLRt 
Flagellin 
TLRS n n m Plasma membrane 
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Figure 1.3: Overview of major TLR signaling pathways. 
All TLR ignal through MyD88 with the exception of TLR3. TLR4 and the TLR2 
subfami ly (TLR I , TLR2, TLR6) a l 0 engage TfRAP. TLR3 s ignal s through TRW 
TRlF is also used in conjunction with TRAM in the TLR4-MyD88-independent 
pathway. Dashed arrows indicate translocation into the nucleus. LPS , 
lipopoly accharide; dsR A, doub le-stranded R ; s RN , s ingle-st randed R 
MAPK, mitogen-activated protei n kinases; NF-K8, nuclear factor-KB; lRF3 , interferon 
regulatory factor-3 . Adapted from Ouin et a!. (van Ouin et a!., 2006). 
LPS are the component of gram negative bacterial cell wall and signals through 
endotoxin receptor TLR-4 through MyD88 and T RI F mediated pathways and 
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results in the maturation and migration of DCs to secondary lymphoid organ. 
The unique feature of the LPS as an adjuvant is that it can be administered 
through any route and different time than vaccine but still it keeps its 
adjuvanticity. LPS is used as an adjuvant in animals only and it is not permitted 
in humans due to its toxicity which is due its signaling through MyD88 
pathway which result in the induction of IFN-y, IL-lP, IL-6 and other 
molecules associated with toxicity of LPS (Mata-Haro et al., 2007). Due to the 
toxic effects of the adjuvants only limited adjuvants are permitted to be used 
with human vaccines. LPS can be detoxified or its toxicity can be reduced from 
100 to 1000 time by removing phosphate group, sugar moiety and ester linked 
fatty acid group (Johansson et aI., 2004). MPLA is such a molecule derived 
from Salmonella which has almost 0.1 % intlamatory cytotoxicity as compared 
to LPS (Evans et aI., 2003). MPLA signals through endotoxin receptor TLR-4 
by TRIF pathway and as an adjuvant it was found equally potent as LPS to 
induce CD4+ and CD8+ T-cells proliferation. Morevoer, MPLA retained the 
induction of type I interferon by TLR4/TRIF mediated signaling which is 
important to generate an antiviral state in mosT -cells by T-cell clonal 
proliferation (Kolumam et al., 2005). 
Prokaryotic DNA includes unmethylated CpG dinuleotides in high frequency 
which are recognized by the innate immune system of the vertebrates (Krieg, 
2002). These sequences signals through TLR-9 (located on endosomal 
memebrane) by My088 pathway (Takeshita et al., 2001). CpG motifs activate 
DCs by upregulating the expression of C080, C086, MHC-II, and transient 
secretion of type I interferon (Verthelyi and Zeuner, 2003, Kerkmann et al., 
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2003). CpG adjuvant is found very effective to induce immunity against very 
weak Ags such as melanoma, malarial Ags (Diwan et aI., 2002). 
1.5 Dendritic cells (DC) and vaccine development 
1.5.1 Dendritic cells (DCs) 
Dendritic cells are professional APC. They playa major role in the initiation 
and control of immune responses by regulating T and B lymphocytes 
activation. These cells are strategically positioned throughout the body in an 
immature state, surveying the tissues for invading pathogens and are unique in 
antigen capturing, processing, and presentation as compared to other antigen-
presenting cells (Banchereau and Steinman, 1998). 
1.5.2 Location of DCs 
DCs are derived from bone marrow progenitors and circulate in the blood as 
immature precursors prior to migration into peripheral tissues. Within different 
tissues, DCs differentiate and become active in the taking up and processing of 
Ags. The location of the DCs inside the body is unique to capture the foreign 
antigens such as body surfaces like the skin, pharynx, upper oesophagus, 
vagina, ectocervix and anus, and at mucosal surfaces, such as the respiratory 
and gastrointestinal systems (Niess et aI., 2005). 
In steady state conditions, in most tissues DCs are immature; unable to 
stimulate the T -cells due to the lack of required accessory signals such as 
CD40, CD54, and CD86, but they are highly equipped with the antigen 
capturing Fey and FCE recptors to uptake the antigens (Banchereau and 
Steinman, 1998). Upon antigen uptake and appropriate stimulation, DCs 
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undergo further maturation and migrate to secondary lymphoid tissues where 
they present Ag to T -cells and induce an immune response (Satthaporn and 
Eremin, 2001). 
1.5.3 Migration of Des to lymphoid tissues 
DCs are highly mobile, they need to migrate from the periphery to the T -cells 
area of the secondary lymphoid organs through lymphatic vessels in order to 
present Ag to Tcells (Randolph et aI., 2005). Body movements drive the lymph 
inside the lymphatic vessels in a unidirectional way from the periphery to the 
lymph nodes (LNs) and ultimately to the heart (Swartz, 2001). Mature DCs 
expressing the chemokine receptor, CC-cemokine receptor 7 (CCR7) move 
towards the lymphatic vessels through chemotaxis as shown in figure 1.4 (Ohl 
et aI., 2004, Sallusto et aI., 1998). Little is known about the expression of 
CCR 7 but it is correlated with the upregulation of major hisocompatibility 
molecule II (MHC-I1) and co-stimulatory molecules which occurs during DCs 
maturation (Sallusto et aI., 1998). [t is proposed that the lymphatic endings 
secrete the CCL 19 and CCL21 chemokines and CCR 7 positive DCs move 
towards these molecules in a concentration gradient dependent manner and 
taken up by the terminal lymphatic vessels. Once inside the LN, DCs present 
antigen to the T-cells and die locally. DCs do not leave the efferent lymph 
which is opposite to the movement of the T-cells (Kamath et aI., 2002). 
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Fioure 1.4: The critical role of chemokine in the migration of dendritic cells to 
lymphoid tissue. 
Precursor and immature dermal DC or langerhan cell s that di play CC R6 are 
attracted by the epithel ium that expresse the p cific ligand MIP-3a. Upon antigen 
capture and activation, dennal DC detach from keratinocyte by downregu lating E-
cadherin. Meanwhile CC R6 i replaced by CC R7, whose ligands a re (a) 6Ckine, 
which i expre sed on lymphatic vessel wall, and (b) MU)-3b, which i expres cd in 
the T-cell area of lymphoid organs. Thi may guide the maturing DC to the T-cell 
areas where they will tart to produce chemokines that attract lym phocytes. Adapted 
from Banchereau et al. (Banchereau et aI., 2000). 
L.5.4 Antigen uptake and processing 
DCs uptake exogenous Ag by different mechani much as pinocytosis or 
receptor mediated-endocytosi which result in the targeting of the soluble Ag 
to di tinct intracellular compartment and antigen presentation to CD4+ or CD8+ 
T -cells (Burgdorf et aI., 2007). Materi al taken up by the APC by pinocyto i is 
targeted to the ndocytic pathway (Burgdorf et aI. , 2007) which i compo ed of 
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three increasingly acidic compartments: early endosome, late endosome and 
finally lysosome. The acidic nature of the endocytic cycle as well as the 
hydrolytic enzymes in the lysosomal compartment degrades the endocytosed 
material into shorter oligopeptides appropriate for recognition by class II MHC 
molecules. 
Classical studies showed that endogenous proteins arc processed through the 
cytosolic pathway and the peptides derived from the endogenous antigens are 
transported to the endoplasmic reticulum where these are loaded on the MHC 
class [ molecule and transferred to the cell surface for antigen presentation. On 
the other hand recent studies showed that APC especially the DCs have the 
ability to process exogenous antigen and present on the MHC I molecules. This 
mechanism is known as cross presentation and is important to induce the 
immune response against the viruses and tumours which are not infecting the 
APC (Heath and Carbone, 200 I). 
1.5.5 Cross-presentation 
The molecular mechanism of the cross presentation is not that clear as the 
MHC I restricted presentation of endogenous antigens. In the cytoplasm, 
endogenous antigens are digested into the shorter antigenic peptides by the 
proteosome which are taken to the endoplasmic reticulum by transfer 
associated with antigenic processing (TAP), where they are loaded on the 
MHC I molecules and transferred to the cell surface through Golgi apparatus 
via the secretory pathway for presentation to cytotoxic T lymphocytes 
(Burgdorf et ai., 2008). 
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When analysed in vitro, DCs and macrophages were found as the key cells 
capable of cross presentation by exposing different bone marrow derived APCs 
to exogenous antigens. However, the cross priming ability of DC invivo has 
been deomonstrated by two methods: Firstly DCs isolated from animals were 
exposed to the Ags exvivo and then injected into the mice which led to the 
activation of CDS+ T-cell immunity due to cross presentation (Pozzi et aI., 
2005). Secondly, deletion of APCs from transgenic mice (CD 11 c-DTR) using 
diphtheria toxin, result into the inhibition of cross presentation which indicates 
that DCs present exogenous Ag on MHC-I molecules and are one of the key 
cells involved in cross presentation (lung et ai., 2002). 
DCs in mice are heterogenous and their subtypes differ in morphology and 
functionality. DCs located in the secondary lymphoid tissues can be both 
resident and migratory DCs (Ardavin, 2003). In spleen resident DCs are 
divided in two subsets: CD8+ and CS- DCs based on the expression of CD8aa 
homodimers. There are many differences between these cell subsets with 
CD8+ DCs preferentially cross presenting the exogenous Ag on MHC-I 
molecules while on the other hand COS- DCs do it on the MHC-II molecules. 
Differential Ag processing in these cells was confirmed by microarray studies 
which showed that CD8+ DCs express more proteins involved in MHC-I 
presentation and CD8- DCs express more proteins which are involved in the 
MHC-II presentation (Dudziak et ai., 2007). Compared to resident DCs very 
little is known about the cross priming abilitites of the migratory DCs. 
Amongst different skin-derived DCs CD103+ DCs are the main migratory 
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subtype which captures the viral and self antigen from the skin and cross 
present (Bedoui et ai., 2009). 
The mechanism involved in the in the cross-presentaion of exogenous Ag have 
been of great interest due to its implications in vaccine development against 
cancer and viral infections. DifTerent groups have tried to elucidate it but still 
the intracellular compartments involved in this process are not well detined. 
So, difTerent theories of cross presentation have been suggested on the basis of 
intracellular pathways used as shown in figure 1.5. Different pathways of 
cross-presentation are described below. 
1.5.5.1 Vacuolar pathway 
This pathway of cross-presentation is distinct from other pathways as it is 
independent to TAP and cytosolic proteasome. So in this pathway the peptides 
for the cross presentation are generated in the phagosome by cysteine protease 
cathepsin S, the MHC-I molecule is transported to the phagosome through 
either a tyrosine-based signal or provided by endoplasmic reticulum (ER) 
through its fusion with phagosome (Shen et ai., 2004). Fusion of ER with 
phagosome is controversial as Touret et ai., failed to demonstrate fusion of ER 
with phagosome by different methods which show that fusion of ER with 
phagosome is an artifact in this pathway of cross-presenataion. So, either 
MHC-I molecule reaches peptide by signal or get ER MHC-I molecule by 
some method other than fusion (Touret et ai., 2005). 
21 
Chapter 1 General introduction 
1.5.5.2 Phagosome to cytosol pathway 
In the phagosome to cytosol pathway of cross presentation, antigen from the 
phagosome is transported into the cytosol for digestion by the cytosolic 
proteasome and peptides are transported back into the phagosome to be loaded 
on MHC-I molecule (Kovacsovics-Bankowski and Rock, 1995). Phagosome 
fuse with ER which provides several proteins including MHC-I molecule, 
tapasin, chaperones and Sce61. Sec61 plays a role for the escape of Ag from 
the phagosome into the cytosol for digestion. The peptides are then carried 
with the help of TAP into ER or back into the phagosome as phagosome after 
fusion with ER includes all essential proteins for loading of peptide on MHC-I 
molecules (Guermonprez et aI., 2003). 
1.5.5.3 Endosome to ER and ER associated degradation pathway. 
In the endosome to ER and ER-associated degradation pathway of cross 
presentation soluble antigens are internalized by DCs and transported into the 
ER. Ag escapes into the cytosol using the ER-associated degradation pathway. 
Ag is digested into peptides by cytosolic proteasome which are taken up by 
TAP and re-tamsported into ER where they are loaded on MHC-I molecules 
and cross presented (lmai et aI., 2005). 
1.5.5.4 Mannose Receptor (MR) to Early Endoplasmic Reticulum 
(EER) pathway 
Burgdorf, Scholz et al. (2008) proposed a cross presentation system on the 
basis of their experimental findings in which they have suggested that the 
soluble model Ag such as Ovalbumin (OVA) is taken up by the DCs with the 
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help of mannose receptor and transported to the stable early endosome 
compartment. From the early endosome OVA is exported to the cytoplasm 
where it is degraded into OVA pep tides by the proteasome. Peptides are then 
reimported into the same early endosome compartment with help of TAP, 
loaded on the MHC I molecule and transported directly (Not through the GA 
and secretory pathway) to the cell membrane for presentation to CTL. 
On the otherhand, Nadine et al. (2009) found that a continuous supply of 
MHC-I peptide is required in order to prime cytotoxic T lymphocytes in vivo. 
In order to provide a continous supply, Ag is stored in a lysome-like organelle 
that functions as a depot (van Montfoort et aI., 2009) but it is clearly distinct 
from EER compartment as described above (Burgdorf et aI., 2008). 
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(a) The vacuolar pathway. MHC class I molecules sample peptides that are generated 
in phago omes in a TAP-independent manner. (b) Phagosome-to-cytoso l-to-
phagosome pathway. Phagosomes acquire MHC c lass I, TAP, Sec6 1 and other ER 
molecules t11rough fusion with the ER. lntemalized antigen is exported (po sibly by 
Sec6 1) to the cytoso l, hydrolyzed by proteasome and the resulting pept ide are then 
re-imported into phagosomes by TAP, where they bind MHC c ia s [ molecules. (c) 
Phagosome-to-cytoso l pathway. Antigen intemalized into phagosomes i exported to 
the cytoso l, hydrolyzed by proteasomes and the resulting peptide are then transpo11ed 
to MHC class I molecules in the ER by TAP. (d) GAP junction pathway. APC 
acquire peptides from other cells through GAP junctions. (e) Endosome-to-ER 
pathway. Antigen in endo omes is transported into the ER and then degraded in the 
cyto 01 by the ER associated degradation pathway (ERAD). The resul ting peptides are 
transported to class [ molecules in the ER by TAP. Adapted from Shen et at. (Shen 
and Rock, 2006) 
1.5.6 DC maturation 
DC maturation refers to the upregulation of costimulatory molecules, 
enhancement in their antigen presenting function, and the expresston of 
chemokine receptors such as CCR 7 which direct the movement of DCs to the 
secondary lymphoid organs (Tacken et a l. , 2007) . [n the absence of m aturation 
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stimulus when DCs encounter the Ag they induce tolerance when they capture 
self and environmental Ag (Hawiger et at., 2001). However in the presence of 
maturation stimulus such LPS a massive migration of the DCs is observed from 
the skin, heart, kidneys and intestines (Roake et aI., 1995). 
Toll-like receptors (TLRs) are the best characterized pathogen recognition 
receptors which recognise the pathogen associated molecular patterns 
(PAMPS) that act as warning signs of infection.(Akira et al., 2006) and (Kawai 
and Akira, 2005). For DCs, TLR agonists have adjuvant effect on the antigen 
presentation by inducing the increase in antigen uptake, MHC I expression and 
loading, and also by stimulating the expression of co-stimulatory molecules. 
From vaccination point of view, targeting the immature DC in the absence of 
maturation stimulus is good strategy to treat allergy, chronic inflammatory and 
autoimmune diseases but on the other side to treat cancer and other infectious 
diseases it is essential to induce the immune response by targeting the mature 
DCs. Time and the route of the administration of the maturation stimuli are of 
the crucial importance to induce the maturation of DCs (Tacken et aI., 2007), 
which modulate the Ag processing by lowering the pH of endocytic, activating 
proteolysis, and transporting peptide MHC complexes to the cell surface for the 
presentation (Trombetta and Mellman, 2005). Maturation stimuli should be 
applied systemically as the stimuli applied too long before or after the Ag 
administration results in the decrease of cross presentation (Wilson et aI., 
2006). Some DC receptors such as CD20S completely loose antigen uptake 
capacity upon full maturation, therefore, it is better to target the antigen and 
maturation stimuli simultaneously (Butler et aI., 2007). To activate DC it is 
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better to use the combination of maturation stimuli as targeting of human DCs 
through mannose receptor in the presence of R848 (signals through TLR7 and 
TLR8) and poly I:C (signals through TLR3) results in inducing the T helper 
cells and CTL responses (Ramakrishna et aI., 2007). 
Mature DCs (mDes) carrying the Ag move towards the secondary lymphoid 
tissues such as local lymph nodes (LN) and present Ag and activate T -cells in 
the presence of endotoxoin, in the T-cell area of the LN. Activated T-helper 
cells are involved in the production of the antibodies in order to remove the 
Ag. On the other hand active cytotoxic T-Iymphocytes and leave the LN 
throught the efferent lymph and kill the infected cells (Steinman, 200 I). But 
the Ag presented by the DCs in the absence of the infection signal such as 
endotoxins results in the T-cell deletion and leads to the peripheral tolerance 
(Janeway and Bottomly, 1994). 
1.6 Exploitation of dendritic cells for vaccine development 
1.6.1 Ex-vivo loading of dendritic cells and their use as adjuvants 
Inaba et. aI., first described the role of DCs as adjuvants. In this study, DCs 
isolated from mouse spleen were primed with the specific antigen overnight. 
DCs processed and presented the antigen epitopes onto MHC molecules and 
Ag-Ioaded DCs were then injected into mice, which led to Ag specific T-cell 
sensitization and development of immunity. The immune response was robust 
when the mouse was challenged again with the DC pulsed with the same 
antigen, due to the presence of memory cells (Inaba et aI., 1990). 
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Methods of preparing DCs have changed since they were considered trace cell 
types of the immune system, when in vitro protocols were employed to grow 
DCs from their progenitors. Inaba et aI., identified and reported clusters of DCs 
from cultures of mouse blood supplemented with GM-CSF (Inaba et aI., 
1992b). Bone-marrow being the precursor of DCs, they were soon thereafter 
identified in the blood culture, and a method was thus described to grow large 
numbers of DCs from bone-marrow (BM) cultures of mice supplemented with 
GM-CSF (lnaba et aI., 1992a). These new methods of DC culture paved the 
way to further characterise DCs and investigate their clinical application. In 
order to investigate the capacity of BM-derived DC (BMDC) to be used as an 
adjuvant to induce immunity against infectious diseases, BMDC were pulsed 
with Bacillus Calmette-Guerin organism, and induced a strong T-cell response 
when injected in-vivo (Inaba et aI., 1993). 
To investigate the role of DCs as adjuvant in humans, they are prepared from 
the culture of blood monocytes supplemented GM-CSF and IL-4 (Romani et 
aI., 1994). Later, a method to generate mature DCs from human blood was 
described in which they used macrophage conditioned media containing 
essential maturation factors (Romani et aI., 1996). Des generated with this 
method were clinically more potent as an adjuvant. When these cells were fed 
with B-cell lymphoma and tumour lysate, and injected as a vaccine into 
patients suffering from B-cell lymphoma (Hsu et aI., 1996) and melanoma 
(Nestle et aI., 1998) respectively, induced Ag specific imunity. 
DCs have been used directly as an adjuvant in immunotherapy 
(Mohamadzadeh and Luftig, 2004) but with limited success as the 
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methodology is very expensive, complex and time consuming. Additionally, 
antigen-loaded DCs accumulate at the site of injection and only 1-2% of the 
antigen pulsed DCs reach the local lymphoid organ. Due to these limitations 
alternative approaches have been developed to target DCs directly in vivo in 
the presence or absence of infectious signals (Shortman et aI., 2009, Tacken et 
ai.,2006). 
1.6.2 Development of vaccine by antibody mediated targeting of 
antigens. 
Antigen targeting with the help of antibodies (Ab) against receptors found on 
DCs is the most specific and reliable method to develop vaccines. In this 
method, antibodies specific for the receptors expressed on DC are used as a 
vehicle to deliver Ag. Given the rarity of DCs in the body, it is better to use 
antibodies to deliver specitic antigen as it results into greater uptake and 
presentation of the antigen by the DCs (Keler et aI., 2007). For instance, the 
efficiency of OVA uptake and presentation was increased lOOO-fold for MHC-I 
molecule and 300 fold for MHC-II molecule when targeted using anti-DEC205 
antibody, as compared to non-specific targeting of OVA (Bonifaz et ai., 2002). 
DCs express endocytic receptors and Ab-mediated Ag delivery through them 
leads to the accumulation of Ag into specialised compartments of the cell 
where they are loaded on to the relevant MHC molecules to elicit the Ag 
specific immune response. Common receptors used successfully for vaccine 
development through this methodology are complement receptors, integrins, 
members of the immunoglobulin superfamily and C-type lectin receptors 
(CLRs) (Keler et ai., 2007). The most common CLRs used in targeting studies 
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are the MR, CD205 and DC-specific intercellular adhesion molecule-3 
(lCAM3)-grabbing non integrins (DC-SIGN). Ag-targeting through ditTerent 
receptors results in different immune outcomes due to different intracellular 
receptor routing, signalling pathways and expression patterns (Tacken et ai., 
2007). Here, we will mainly focus on the potential of MR as a candidate tor 
vaccine development by its specific targeting using anti-MR mAb, anti-MR 
chimeric antibody and glycopolymers. 
1.6.2.1 DEC205 
DEC-205 belongs to MR family, and it was first identitied as a receptor on 
mouse DC. It is a 200 KDa glycoprotein composed of a cysteine-rich domain, 
tibronectin type II domain, and 10 CTLD domains for which natural ligands 
have not yet been identified. It is an endocytic receptor which takes up the 
antigen cargo and delivers it to the intracellular compartment of DCs, where it 
is loaded on MHC molecule and presented to T-cells (East and Isacke, 2002). 
Ab-mediated antigen delivery through DEC-205 has been found to be 100-fold 
more efficient as compared to non-specific targeting. Model antigens such as 
HEL (Hawiger et aI., 2001) and OVA (Bonifaz et aI., 2002) have been fused 
with anti-DEC205 antibody; and when immunised in the presence of an 
appropriate adjuvant like anti-CD40 agonist, elicited strong CD4+ helper T-cell 
antibody response (Boscardin et aI., 2006) and strong CD8+ T-cell immunity 
(Bonifaz et aI., 2004). Different antigens of common infectious diseases such 
as the circumsporozite protein of malaria parasite (Boscardin et aI., 2006), gig 
protein of HIV (Bozzacco et aI., 2007) and nuclear antigen of Epstein-Barr 
virus (Gurer et aI., 2008) have been targeted through DEC-205 in the presence 
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of anjuvant and result into strong antigen specific immunity. On the other hand, 
in the absence of infectious signal antigen targeting through DEC-20S lead to 
antigen specific T-cell tolerance. In this respect, /3 cell antigen targeting result 
in deletion of auto reactive CD8+ T-cells, which causes type I diabetes mellitus 
(Mukhopadhaya et a!., 2008). 
1.6.2.2 DNGR-l 
C-type lectin 9a (Celc9a) is a C-type lectin like molecule expressed on the 
surface of CD8+ mouse cDCs and BDCA-3 human DC subtype. It is a type II 
transmembrane receptor having one extracellular C-type lectin like domain 
(CTLD). DC NK lectin group receptor-l (DNGR-l) is characterised as a 
member of C-type lectin of the NK receptor group and it was identified on 
mouse CD8u + cDCs and partially on pDCs. It is an endocytic receptor of 
molecular weight 51 KDa found in dimmers. CD8u + DCs are specialised in 
cross presentation and the induction of CTL based immunity and DNGR-l 
selectively expressed on these DCs (Sancho et a!., 2008). Ag-targeting through 
this receptor can therefore be used to treat some chronic infectious diseases 
such malaria, HIV and cancer. The potential of DNGR-l for Ag-targeting and 
the vaccine development portal was assessed by immunisation of mice with 
anti-DNGR-l, coupled with melanoma antigen S 1 along with anti-CD40 
adjuvant. The mice were challenged with B 16 melanoma cells and anti-DNGR-
1 targeting resulted in strong and long lasting T-cell memory, which leads to 
eradication of 8 16 melanoma lung pseudometastases (Sancho et a!., 2008). 
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1.6.2.3 DC-SIGN 
DC-specific ICAM-3 grabbing non-integrin (DC-SIGN) and its equilent DC-
SIGNR belongs to the family of type II transmemranne CLRs initially 
discovered during search of DC surface receptors involved in DC and T-cell 
interaction. The identified receptor showed Ca dependent binding with ICAM-
3 and composed of a single extracellular C-type lectin like domain, a 
transmembrane and cytoplasmic tail. CLRs such as Dectin-l, Dectin-2, 
Langerin and MGL which signals either directly or indirectly through their 
interaction with some TLRs are expressed on APCs and largely used for the 
antigen targeting and have a lot of scope to treat different infectious diseases 
(Tacken et al., 2006). 
1.6.2.4 MR 
Mannose receptor (MR, C020S) was the first discovered member of the MR-
family, found to be involved in the clearance of endogenous glycoproteins. MR 
was thus named because of its lectin activity to proteins glycosylated with 
mannose, fucose or N-acetyl glucosamine. MR demonstrates structural 
homology with other receptors, most significantly DEC205 (CD205), Endo 180 
and the phospholipase A2 receptor. MR is an endocytic receptor and type-I 
protein of molecular weight 175 KDa. It is composed of three extracellular 
domains: a Cysteine-rich (CR) domain that shows calcium independent binding 
with sulphated sugars; a Fibronectin type II (FNII) domain that is the most 
conserved region of MR and binds with collagen; and eight C-type lectin-like 
carbohydrate recognition domains that bind in a calcium-dependent manner 
with sugars or proteins terminated m mannose, fucose and N-
acetylaglucosamine. Moreover, it contains a transmembrane domain and a 
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short C-terminal cytoplasmic tail that mediate receptor intemalisation (East 
and !sacke, 2002) as shown in figure 1.6. 
•• 
CR : Cysteine- rich domain Recognises 
sulphated carbohydrates terminated 
in S04-(3)-Gal- or S04-(3/4)-GaINAc-
FNII . Flbronectln type II domain 
Binds to Collagen I II , III and IV 
CTLD: C-type lectin-like domain Binds complex 
carbohydrates terminated in mannose, fucose 
or N-acetyl -glucosamine 
Figure 1.6: Domain structure ofMR and their ligands. 
MR consists of tllree extracellular domains, CR: cysteine-rich domain, F II: domain-
containing fibronectin type rr repeats, CTLD: C-type carbohydrate- like domain and 
TM: transmembrane domain, CT: cytoplasm ic tail. 
1.7 Antigen targeting through MR 
Targeting of model antigen OVA through MR results in the cross presentation 
and activation ofT-ceil responses against OVA is the fascinating finding which 
make MR a strong candidate for the development of therapeutic vaccines 
against infections which need T-cell immunity such a viral and tumour 
infection (Burgdorf et aI., 2008). MR is an efficient endocytic receptor 
expressed by DC (CDllc+, MHC-!I+, CDllb+, DEC205+, CD8u-) in T-cell 
area of peripheral L in the presence of selected TLR agonists in mouse 
(McKenzie et aI., 2007) and, possibly, humans (Martinez-Pomares et al. 
unpublished). Importantly, it appears that the fate of Ag internalised through 
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the MR is dictated by the type of MR ligand and Ag presenting cell used, and, 
probably, by the differential engagement of additional PRR in each 
experimental model. 
1.7.1 Antibody mediated MR targeting 
Rather than using the mannosylated or mannan linked Ags, antigen delivery by 
using anti-MR Ab is the most specific and efficient method to deliver Ag to 
APCs (Keler et ai., 2007). Ramakrishna et ai. first described MR targeting by 
using human anti-MR mAB (B 11) fused with melanoma Ag, pmeIl7 (B 11-
pmeIl7). In this study monocyte derived DCs were fed with Bll-pme1l7 and 
co-cultrured with T -cells in order to generate Ag specific CD4+ and CD8+ 
effector T -cells. The reactivity of the effector T -cells was assessed by 
chromium release assay and they were found cytotoxic towards gp 100+ HLA 
matched melanoma targets. This study demonstrated that the antibody-
mediated targeting of exogenous tumour Ag through MR leads to the Ag 
presentation in context of MHC-I and MHC-II molecules and result in the 
induction of cytotoxic and helper T-cells (Ramakrishna et aI., 2004). In order 
to perform in-vivo studies transgenic mice expressing hMR were generated and 
immunized with B II-OVA fusion proteins. BII-OV A targeted OVA through 
MR and efficiently presented to CD4+ ad CD8+ Tcells which led to the 
induction of Ag specific humoral and cellular immunity. In order to assess T-
cell effector response mice were challenged with melanoma cells transfected 
OVA and hMR transgenic mice immunized with BII-OV A along with CpG 
induced OVA specific tumour immunity while WT mice failed to induce 
protective immunity (He et aI., 2007). Recently, Tsuji et al. fused a cancer 
testis Ag NY-ESO-l with anti-MR hmAb Bl1 (Bl1-NY-ESO-l) and found 
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that this construct efficiently target MR on APCs and result in antigen specific 
induction of CD4+ and CD8+ T-cells derived form PBMCs of cancer patients. 
These findings make MR-ESO fusion proteins a strong candidate to assess its 
potential for clinical cancer vaccine trials in cancer patients expressing NY-
ESO-I Ag (Tsuji et aI., 20 I 0). 
1.7.2 Chemical glycosylation of antigens to facilitate MR-mediated 
Ag targeting 
Mannosylation of Ags is a promising strategy to target DCs efficiently through 
MR and development of Ag specific immunity. Although antibody mediated 
targeting of Ags is the most specific and et1icient method to target DCs and the 
development of vaccines but the generation of the antibodies is an expesive, 
time taking and immunogenic in many patients. Synthetic carbohydrates can be 
used alternatively to target DCs and the development of vaccines (Adams et aI., 
2008). Tan et aI. chemically linked 2-6 mannose residues with the Ag petides 
and showed that mannosylated peptides or proteins were 200 to 10,000 times 
more efficient in inducing MHC-II restricted T-cell proliferation (Tan et aI., 
1997). In another study 6 different types of carbohydrates were conjugated 
with model Ag OVA by using cross-linker molecule SMCC. Carbohydarte-
OV A conjugates increased the efficiency of antigen presentation by DCs via 
MHC-I and MHC-II molecules and leads to a 50 fold enhancement of Ag 
presentation to CD4+ T-cells and 10 fold to CD8+ T-cells (Adams et aI., 2008). 
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1.7.3 MR-mediated targeting of glycosylated proteins expressed in 
fungi 
Fungi have a natural ability to glycosylate proteins with mannose residue. Lam 
et al. generated recombinant glycosylated OVA Ags containing N an O-linked 
glycosylation in the yeast Pichia pastoris which were found more potent to 
induce OVA specific CD4+ T-cell proliferation as compared to unglycosylated 
OVA proteins expresseid in Escherchia coli (Lam et al .. 20(5). Most of the 
licensed vaccines for humans are based on the induction of antibody mediated 
immune response. However the induction of cell mediated ann of the immune 
response is essential to provide protection against tumours and viral infections. 
In order to induce CTL immunity Stubbs et al. used recombinant 
Saccharomyces cerevisiae yeast expressing tumour or HIV-I Ag. In vivo 
immunisation of recombinant yeast expressing OVA provided protection 
against tumour fonnation in E.G7-0VA tumour model in which mouse EL-4 
lmyphoma cells transfected with OVA have beed employed (Stubbs et aI., 
2001). 
Luong et ai. assessed the effect of fungal Nand O-lniked glycosylation on 
antigen specific CD8+ T-cell proliferation (Luong et aI., 2007). During 
glycosylation in P pastoris, the N-linked glycan structure has high mannose 
configuration as compared to O-linked glycans consist of only 2-3 mannose 
residues (Trimble et aI., 2004). Fungal O-linked glycosylation of OVA was 
found to increase T-cell proliferation while N-linked glycosylation led to 
decreased T-cell proliferation which may be due to the antigen uptake by 
different mannose receptors (MRs). Mannosylated proteins target MRs such as 
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MMR (CD206) and DC-SIGN expressed on DCs. Oligosacharides containing 
tenninal mannose binds MMR and deliver Ag into EER where it is cross 
presented the Ag on MHC-I molecule (Burgdorf et ai., 2007) while the Ags 
associated with high mannose structures binds with DC-SIGN and delivered to 
late endosome and MHC-II presentation pathway (Guo et ai., 2004). 
1.7.4 MR-mediated delivery of Ag by using liposomes with 
associated sugars 
Liposomes are good carriers for the vaccines and drug delivery also less they 
are immunogenic and non-toxic which makes them an attractive vaccination 
vector (AI tin and Parish, 2006). Liposomes structures are flexible and could be 
manipulated in tenns of its composition and the type of cargo (Ag, adjuvant or 
cytokines) to generate CTL immunity. Enhanced phagocytosis and stability of 
liposomes in the blood circulation are required to induce liposome mediated 
CTL immunity. In order to stabilize the structures of liposomes and to 
increased the retention time of liposomes in the blood, PEG-moditied 
liposomes have been employed which greatly enhanced the generation of CD8+ 
T -cell responses (Lasic et ai., 1991). To increase phagocytosis liposomes have 
been coated with carbohydrates which facilitated the delivery liposomes 
vesicles to APCs through MRs which led to more phagocytosis and effective 
induction of CTL immunity (Sallusto et aI., 1995). Kojima et al. evaluated the 
potential of oligomannose-coated liposomes (OMLs) to deliver tumour Ag to 
APCs and generate effective anti-tumour immunity. Mice immunized with 
OMLs carrying OVA Ag showed strong cytotoxic activity against E.G7-0VA 
melanoma cells and reduced the tumour growth. Similar tumour regression was 
observed when EL4 tumour cell lysate was also used as antigen in OML based 
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immunisation. This study indicates that OMLs-based vaccinations lead to the 
induction of antigen specific CTL immunity and can be clinically usefull in 
cancer immunotherapy (Kojima et al., 2008). 
1.7.5 Glycopolymers to deliver antigen through MR 
Gylcopolymers and their application in the development of vaccine by antigen 
targeting to APCs through MR is described in chapter 6. 
1.8 Aim of the project 
The basic aim of this project is to dissect how the interaction between MR and 
a MR ligand-Ag complex influences Ag processing and T-cell differentiation. 
To address this question we propose the following aims: 
1. Generation of recombinant proteins consisting of the model Ag 
ovalbumin (OVA) fused to the binding site of the anti-MR mAb 503 
and detennination of the nature and magnitude of C04+ T-cell and 
C08+ T-cell responses elicited by 5D3:0VA in vitro and in vivo in the 
presence or absence of selected ligands for Toll-like receptors. 
2. Chemical coupling of anti-MR mAbs and their isotype control to the 
melanoma Ag TRP-2 and assess their potential to induce TRP-2 
specific CO 8 T-cell response in vitro and in vivo when immunised in 
the presence of adjuvant. 
3. Conjugation of recombinant OVA mini-protein containing important 
CD4+ and CD8+ epitopes to different novel glycopolymers to analyse 
their ability to induce T-cell activation in vitro. 
Our results will be greatly helpful in the development of antigen delivery 
methods suitable for robust T-cell activation. 
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2 Materials and methods 
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2.1 General Materials 
2.1.1 Mice 
Wild type (WT) C57BLl6, MR-/- mice on a C57BLl6 background (Lee et aI., 
2002) and BALB/C mice were bred, at BMSU under specific pathogen-free 
conditions while wild type (WT) mice were purchased from Charles River. In 
all experiments, mice between 7 to 10 weeks of age were used according to the 
local animal handling and experimentation guidelines of The University of 
Nottingham. 
2.1.2 Media 
1- RIO medium 
RPMI 1640 (Gibco Invitrogen, UK) 
10% volume/volume (V/V) fetal calf serum (FCS) (Gibco Invitrogen, UK) 
100U/ml Pencillin-l O O ~ g / m l l Streptomycin (Sigma-Aldrich, UK) 
2 mM L-glutamine (Gibco Invitrogen, UK) 
For dendritic cells culture RIO media was supplemented with mouse GM-CSF 
(R&D sytems UK) and also FBS used in this medium was low endotoxin, 
filtered instead of heat inactivated high quality FBS purchased from Sigma 
(Catalogue no. F6178). 
2- DMEMIO medium 
DMEM Glutamax plus medium (Gibco Invitrogen, UK) 
10% volume/volume (VN) fetal calf serum (FCS) (Gibco Invitrogen, UK) 
100U/ml Pencillin-l O O ~ g / m l l Streptomycin (Sigma-Aldrich, UK) 
2mM L-glutamine (Gibco Invitrogen, UK) 
3- OPTI-MEM medium 
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Opti-mem Glutamax plus (Gibco Invitrogen, UK) 
100U/ml Penciliin-IOOJlglml Streptomycin (Sigma-Aldrich, UK) 
4- F12 medium 
F 12 medium Glutamax plus (Gibco Invitrogen, UK) 
100U/ml Pencillin-I 00 Jlglml Streptomycin (Sigma-Aldrich, UK) 
10% volume/volume (V/V) fetal calf serum (FCS) (Gibco Invitrogen, UK) 
5- [MDM complete mdium 
Iscove's Modiiied Dulbecco's Media ([MDM) medium (Gibco Invitrogen, 
UK) 
10-20% volume/volume (V/V) fetal calf serum (FCS) (Gibco Invitrogen, UK) 
100U/ml Pencillin-l OOJlg/ml Streptomycin (Sigma-Aldrich, UK) 
2mM L-glutamine (Gibco Invitrogen, UK) 
2.1.3 Antibodies and Reagents 
503 and 6C3 have been previously purified in our laboratory from 
supernatants from 503 and 6C3 hybridomas respectively, MR-derived 
constructs such as CTL04-7Fc and CR-FNIICTLOI-3Fc were prepared in the 
lab by Dr. Martinez-Pomares as described (Martinez-Pomares et aI., 2006). 
GM-CSF was purchased from R&D System. Antibodies used for the 
phenotypic analysis of cells by F ACS are shown in Table 2.3. Anti-ovalbumin 
rabbit polyclonal antibody (Lifespan biosciences) was used to confirm the 
presence of OVA by western blotting. Common secondary antibodies used for 
western blotting and ELISA were HRP and AP labelled donkey anti-mouse 
IgG (Jackson Immunoresearch laboratories) and goat anti-rat-IgG (CHEMI-
CON). Antibodies used for the IL2 capture ELISA, rat anti-mouse IL-2 (Cat. 
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No. 554424), biotin rat anti-mouse IL-2 (Cat. No. 554426), and recombinant 
mouse IL-2 (Cat. No. 550069) used as ELISA standard, were purchased from 
BO Pharmingen, UK. 
Sr. No. Product Supplier 
1 Sensor Chip CMS R4 GE healthcare Biosciences 
2 HBS-EP Buffer G E healthcare Biosciences 
3 Acetate buffer pH4.0 GE healthcare Biosciences 
4 Acetate buffer pH4.S GE healthcare Biosciences 
5 Acetate buffer pHS .O GE healthcare Biosciences 
6 Acetate buffer pHS .S G E healthcare Biosciences 
Table 2.1: Reagents and buffers used in the BIACORE studies. 
TLR Agonist SOllr('e/Slipplier 
TLR4 Monophosphoryl Lipid A (MPLA) Alexis Biochemicals, UK 
from Salmonella minnesota R59S 
(TLR grade) 
TLR-9 CpG-B (OON 1826) Alexis Biochemicals, UK 
TLR-4 Lipopolysaccharide (LPS) In vi vogen, UK 
, , 
Table 2.2: Reagents used as mnate stimuli 10 ImmuDlsatlOn studies. 
Antigen Conjugati(}11 Clone [ .... ·(}type Source 
CD206 Alexa488 MRS03 Rat [gG2a Biolegend, UK 
(MR) 
CDllb PE/Cy7 M I170 Rat [gG2b K BO 
Pahrrningen, 
UK 
CDllc PE HL3 Armenian BO 
Hamster Pahrrningen, 
[gGI , /",1 UK 
MHC-U PEiCyS MS/l14.IS .2 Rat [gG2b, K Ebio ciences, 
UK 
CD80 PE 16.IOAI Rat IgG2a Ebio ciences, 
UK 
CD86 PE GLI Armenian Ebiosciences, 
Hamster [gG UK 
CD24 PE 30.F t Rat [gG Abeam, UK 
CD206 unconjugated MR503 Rat [gG2a Prepared in our 
(MR) lab 
CD3 Unconjugated KT3 Rat IgG2a Prepared in our 
lab 
CD68 Unconjugated FA.11 Rat IgG2a Prepared in our 
iMacrosialin) lab 
Donkey anti- A1exa- Secondary Invitrogen 
Rat Fluor488 Ab. 
Table 2.3: Antibodies (Abs) used for F ACS staining and immunohistochemistry. 
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2.1.4 Buffers 
1- Tris-saline Buffer 
10 mM Tris-HCI (pH 7.4), IOmM CaCI 2, 154mM NaCI 
2- Cell Lysis buffer 
10 mM Tris-HCI, pH-8, 2% Triton X-I 00, 150 mM NaCI, 2 mM NaN), 2 mM 
Complete, Mini, EDTA-free inhibitor cocktail (Cat. No. 0469315900 I, Roche) 
1 tablet per 5 ml of lysis buffer) 
3- ELISA Washing Buffer 
PBS supplemmented with 0.1-0.05% Tween 20 (Sigma) 
4- ELISA Blocking Buffer (all other ELISA) 
PBS supplemented with 3% BSA 
5- ELISA Alkaline phophatase (AP) substrate buffer 
Distilled water containing 100mM Tris-HCI pH 9.5, 100 mM NaCI, 1 mM 
MgClz.6H20 . 
6- ELISA Alkaline phophatase (AP) substrate solution 
p-Nitrophenol phosphate tablets (Sigma) prepared at 1 mg/ml In Alkaline 
phosphatase (AP) Substrate Buffer 
7- TBS 
10 mM Tris-HCI, pH 7.5, 10 mM Ca2+, 154 mM NaCI and 0.05% (w/v) Tween 
20 
8- TBS-IM NaCI 
10 mM Tris-HCI, pH 7.5, 10 mM Ca2+, 1M NaCI and 0.05% (w/v) Tween 20 
9- PBS 
Prepare from tablets; I tablet per 100mi dH20 (Oxoid Ltd. UK) or purchased 
from SIGMA 
10- FACS Blocking Buffer 
PBS, 5% v/v normal rabbit serum (Gibco), previously heat inactivated at 56 C 
for 30 mins. 0.5 % (w/v) BSA, 5mM EDT A, 2mM NaN) 
11- F ACS Washing Buffer 
PBS, 0.50 w/v BSA, 5mM EDT A, 2mM NaN3 
12- FACS Fixing solution 
PBS supplemented with 1% v/v formaldehyde (Sigma) 
13- Ultra Pure Distilled water (DNase, RNase free) 
Used for DNNRNA work. 
14- SDS-PAGE Running buffer 
25 mM Tris, 90 mM glycine, 0.1 % SDS (Biorad) 
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15- SDS-PAGE Loading Buffer (4X) 
0.25 M Tris-HCl pH6.8, 8% SDS, 40% Glycerol, 0.1 % Bromophenol blue, 
dH20 
16- Western Blot Blocking buffer 
PBS, 5% (w/v) non-fat milk powder, 0.1 % Tween 20 
17- Western Blot Wash Buffer 
PBS supplemented with 0.1 % Tween 20 
18- Western Blot Transfer Buffer 
25 mM Tris, 90 mM glycine, 20% methanol (Biorad) 
2.2 General Methods 
2.2.1 Protein expression and its downstream processing 
Routine plasmid DNA isolation was done with the Qiagen mini prep kit 
following the manufacturer instructions but for transfection and protein 
expression large scale endotoxin-free plasmid isolation was done using the 
endotoxin-free plasmid DNA isolation kit (MACHEREY-NAGEL) following 
the protocol provided. 
HEK-293T were grown in DMEM medium supplemented with FCS (10%), 
Glutamine (2mM), penicillin and streptomycin (I OOU/ml) until cells reach at 
50-60% confluency. As HEK-293T are highly prone to sloughing o f t ~ ~
changing the media and washing had to be done with great care. On the day of 
transfection media was replaced with 25ml of fresh complete DMEM media in 
the morning. In the afternoon endotoxin free plasmids (l8Ilg) were mixed with 
Gene juice (Novagene), or home prepared Polyethylenimine (PEl) transfection 
reagent (54Jll) in OPTI-MEM medium (1.8ml) and added onto the HEK-293T 
dropwise cultured in T -175 tissue culture flask. The day after transfection the 
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media was replaced with OPTI-MEM supplememnted with Glutamine (2mM), 
penicillin I OOU/ml-streptomycin 100/lg/ml. After 4-5 days the supernantan was 
collected and centrifuged at 21 ~ O g g for 15 mins two times. The supernatant was 
filtered using a 0.2/lm filter (Ministart) and stored at 4°C. Protease inhibitors 
(Roche) were added in some instances. 
2.2.1.1 Protein purification by Affinity Chromatography using Protein G 
and Protein A Sepbarose 
The antibodies and recombinant proteins 10 supernatants were purified by 
affinity chromatography on Protein G Sepharose (GE Healthcare, Amersham, 
UK), Protein A-Sepharose (GE Healthcare, Amersham, UK) or by using nickel 
column (GE Healthcare, Amersharn, UK) depending on the nature of protein. 
Antibodies were eluted by using 0.1 M glycine (pH 2.8), and immediately 
neutralising with 1 M Tris-HCI (pH 8). The fractions collected were dialyzed 
against phosphate-buffered saline (PBS) using a dialyser cassette (Pierce, UK) 
in order to remove the low molecular weight contamination. Concentration of 
the purified Abs and other molecules was determined by SCA protein 
quantification assay which is based on bicinchonininc acid (SCA) for the 
colorimetric detection and quantification of proteins (Pierce, UK). BeA Assay 
was performed according to the manufacturer's instructions by comparison 
with a standard curve made from BSA standards prepared in same diluents as 
the test samples. 
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2.2.1.2 Nickel affinity chromatography purification of His-tagged 
recombinant proteins 
His-tagged proteins were purified using nickel-agarose columns (I mL His-
Trap HP column, GE Healthcare), exploiting the high affinity interaction 
between the nickel ion and the 6x histidine tag incorporated into the proteins. 
Protein was purified from 50 ml culture supernatant using an AKT A Prime 
apparatus. The column was first equilibrated in 5 column volumes of binding 
buffer (PBS containing 300 mM sodium chloride). The supernatant was loaded 
onto the column and the column was washed in buffer A (NaHzP04 20mM, 
NaCI 300mM and Imidazole 10mM). The elution procedure used consisted in 
rising step-wise increments in the concentration of imidazole to reach to 
500mM in PBS with 300mM sodium chloride. All components (t1ow through, 
starter and eluted materials) were collected. Eluted components were analysed 
by SDS-PAGE and fractions containing the required protein were collected and 
concentrated using ultra-IS centrifugal filter device (Millipore) with a 5 kDa 
molecular weight cut off. 
2.2.2 SDS-PAGE 
2-5Jlg of purified proteins samples were prepared in I x SDS-P AG E loading 
buffer (0.12mM Tris-HCI, pH 6.8, O.4%SDS, 5% glycerol, 0.02% 
bromophenol blue, dH20) containing 5% ~ - m e r c a p t o e t h a n o l l as reducing agent 
if required. The protein samples were heated at 100°C for 5 minutes and loaded 
into a 6-12% SDS-PAGE using Mini-PROTEAN III gel system (BioRad, 
USA). Electrophoresis was performed at 30 rnA The gels were stained in 
Simply Blue safe Stain ([nvitrogen) for one hour and destained in distilled 
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water for one hour according to the manufacturer's instructions. Gels were 
dried and stored using gel drying system (Invitrogen) according to the 
manufacturer's instructions. 
2.2.3 Western Blotting 
Gels were transferred to Hybond C membranes using a wet transfer apparatus 
over night at 200 rnA. After transfer, filters were incubated in blocking buffer 
(5% non-fat milk in PBS-O.I % Tween 20) for one hour. After this the primary 
antibodies were added diluted blocking buffer and left to shake for an hour. 
After washes in blocking buffer secondary antibodies peroxidase 
conjugateddiluted in blocking buffer were added for I hour after which the 
filters were washed 3 times with PBS-O.I % Tween. The tilters werer then 
incubated for one minute with EeL Western Blotting Detection Reagents (GE 
Healthcare) and dried with blotting paper. The tilter was placed in the Kodak 
exposure box under a transparent sheet, and in the dark room the Kodak x-ray 
film is placed onto the transparent sheet and closed for a number of seconds 
depending on the exposure sought. The X-ray film was developed manually 
and hung to dry in an airing cupboard. 
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2.2.4 ELISA 
2.2.4.1 ELISA 
MAXISORP 96 well flat-bottomed plates (Nunc Cat no 439454) were coated 
with 5 Jlglml of antigen in PBS and incubated overnight at 4'C. The next day 
the plate was twice washed with PBS and blocked with 3% BSA in PBS tor an 
hour at 3TC. [t was then washed and incubated with primary antibodies diluted 
in PBS for 1 h. After washes secondary antibodies conjugated to alkaline 
phosphatase diluted in PBS were added for one hour. The plate was again 
washed, followed by 2 washes with AP developing buffer (100mM Tris-HCI, 
100mM NaCI, ImM MgCh.6H20 pH 9.5), before being incubated with 
Imglml of p-nitrophenyl phosphate substrate (SIGMA) diluted in AP buffer. 
The 00 absorbance was measured at 405nm on a 96-well plate reader 
(MultiskanEX; Labsystem) after incubating the plate for a few minutes at room 
temperature (3-5mins). All washes and incubations were carried out in 250JlI 
PBS 0.1 % (V/V) Tween-20 unless stated otherwise. 
2.2.4.2 Lectin ELISA 
The binding of different ligands to MR-constructs was analysed by Lectin 
ELISA. MAXISORP 96 well flat bottomed plates were coated with 50 JlI of 
relevant ligand or control sugars at required concentration diluted in PBS and 
sealed in parafilm before being incubated overnight at 4'C. The next day the 
plates were washed 3 times with TBS (10 mM Tris-HCI, pH 7.5, 10 mM Ca2+, 
154 mM NaCI and 0.05% (w/v) Tween-20) and incubated with 5 Jlglml of MR 
constructs (CTLD4-7-Fc or CR-FNII-CTLDl-3Fc) for 1.5-2 hours at room 
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temperature. Then, they were washed 3 times with TBS and incubated with a 
I: I 000 dilution of anti-human IgG Fe-specific, alkaline phosphatase conjugate 
in TBS (SIGMNJackson Laboratories) for an hour. The plates were again 
washed 3 times with TBS, followed by 2 times with AP developing buffer (100 
mM Tris-HCI, 100 mM NaCl, I mM MgCh.6H20 pH 9.5), before being 
incubated with 1 mg/ml of p-nitrophenyl phosphate substrate (S IGMA). The 
00 absorbance was measured at 405nm on a 96-well plate reader 
(MultiskanEX; Labsystem) after incubating them for couple of minutes (3-
5mins). Note that all washes were carried out in 2 5 0 ~ 1 1 TBS unless stated 
otherwise. Incubations were performed in 50 ~ l l and development in I 00 ~ l . .
2.2.4.3 Inhibition ELISA 
To confirm the specificity of the binding of MR constructs, 2 ~ g l m l l solutions 
of MR constructs were prepared in TBS-I M NaCI with or without the 
competing sugars (D-galactose or D-mannose 50 mM) and incubated for 30 
min at room temparature. These solutions were then used for the incubation 
with the test ligands. The rest of the procedure was performed as described in 
the previous section. 
2.2.4.4 IL-2 Capture ELISA 
A 96-well microtitre plate was coated with capture monoclonal antibody rat 
antimouse IL-2 (PharMingen; Cat: 554424) I :500 diluted in PBS, overnight at 
4°C. A blocking buffer (PBS, 10% FCS, 0.1 % NaN) was then added after 
washing 3 times with PBS-0.05% Tween-20 followed by 45 min incubation at 
37°C. Again, the plate was washed 3 times in washing buffer (PBS 
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supplemented with 0.05% Tween -20) before transferring 50fll of supernatant 
or recombinant mouse IL-2 (cat: no. 550069) standard diluted in RIO media to 
appropriate wells and left at room temperature for 2 hours. After that wells 
were washed 4 times with PBS/Tween, and biotinylated secondary mAb rat 
antimouse IL-2 (PharMingen; Cat: 554426) was added which was made at 
1 :400 diluted in blocking buffer. After I hour, wells were washed with 
PBS/Tween, and a 1:1000 dilution of ExtrAvidin-AP (Sigma; Cat: E3626) was 
added for another hour, washed thoroughly 4 times with PBS/Tween, and 2 
times with AP developing buffer before p-nitrophenyl phosphate substrate 
(SIGMA) was added into each wells. The 00 value absorbance was read at 
405nm. 
2.2.5 Endocytosis assay 
In order to analyze MR mediated internalization capacity Chinese Hamster 
Ovary (CHO) cells expressing MR (Martinez-Pomares et aI., 2003) were used. 
The CHO-MR and CHO cell lines were grown in 24-well plates in F 12 media 
(Invitrogen) containing 10% FBS and 100U/ml Pencillin-IOOflg/ml 
Streptomycin. Once the cells were ready reached desired density the media was 
removed from the wells and Iml of the F-12 with Glutamax andlOOU/ml 
Pencillin-l00flg/ml Streptomycin (PIS) was added to remove the serum and 
cells were incubated for 30 minutes at 37°C. The plate was washed with PBS. 
Next, test ligands were added diluted in RPMI 1640 containing PIS. After 30 
minutes incubation, cells were fixed with 2% formaldehyde in PBS on ice for 
20 minutes, washed with PBS (Iml per well) and permeabilized and blocked by 
incubation with 0.1 % saponin in blocking butfer (5% heat-inactivated rabbit 
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serum; 0.5% BSA; 2mM NaN3; 5mM EOT A in PBS) tor 30 minutes. To detect 
uptake of rat anti-MR antibodies cells were incubated with anti-rat IgG-Alexa-
488 on ice for one hour followed by three washes with washing butTer (0.5% 
BSA; 2 mM NaN3; 5 mM EOTA in PBS) containing 0.1 % saponin. Then, 
250111 of 2mM Trypsin-EDT A solutions were added into each well and left for 
few minutes. Cells were detached and transferred to F ACS tubes containing 
250111 of 2% formaldehyde. Samples were analysed on a Cytomics FC500 
(BeckmanCoulter), flow cytometer and data was analysed using WEASEL 
software. 
2.2.6 Labelling and flow cytometric analysis of cells 
Supernatants were removed and cells were incubated with 50 ul of blocking 
buffer containing 10ug/ml of 2.402 (Anti-Fc receptor Ab) on ice for 30 
minutes. Then they were mixed with SOul of 20uglml of labelled antibody in 
F ACS blocking buffer and kept on ice for an hour. Cells were washed 3 times 
with FACS Wash (0.5% BSA; 2 mM NaN3; 5 mM EOTA in PBS). They were 
transferred into F ACS tubes containing 250 ul of 2% formaldehyde in PBS. 
Flow cytometry was performed on a CytomicsFC500 (BeckmanCoulter) and 
data were analysed with WEASEL software. The cells were labelled with 
following antibodies along with their isotype controls; anti-MR (503) labelled 
with Alexa-488, anti-MHC class II of PECy5 labelled, anti-COlIc of PE 
labelled and anti-Oectin-l FITC-Iabelled. 
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2.3 Culturing of primary cells 
Tissue culture plastic was purchased from BD Biosciences (UK), BDH (UK), 
Coming Corporation (USA) and Fisher scientific (UK). 
2.3.1 Harvesting mouse bone marrow and generation of GM-CSF 
induced DC (8M-DC). 
After removing all muscles and rotulas from the femurs and tibias with clean 
tissue, the bones were placed into a petri dish containing 70% ethanol for a 
minute to sterilise the bones. Then they were washed 3 times with RPM[+P/S 
medium. Both ends of the bones were cut with sterilised scissors and the cut 
bones were placed in a clean petri dish and the bone marrow was flushed out 
using 10 ml syringes filled with RPMI medium 1640 supplemented with 10% 
FBS (SIGMA-Aldrich), 2mM L-glutamine, 100 units/ml Penicillin-l 00 
units/ml streptomycin. 21 G needles were used for femurs and 25G for tibias. 
The bone marrow was centrifuged at 235g, 4°C for 5 min. Supernatant was 
removed and the cells were resuspended in -1 Oml of RIO medium containing 
GM-CSF 1000 U/ml (R&D systems catalog no.415-ML) while harshly 
pipetting in and out to break up the bone marrow. The cells then were counted 
before being plated in media in the presence of GM-CSF 1000 U/ml at density 
of no more than 4x 105cells/ml in 100 mmx20mm TC plates (Coming). Cells 
were placed in incubator at 37°C/ 5% CO2 and at day 3, the media was gently 
removed with vacuum by holding culture dish at shallow angle after gentle 
swirling, leaving enough media in the dish to cover the bottom so that the cells 
do not become dry. Media containing GM-CSF 1000U/ml was replenished 
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afterwards betore leaving them in the incubator. The same wash was repeated 
on day-6 and BMDCs were collected at day 7. 
2.3.2 Generation of bone marrow derived macrophages 
Bone marrow was collected according to the protocol described in section 2.3.1 
and resupended in 25 ml of RPMI medium 1640 supplemented with 10% FBS, 
2 mM L-glutamine, 100 Ulml Penicillin, I O O ~ g 1 m l l streptomycin and 15% L-
conditioned media (LCM) added to alSO mm petri dish. On day 3, 15 ml of 
RPMI complete media was added into each petri dish. On day 6 the old media 
was replaced with the fresh 25 ml RPMI complete media containing LCM. 
Macrophages were collected by treating the cells with cold PBS containing 
10mM EDT A. Macrophages were resuspended in RPMI complete media and 
plated for further use. 
2.3.3 Generation of monocyte derived human dendritic cells 
The blood was mixed with PBS or Hank's solution at a I: I ratio. The mix was 
layered on Sml of histopaque (Histopaque-l 077, Sigma-Aldrich, UK) using a 
Pasteur pipette and centrifuged at 800 g for 23 minutes (acceleration I, de-
acceleration 0). After centrifugation, peripheral blood mononuclear cells 
(PBMC) were collected using Pasteur pipette, diluted with 30 to 40 ml of 
Hank's and centrifuged again and resuspended in IOml of Hanks followed by 
cell counting. Cells (107) were incubated with mouse anti-human CD 14 mAb 
conjugated to magnetic beads (20 1Jl) in 80 IJI MACS butfer (Miltenyi Biotec, 
UK) for 20 min at 4°C,. The cells were washed with Ix MACS buffer and 
loaded onto MS-Column in the presenc of a magnetic tield; the column was 
washed three times with 50IJI MACS buffer and removed from the magnetic 
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field and cells were collected into a new tube with 2 ml MACS buffer by 
applying a plunger. The cells were washed with RPMI medium and 
resuspended in DC-medium (RPMI + 10% FCS) supplemented with IL-4 (250 
IU/ml) and human GM-CSF. Fresh DC-media supplemented with human IL-4 
and human GM-CSF (50 nglml) (R&D Systems) was added at day 3. Dendritic 
cells were used at day 6. 
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3 Generation of chimeric anti-MR Ab by genetic 
engineering 
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3.1 Introduction 
DCs are professional APC that have much scope for the development of 
vaccines through different immunotherapeutic approaches. Synthetic peptides 
or antigens have a very short half life and do not induce strong immune 
responses as they don't speci ficall y target the APCs. Therefore di fferent 
strategies are adopted; including immunisation with DCs pulsed with 
appropriate Ag, naked DNA using gene gun methodology and mixtures of Ags 
and adjuvants (Bellone et aI., 2000). A new trend in the immunotherapy is to 
deliver protein Ags to the APC using receptor-specific Abs. Targeting Ag 
through antibodies against DC receptors is the ideal technique due to their 
specificity and higher affinity (Keler et aI., 2007). Receptors used in Ag 
targeting mostly belong to the C-type lectin receptor (CLR) family, which are 
calcium-dependent lectins and share primary structural homology in their 
carbohydrate recognition domain (CRD). The common CLRs used in targeting 
studies are the mannose receptor (MR, CD206), CD205 and DC-specific 
intercellular adhesion molecule-3 (ICAM3)-grabbing non-integrin (DC-SIGN). 
Ag targeting through different receptors might result in different immune 
outcomes due to different intracellular receptor routing, signalling pathways 
and expression patterns (Tacken et aI., 2007). 
Targeting of antigen through MR using anti-MR antibody (Ramakrishna et aI., 
2004, He et aI., 2007, Tsuji et at., 201 0) or glycosylated Ags such as the model 
antigen ovalbumin (OVA) results in cross presentation and activation of 
cytotoxic T-cell responses. This fascinating finding makes MR a strong 
candidate for the development of therapeutic vaccines against infections that 
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require T -cell-mediated immunity such as viral infections and tumours 
(Burgdorf et aI., 2008). MR is an et1icient endocytic receptor expressed by 
murine bone-marrow derived DCs and its APC subtypes present in mice 
(Linehan et aI., 2001, McKenzie et aI., 2007). MR specitic antibodies fused 
cancer antigen NY -ESQ-l have been used to target dendritic cells specitically 
and result in the induction of antigen specitic C08+ and C04+ T-cells. OCs 
targeting through MR in the presence of an appropriate adjuvant leads to corss-
presentation of Ag and induce of powerful CTL immunity to facilitate 
immunotherapy of cancer (Tsuji et at., 2010). 
Martinez-Pomares and Reid et aI. described the first panel of mAb against 
murine MR and have characterised several mAb with distinct binding abilities 
(Martinez-Pomares et aI., 2003). While the anti-MR mAb 6C3 targets 
efficiently to MR+OC in vivo, investigation into the humoral responses elicited 
in response to anti-MR mAb demonstrated that another anti-MR specific Ab, 
with a higher affinity for MR, 503, elicited a more robust response than 6C3 
even though both Ab were raised against the same region of the receptor 
(McKenzie et aI., 2007). These results suggest that increased ability to bind to 
MR (as shown for 5D3) could lead to enhanced T-cell responses. Based on 
these observations we propose that one of the factors that could int1uence how 
MR-targeted Ag is presented to the immune system is the strength of the 
ligand-receptor interaction. Based on these observations and other studies 
showing antigen targeting through MR leads to cross-presentation, we aimed to 
generate chimeric anti-MR antibodies carrying model antigens. 
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The present chapter describes the generation of chimeric anti-MR mAb (503-
HEL) bearing a mutated Fe portion of mouse IgG 1 and a hen egg lysozyme 
(HEL) derived epitope. Plasmid constructs carrying anti-OEC205 Ab-HEL 
fused to a mutated Fc region of mouse IgG I (Clynes et aI., 2000), kindly 
provided by Prof Nussenzweig (Rockefeller University, New York) were used 
as starting materials. Binding properties of the anti-MR mAbs 503 and 6C3 
were compared using BIACORE. The variable regions; VH and VL of 503 
were cloned and used to replace the variable region of DEC205-HEL to obtain 
503-HEL. This chapter also describes expression of OEC205-HEL, 503-HEL 
and the control protein IgO I-HEL, and their initial characterisation in terms of 
their binding to OEC205 and MR respectively. 
3.2 Materials and methods 
3.2.1 Characterization of starting materials: 503 and 6C3 anti-MR 
monoclonal antibodies 
3.2.1.1 SDS-Polyacrylamide gel electrophoresis (PAGE) 
S - I O ~ g g of purified anti-MR mAbs were analysed usmg SOS-PAGE by 
following the protocol described in section 2.2.2. 
3.2.1.2 Two-dimensional gel electrophoresis and Q-TOF sequence analysis 
of spots corresponding to light chains 
Purified mAbs (SD3 and 6C3) ( 3 0 - S 0 ~ g ) ) were dissolved in rehydration buffer 
(Lysis buffer) containing 7M urea, 2M thiourea, 4% CHAPS (w/v), lOmM 
DDT, O.S% (w/v) carrier ampholyte (pH3-10) and 0.002% bromophenol blue 
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(w/v). The strips loading tray was washed with 10% SDS and rinsed with 
distilled water. The samples were loaded on the tray and 17cm pH3-10 IPG 
ready strips were placed over it carefully, ensuring no bubbles were formed 
under the lid. The tray was placed in a Biorad Protean isoelectric focussing 
(IEF) Cell and was set to passive rehydration mode at 20°C overnight. After 
rehydration the strips were transferred into the IEF cell and wet electrode wicks 
were placed underneath each strip. The conditions used for IEF were: 250V for 
15 min, 1O,000V for 3 h, 70,000 V for approximately 12 h and hold at 500V at 
20°C. After IEF, IPG ready strips were washed three times on the shaker for 15 
min in equilibration buffer-I, containing 50 mM Tris-Hel, 6 M urea, 29.3% 
(v/v) glycerol, 2.0% (w/v) SDS, 0.002% (w/v) bromophenol blue and 1% (w/v) 
dithiothreitol (pH 8.8). This was followed by an additional 15 min wash in the 
same buffer with 2.5% (w/v) iodoacetamide in place of dithiothreitol. After 
equilibration, the IPG strips were sealed on top of 12% SDS-PAGE gels with 
0.5% (w/v) agarose containing 0.002% (w/v) bromophenol blue. The SDS-
PAGE was run at a constant current of 60 rnA for 4 h, using Protean-II Gel 
electrophoresis system (Biorad). The gels were stained with Simply Blue safe 
stain (lnvitogen) and scanned onto a densitometer. Images were analyzed using 
PO Quest and spots of interest were cut from the gel for identification by Q-
TOF sequencing at the Biopolymer Synthesis and Sequencing Facility, 
University of Nottingham. 
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3.2.1.3 Analysis of binding properties of 5D3 and 6C3 by surface plasmon 
resonance (SPR) 
Binding properties of the Anti-MR mAbs, 503 and 6C3 were compared by 
surface plasmon resonance (SPR) using BlAcoreX (BAlcore AB). CM5 
research grade biosensor chips, N hydroxysuccinimide (NHS), N-ethyl-NO-(3-
diethylaminopropyl) carbodiimide (EOC), ethanolamine-HCI, and HBS-EP 
buffer were obtained from (GE Healthcare, UK). Recombinant ligands 
CTL04-7-Fc and CR-FNII-CTLOI-3 were expressed in 293T-cells and 
purified by affinity chromatography on Protein A Sepharose (GE Healthcare) 
in our lab as described in Material and Methods (Linehan et aI., 200 I) and used 
to assess MR specific binding of anti-MR mAbs. Two channels of a research-
grade carboxymethyl dextran chip (CM5) were activated with NHS/EOC for 5 
min to give reactive succinimimed esters and to facilitate the conjugation of 
ligands using an amine coupling procedure as described previously (Johnsson 
et aI., 1991). Recombinant ligands CTL04-7-Fc and CR-FNlI-CTLOI-3-Fc 
were diluted in sodium acetate buffers with different pH (pH5.S, pHS, pH4.5, 
pH4) to a final concentration of 30J.l.g/ml in each sample in order to tind out 
their appropriate immobilisation pH. The ligands prepared at pH 4.5 were 
injected until 10,000 resonance units (RU) of protein were coupled. Remaining 
activated groups were then blocked with a 5-min injection of I M ethanolamine 
(pH 8.5). After this, purified 503 and 6C3 at a range of concentrations (1.5-
3J.l.M) were injected over the chip in order to determine their binding capacity 
to the immobilised ligands. The dissociation phase was then monitored for 900 
s, followed by a 50 J.l.I injection of 10mM glycine, pH 2.0, to regenerate a fully 
active chip by removing the bound antibodies. All kinetic experiments were 
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performed at 25°C in a buffer containing 10mM Hepes, pH 7.4, 150mM NaCl, 
and 0.005% Tween -20, at a flow rate of 20llllmin. In control experiment, CR-
FNII CTLOI-3-Fc was used instead of CTL04-7-Fc to evaluate the non-
specific binding of 503 and 6C3, and rat IgG2a was used to assess non specific 
binding of antibodies. To remove contributions of non-specific binding and 
refractive index, the control responses were subtracted from those obtained 
from the active surface. The kinetics parameters such as the rate of association 
and dissociation were calculated using BlA evaluation software 3.1 (Biacore 
AB) (Myszka and Morton, 1998). 
3.2.2 Characterization of the DEC205-HEL and IgGI-HEL control 
3.2.2.1 Plasmids constructs 
The plasmid constructs encoding for the variable region of the control rat 
IgG2a (IgG I-HEL) and DEC205 (DEC205-HEL) fused to a mutated Fc region 
of mouse IgGI unable to bind Fe receptors (Hawiger et al., 2001) were 
provided by Prof. M. Nussenzweig (Rockefeller University). A DNA fragment 
encoding the HEL peptide 46-61 was present at the C-terminus of the heavy 
chains of these plasmid constructs. The DEC205-HEL vectors (Figure 3.1) 
contain the restriction sites EcoRI and Not-Ion both sides of the gene and have 
the ampicillin resistance gene for the selection of transformed bacteria but the 
exact nature of the expression vector was unknown. 
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EcoRI EcoRI 
DEC·205·HEL DEC-205-HEL 
Figure 3.1: DEC205-HEL vectors carrying the heavy and light chains of the anti-
mouse DEC20S-HEL antibody 
3.2.2.2 Plasmid DNA isolation 
Routine plasmid DNA isolation was done using the Qiagen mini prep kit 
according to the manufacturer s instructions. Endotoxin-free plasmid isolation 
was done using the endotoxin-free plasmid DNA isolation kit (MACHEREY-
NAGEL) following the protocol provided. 
3.2.2.3 Transformation 
Plasmids were transformed in the high efficiency DH5a competenT-cells or 
Top 1 0 (lnvitrogen) according to the manufacturer's instructions. The 
transformed cells were grown overnight in LB Agar (SIGMA) in the presence 
of ampicillin sodium salt (Sigma) (IOO)..lglml, Sigma) with X-gal, (40flglml , 
Roche) and [PTG (O. lmM, Roche) when required. 
3.2.2.4 Restriction digestion 
Roche restriction enzymes (EcoRI, NotI, Hpa[, Apa[ and PstI) were used in 
this work according to the manufacturer's instructions. Reactions were 
incubated at 37°C for 2-4 hours. 
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3.2.2.5 DNA Gel electrophoresis 
DNA samples were analysed using Sybersafe-stained 1-2% (w/v) agarose 
(Invitrogen) gel in Tris-Acetate-EDTA (TAE) buffer (4.8 gm/I Tris base, 1.14 
gmll acetic acid and mlM EDTA, pH 8.5) and analysed under the UV by Gel 
documentation and an imaging system. For the retrieval of DNA for cloning 
purposes Blue Light, Dark reader transilluminator (Clare Chemical Research) 
was used. In some instances gels were stained using Ethidium Bromide (10 
nglml). 
3.2.2.6 Gel extraction 
DNA was extracted from gels using the Qiagen DNA extraction kit according 
to the manufacturer's instructions. 
3.2.2.7 Ligation reaction 
DNA was ligated with the help of T4 DNA ligase (Roche) using a 3: I molar 
ratio of insert to vector in a final volume of 1 O ~ I I and incubated on ice 
overnight allowing the ice to thaw. 
3.2.2.8 Sequencing of the vector carrying DEC205-HEL 
Primers were designed on the basis of the known heavy chain sequence 
(Appendix-I) and obtained from MWG-Biotech. A partial sequence of the 
vector was obtained using the HR-I and HF-I primers in the Biopolymer 
synthesis and analysis unit, Nottingham University. The sequences of the 
primers are given in Table 3.1. 
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Table 3.1: Forward (HF -1) and reverse primers (HR-l) used for the sequencing 
of the vector carrying DEC205-HEL. 
3.2.2.9 Expression of DEC20S-HEL and IgG2a in HEK-293T 
DEC205-HEL and IgG2a-HEL antibodies were expressed in HEK-293T by 
following the protocol as described in section 2.2.1. 
3.2.2.10 Purification of DEC205-HEL and IgGI-HEL antibodies by 
affinity chromatography 
The supernatant collected from transfected cells was purified by affinity 
chromatography on Protein G Sepharose Gamma bind plus (GE Healthcare, 
Amersham, UK) as described in section 2.2.1.1. Containers used in protein 
purification such as beakers and tubings were washed in trigene, 0.5 M NaOH 
and rinsed in water and PBS to avoid LPS contamination 
3.2.2.11 SOS Polyacrylamide gel electrophoresis (PAGE) 
5-10l-lg of purified DEC205-HEL and [gG2a-HEL were mixed with SDS-
PAGE loading buffer containing 5% ~ - m e r c a p t o e t h a n o l l as reducing agent and 
resolved on a 12% SDS-PAGE by following the protocol described in section 
2.2.2. 
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3.2.2.12 Preparation of thymus lysate and its analysis by western 
blotting 
In order to prepare thymus lysate, mouse thymus was collected and sliced into 
pieces using a scalpel. The tissue was homogenized using mortor and pistle in 
the presence of lysis buffer (lOmM Tris-HCI, pH 8, 2% Triton X-IOO, and ISO 
mM NaCI, 2mM NaN3, 2mM EOTA) supplemented with protease inhibitors 
(Roche). This grounded tissue was centrifuged to eliminate the debris and 
insoluble material and soluble protein was quanti tied by BCA quantification 
method. 1 5 - 2 0 ~ g g of thymus lysate was loaded onto 6 % SOS-PAGE gels. Gel 
electrophoresis was performed at 30 rnA per gel; after all the samples had run 
through the gel, they were transferred to Hybond C (GE, Healthcare, UK) 
membranes using a wet transfer apparatus overnight at 200mA. 
Filters were incubated in blocking buffer (5% non-fat milk 10 PBS 0.1 % 
Tween- 20) for one hour. Primary antibodies (OEC205-HEL and [gGI-HEL) 
were then added at 2 ~ g l m l l in blocking butTer and left to shake for an hour. 
After washes the secondary antibody, donkey anti-mouse [gG peroxidase 
conjugated (Jackson laboratories) [diluted I :2000 dilution in Blocking buffer] 
was used for I hour and films were developed by following the protocol 
described in section 2.2.3. 
3.2.3 Amplification of the variable region of 5D3 monoclonal 
antibody using 5' -RACE 
3.2.3.1 Hybridoma culture and RNA extraction 
503 hybridoma cells were cultured in IMOM complete medium containing 
20% FCS. 5xlO6 to 10xl06 hybridoma cells were used for RNA isolation. The 
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cells were centrifuged for 10 min at 233 g. The supernatant was discarded and 
the cells were washed with PBS. Total RNA was iso lated using the A&B gene 
RNA isolation kit or the RNeasy Mini Kit (Q[AGEN), according to the 
manufacturer's protocols. 
3.2.3.2 cDNA synthesis 
cDNA synthesis was done according to the manufacturer' s instructions 
provided with the 5'RACE, Clontech kit using 5'CDS primer A mix (random 
primers) and the MML V reverse transcriptase (h1Vitrogen). 
3.2.3.3 Amplification of variable genes by 5'RACE 
5' primers were designed against the conserved regions of the heavy and light 
chain of rat immunoglobulin (rgG 2a kappa) for the 5' RACE in order to get the 
variable regions of the heavy and light chain of 503. The e primer were 
obtained from MWG Biotech; their sequences are shown in Table 3.2. 
Primer name Primer sequence GC content (%) 1m rC) 
VHC-1 TGACGGTCTCGCTGGGCCAGGTG 69.2 72.7 
CTG 
VKC-1 GAAGGAACTGGGGTGCAGGTGG 64.0 69 .5 
CAC 
Table 3.2: Primers designed against the conserved regions of the heavy (YHC-l) 
and light chains (VKC-l) for S'RACE and amplification of the variable regions 
ofSD3. 
5' RACE ready cDNA was used for the 5'RACE of the heavy and light chains 
using Clontech, ''SMART™ RACE cDNA Amplification Kit" and 
Adanvantage2 PCR enzyme system (Clontech), according to the following 
PCR programme: 
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5 cycles: 94°C 30 sec; 72°C 3 min 
5 cycles: 94°C 30 sec; 70°C 30 sec; 72°C 3 min 
25 cycles: 94°C 30 sec; 68°C 30 sec; noc 3 min 
5' RACE products were analysed by agarose gel electrophoresis (1 % w/v) and 
were extracted from the gel using the gel extraction kit provided with the 
SMART RACE cDNA amplification kit, or using QIAGEN gel extraction kit, 
according to the manufacturer's instructions. This extracted DNA was cloned 
into the 2.1 TOPO cloning vector provided with the TOPO T A cloning kit 
(Invitrogen, Figure 3.2) and transtormed into One Shot E.coli cells. The 
transformed cells were incubated overnight at 37°C on LB agar plates 
containing 100 Jig/ml ampicilln, 0.1 mM IPTG and 40Jig/ml X-Gal. White 
colonies were selected and screened by restriction digestion with EcoRI and 
colony PCR using M 13 forward primer and M 13 reverse primers. Positive 
clones were sequenced at Biopolymer Synthesis and Analysis unit of 
Nottingham University. 
3.2.3.4 DNA Sequence analysis 
Sequences obtained were analysed using MEGA 4.1 and SEQ-MAN software. 
DNA contigs of the clones were made by equating the forward and reverse 
sequences of the clones. DNA contigs of the clones were translated with 
MEGA 4.1 and nucleotide sequences of light and heavy chains were further 
analysed by IMGT V -Quest software (Ruiz et aI., 2000). 
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Figure 3.2: The map shows th e features of pC R®2.1-TOPO® and the sequence 
surrounding the TOPO® Cloning site 
3.2.3.5 Replacement of the variable region of anti-DEC205 (Hcavy and 
light chain) with the variable region of 503 by restriction cloning 
The variable region of O EC205-H EL was replaced with the variable region of 
50 3 Ab by restriction cloning. Restrict ion sites in the constant regions of the 
heavy and light chains were predicted by using the ' Gene Tool Lite' oftware. 
Restriction digestion was performed with the selected restriction enzymes in 
order to confi rm that they would cut onl y one pecific site in the who l 
plasmid. 
Restriction primers were designed based on the 0 A sequence of the heavy 
and light chains of the 50 3 and OEC205 -H EL antibodies. 
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Primer name Primer sequence GC content Tm (C) 
(%) 
FH (EcoR1 ) TATAGAATTCTGCCATGGACAGGCTTA 42.4 67.0 
CTTCCT 
RH (Apal ) ATATGGGCCCGTTGTTTCAGCTGAAGA 48.5 69.5 
CAGT 
FL (EcoR1 ) TATAGAATTCCACCATGGCCATGAAGA 50.5 70.7 
CGCCTGC 
RL (Hpal ) ATATGTTAACTGCTCACTGGATGGTGG 43.6 70.5 
GAAGATGGATAC 
Table 3.3: FH (EcoRI) and RH (ApaIA) are the forward and reverse primers for 
the heavy chain; FL (EcoRI) and RL (HpaI) are the forw ard and reverse primers 
for the light chain. Restriction sites are highlighted 
Clones carrying the vari able regions of the heavy and light chains of 50 3 were 
used as template and amplified wi th Advantage 2PCR kit (Clontech) on 
' Primus 96 advances Gradient Thermocycler' (peQLab) by adopti ng the 
fo llowing cycli ng parameters: 95°C fo r I min and 25-35 cycles; 95°C fo r 30 
sec, 68°C fo r I min, and 68°C for I min. PCR products carrying the relevant 
restriction sites and plasm ids were digested with the same set of enzymes and 
puri fied by gel extraction kit (Q[AGEN). The products were ligated into the 
pre-digested OEC205 -H EL vector using T4 DNA ligase (Roche) as described 
in section 3.2.2.7. Ligated clones are transformed into TO P-1 0 chemically 
competent E.co li and screened by colony PCR, restriction digestion and 
sequencing using the OEC-205-HE L vector specific primers as shown in Table 
3.4. 
Primer name Primer sequence GC content Tm (C) 
(%) 
MV-F-Primer CACATACGATTTAGGTGACAC 42.9 55.9 
MV-F2-Primer GGATCCCTGTCCAGCGGTGTGC 68.2 67.7 
MV-R-Primer GGTGCTGCGCGAATTAATTCCCGATCC 55.6 68.0 
Table 3.4: The product cloned into the DEC20S-HEL vector was sequenced by 
using vector specific primers such as MV-F and MV-R-primers . . MV-F2-Primer 
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was designed complementary to the constant region of the heavy chain to 
facilitate the sequencing of long strand of heavy chain insert. 
3.2.4 Expression of anti-MR chimeric antibody carrying REL 
antigen (5D3-HEL) and analysis of its bining properties using 
ELISA 
Chimeric antibodies (503-HEL) and isotype control (IgG I-HEL) were 
texpressed in HEK-293T. Antibody purification was performed as described in 
Section 2.2.1. Expression of the antibodies was confirmed by Western Blotting 
using donkey anti-mouse IgG conjugated to peroxidase according to the 
protocol described in Section 2.2.3. 
The binding of 503, 5D3-HEL (chimeric antibody) and their isotype controls 
was analysed by ELISA. MAXISORP 96 well flat-bottomed plates (Nunc Cat 
no 439454) were coated with 5J.lglml of chimeric antibodies. The coated plates 
were incubated overnight at 4°C. The next day the plate was twice washed with 
PBS and blocked with 3% BSA in PBS for an hour at 37°C. It was then washed 
with PBS 0.1 % (v/v) Tween-20 and incubated with 1: 1 000 dilutions of 
secondary antibodies: anti-rat IgG-AP (SIGMA) and anti-mouse IgG-AP 
(SIGMA) respectively for one hour. The plate was again washed 3 times with 
PBS 0.1 % (V IV) Tween-20, followed twice with AP developing butfer (l00 
mM Tris-HCI, 100 mM NaCI, 1 mM MgC12.6H20 pH 9.5), before being 
incubated with Imglml of p-nitrophenyl phosphate substrate (SIGMA) in AP 
buffer. The 00 was measured at 405nm on a 96-well plate reader 
(MultiskanEX; Labsystem) after incubating for a few minutes (3-5mins). All 
washes and incubations were carried out in 250111 PBS 0.1 % (V/V) Tween-20 
unless stated otherwise. 
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3.3 Results 
3.3.1 Characterisation of anti-MR mAbs 503 and 6C3 
3.3.1.1 Analysis of the binding properties of 503 and 6C3 using Surface 
Plasmon Resonance (SPR) 
We hypothesised that the strength of interaction between MR and anti-MR 
mAb could influences Ag processing and T-cell differentiation. The binding 
pattern of two anti-MR mAbs (503 and 6C3) was analysed and compared 
using BIAcore, to quantitatively study their interaction with MR. In order to 
immobilise the required reactive units of the ligands on the chip, the binding of 
ligands CTL04-7-Fc and CR-FNII-CTLOI-3-Fc (Martinez-Pomares et aI., 
2006, Zamze et aI., 2002) to the chip surface was analysed at different pHs 
(pH5.5, pHS, pH4.5, pH4). Optimal binding of the recombinant ligands to the 
chip was observed at pH 4.5 (Figure 3.3). Once MR ligands were immobilised 
onto the two channels of the biosensor chip, 503 and 6C3 mASs were passed 
over them at different concentrations (in the range 0 . 2 5 ~ M M - 3 . 0 ~ M ) ) to analyse 
their binding characteristics. The association rate of 6C3 (1.6Ie-4) was found 
higher than that of 503 (1.Ie-4); however, the dissociation rate of 6C3 (2.27e3) 
was also higher than 503 (1.83e3), indicating that the interaction of 503 with 
MR (CTL04-7 Fc) is more stable than 6C3 (Table 3.5). 
70 
Chapter 3 Genera ti o n o f chimeric anti-MR a ntibodies 
;., ~ J J,,,., 
lIOOl 
'JXO 
i -
r-.. ~ ~I .., 
. -~ ~ i 
:-1 '--.r- . 
--' 
JXl 
~ I I L 
-
lXD ' 
. 40 . ~ ~ ;0 II 1'Tl II 1m H 
A />1 B !tl 
Figure 3.3: pH-dependency of the coupling of CTL04-7-Fc and CR-FNII-
CTLOI-3Fc to the sensor chip. 
Sensograms show the binding of recombinant ligands ( ) CTL04-7 -Fc and (8) R-
FRU-CTLOl-3-Fc via amine coupling to the chip at pH 4.0, pH 4.5 , pH 5.0 and pH 
5.4 
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-
CTLD4-7 (Channel-1) 
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503 6C3 IgG2a 
' - - _ ~ : ~ ~ CTLD4-7 
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Figure 3.4: Specific recognition of CTL04-7-Fc by anti-MR mAb 503 and 6C3. 
Sensor chip was coated with MR ligand such CTL04-7-Fc and CR-F [I in channel-l 
and channel-2 respectively. Curves shown in red line indicate the binding of 503 , 6C3 
and IgG2a with CTL04-7-Fc and in green it how their binding with CR-F II , u ed 
as a negati ve control. 
71 
Chapter 3 Generation of chimeric anti-MR antibodies 
RU III 
4IXI 
<XI) • 
-
3 C ~ ~ I I ~ . .
3 ' . . ~ I I
J 
15 .J1\' 15 ~ t t
( .,,-') :311 . r- o - ~ ~ It<1 
Ot .'p\ 1 
Ibl 0 5 0 0 1 1 1 . 11 30< 
o . ~ : : ~ i V l l I O ~ · · ~ M M
00 
• 1S , ~ ~ 1i1 Zi1 n lie. .ICO · 
. 
-
. I' .:s is 115 ,;OS ) ~ ~ l iS 
A 
,. 
B n. 
Figure 3.5: ensogram showing the binding characteristics of 503 (A) and 6C3 
(B) at different concentrations from O.2J.1M to 3.0J.1M. 
Table 3.5: Association (Ka) and dissociation (Kd) rate, and association (KA) and 
di sociation (KO) constant of anti-MR mAbs (503 and 6C3) derived from 503 
and 6C3 sensoaram data using BlA evaluation software 3.1 (Biacore AB) 
(Myszka and Morton, 1998). 
3.3.2 Cloning and sequencing of the variable region of 503. 
U ing as template the total R fro m the 5D3 hybridoma, 5' ready cD A wa 
ynthesised using the method described in Material & Methods. Both RNA 
and cD A were analysed on 1.25% agaro e gel to confirm their quality and 
identity. R A fro m the hybridoma howed two band typica ll y imilar to 
mammali an R at 4.5Kb and 1.9Kb corre ponding to the 28 and 18S 
ribo omal RN (Figure 3.6 A). The region encoding the variable region of the 
heavy and light chains of 50 3 were amplifi d using Taq polymera with gene 
specific primer (GSP) (Table 3.2) and uni ver al primer mi x (U PM), as 
de cribed in Materi als & Methods. P R product were eparatcd on a 1% 
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preparative agarose gel with the V H of 503 appearing as a bright band of 
:::::750bp, while VL amplification was suggested by a band of :::::900bp (F igure 
3.6 B). Both bands were cut and the 0 A was purified. 
Gel purified V H and V L were cloned into the pe R 2. 1 vector (F igure 3.2) and 
transfo rmed into One Shot competent E. coli. T he clones were selected on LB-
agar plates containing IPTG and X-Gal. 15 white co lonies deri ved from the VL 
ligation and 25 white co lonies deri ved from the VH ligati on were observed. 
These colonie were furt her screened by restri cti on dige tion with EcoR[ and 
gel electrophoresis on 1% agarose gel as shown in fi gure 3.7. Fi ve of the 25 
VH clones (V H8, VH I7, VHI 8, VH20 and VH25) and fi ve o f the 15 VL 
clones (VL 1, VL6, VL 7, VL8, VL11 and VL1 3) were fo und positive o n the 
basis of restri ction digestion screening. These positi vely screened c lones were 
equenced at the Biopolymer Synthes is and Sequencing Faci lity, Uni ver ity o f 
Notti ngham, using of M 13 fo rward and M 13 rever e primers. 
3000 bp 
2000 bp 
1000 bp 
A 
1000 bp 
750 bp 
500 bp 
B 
Figure 3.6: Amplifi cation of the variable r egions of 503 heavy and light chains by 
5' Rapid Amplification of cONA ends (RACE). 
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(A) Total RNA from 5D3 hybridoma showed two bands typically si mil a r to 
mammalian RNA at 4.5Kb and 1.9Kb cOITesponding to the 28S and 18S 
ribosomal R A. (8) Products: V II variable region of heavy chain, V L variable region 
of light chain obtained after the final peR were resolved on 1 % agarose ge l. 
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Figure 3.7: Screening of VH and VLclones by restriction diges tion. 
Plasmids were digested with EcoRI and separated on 1% agarose gel. (A) 25 clone 
were screened for the presence of heavy chain and (B) 15 c lones were screened for the 
presence of light chain. Products of interest (positive clones) are indicated in red 
3.3.3 5D3 hybridoma expresses an aberrant kappa chain 
The sequences obta ined were analysed us ing C hromas and SEQ-MAN 
softwares. All the VH c lones showed the same sequences while two distinct 
types of 5D3 seq uences were obtained for clones carrying the light cha in 
variable region. C lones VL7 and VLlI were fo und s imilar to the anti-NGF30 
antibody kappa chai n [Appendix] , and were presumed to represent the light 
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chain of 503 . Clones VL6, VL8 and VL13 were found to correspond to the 
myeloma kappa chain found in hybridoma cell line A YG. I.2.3 , which could 
originate from the hybridoma partner (Crowe et ai. , 1989). The presence of 
two light chains in the hybridoma expressing 503 mAb was contirrned by 20 
gel electrophoresis (see section 3.3.3 . 1). 
The variable regions of the heavy and light chains of 503 mAb were analysed 
using the [MGT software (Lefranc et al. , 1999) and their nucleotide, amino 
acid sequence and 20 structures are shown in Figures 3.8 and 3.9. Gene or 
allele segments used in the variable region 0 f the heavy and light chains of 50 3 
are described in Table 3.6. 
Antibody !sotype VII D gene/allele Jff 
503 IgG2. k IGHV8SII *01 IGHOI-8*-01 IGHJ3*01 IGKVII-125*01 IGKJI *OI 
OEC205 IgGI. k IGHV7-3 *01 IGHOI-3*01 IGHJ2*OI IGKVI 5-I03*OI IGKJI *OI 
Table 3.6: Genes or allele segments used in the heavy and light chains of 5D3 and 
DEC205 antibodies. 
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A B 
Figure 3.8: 20 graphical representation of the 503 heavy chain (A) and light 
chain (8) generated by the [MGT/Collier de perles tool (Lefranc et aI., 1999). 
5D3H MDRLTSSFLL LIVPAY-VLS QVTLKESGPG ILQPSQTLSL TCTFSGFSLS TYGMG VGWIR [ 601 
DEC205H 
. G-WSCII . E' . VAT . TG . H. E. K.L . .. G . LV . . GGS . R. S.M . .. TE'N DE'Y. N-- .. . [ 601 
5D3H QPSGKGLEWL AN IWWDDGKY ---YNPSLKN RLTISKDTSN NQAE'LKITNV DTVDTMYYC [120J 
DEC205H 
. . P. QAP . .. GV . RNKGNG . TTEV . T. V. G . E' ... R. NTQ . ILY .QMNSL RAE . . . I .. . [120J 
5D3H FR-IPFYY-- HDADHWG GT LVTVSSAETT APSVYPLAPG TALKSNSMVT LGCLVKGYE'P [180 I 
DEC205H A.GG . Y .. SG D .. PY . ... V M ..... . T . K G .... . .. . . S . AQT . . .. . .......... [180] 
5D3H EPVTVTWNSG ALSSGVHTFP AVL SGLYTL TSSVTVPSST WPSETV- --- ---------- [240 ] 
DEC205H ... . ... .. . S .... .... . ... .. D .. .. s .... .. . .. ------ ---- [24 OJ 
A. 
5D3K MAMKTPA AL AIWLLWVSGA RC DIQVTQSP SSLLASLGER VTITCQTSQT ISKNLNWYQQ [ 60] 
DEC205K 
. GWSC --- II LFLVATAT . V HS ... M ... . . F . ST . .. NS 1. .. . H.A . . N . KGW. A . . . . [ 601 
5D3 K KPGQVPILLI YFATSLQTGM PSRFSGQYSG RSFTLTI TSL EPEDIANYE'C LQHYNPPWTE' [120 ] 
DEC205K 
. S . NA . Q . .. . K. S .. . S . v . . . .. . SG . . TDYIF.. SN. Q .. ... T . Y . QHYQSF .. . . [120 ] 
5D3K GGGTKLELKR ADAAPTVSIE' PPSMEQLTSG GATVVCE'VNN E'YPRDISVKW KIDGSEQRDG [180] 
DEC205K .. . .. . ... . . .. . .. .. . . .. . S .. .... .. S .. .. L .. .. . K .. N .. . .... .. R N . [ 180J 
SD3K VLDSVTO OS KOSTYSMSST LSLTKVEYER HNLYTCEVVH KTSSSPVVKS f' RNEC'--- [240 ] 
DEC205K .. N. W .. .. . . . .. ... . . . . T .. . 0 .... . . S . . .. AT . .. . T .. I ... [240 J 
B. 
Figure 3.9: Protein sequence comparison of the heavy (A) and light chains (8) of 
the 503 and OEC205 antibodies. 
Variable regions are shown in blue and the complementary determining regions 
(C DRs) in the V-region are in green color. Red coloured letters indicate the 
junction region of the heavy and light chains of the antibodies 
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3.3.3.1 Identification of the heavy and light chains of 503 hybridoma by 2-
dimensional Gel electrophoresis 
Purifi ed 503 wa analysed on a reducing SOS-PAGE, and two di stinct bands 
of the mAb heavy and light chain were observed by Coomassie-staining. 
Amplification and cloning of the vari able region of the 503 li ght chain yie lded 
two different sequences, which indicated that the 503 hybridoma could conta in 
more than one light chain that might interfere with the cloning of the 503 
variable region. To investigate this 20 -PAGE analysi of the purified mAb 
produced by each of the cell lines was performed (Figure 3.10). 
3 H 10 17em 3 pH 10, 17cm 
225 K 22CK 
H·ehn 
~ ~ H Ctou11't 
MW I ~ ~ r-J.V'I t,C h ... 
v 00 
12K 12K 
A B 
Figure 3.10: Purified mAbs 5D3 (A) and 6C3 (8) were separated on 2D-PAGE in 
order to identify heavy and light cbains being expressed by the hybridoma. 
Molecular marker are shown on the left side of the gel and the pH range used for the 
isoelectric focu ing is shown at the top. 
The light and heavy chains were separated under the reducing condition of 
the 20-PAGE. Multiple spots was observed for the heavy chain, most likely 
due to the effects of glycosylation and other sources of charge heterogeneity 
(Perkins et a I. , 2000). Two spots of different molecular weight, for the light 
chain were observed coinciding with the results obtained from the Q-TOF 
sequence anal y i (F igure 3 .11). In order to confinn whether these two li ght 
chains occur by di fferential glycosylation or if the cell i producing more than 
one type of light chain the L1 and L2 pots of the 503 were analysed by Q-
TOF equencing along with the heavy chain of 503. 
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A. 
MAMKTPAQAL AIWLLWVSGA RC DI QVTQSP SSLLASLGER VTITCQTS QT ISKN LNWYQQ [ 60] 
KPGQV PILLI YFATSLQTGM PSR FSGQYSG RSFTLTITSL EPEDIANYFC L HYNPPWTF [120 ] 
GGGTKLELKR ADAAPTVSIF PPSME LTSG GATVVCFVNN FYPR DISVKW KIDGSE RDG [180] 
VLDSVTD DS KDSTYSMSST LSLTKVEYER HNLYTCEVVH KTSSS?VVKS fNR E * [240] 
B . 
MES T VLMS LLLW SGTCG DFVMTQSPSS LAVSAG ETVT I NCKSSQSLF YSGNQKNYLA [ 60] 
WYQQKPGQSP KLLIYWASTR QSGVPDRFI G SGSGTDFTLT I SSVQAEDLA IYYCLQYYET [120] 
PYTFGAGTKL ELK RADAAPT VSIFPPSTEQ LATGGASVVC LMNNfYPR DI SVKWKIDGTE [180] 
RRDGVLDSVT DQDSK DSTYS MSSTLSLTKA DYE SH NLYTC EVVHKTSSSP VVKSFNRNEC [240] 
* [ 241] 
C. 
MDRLTSSFLL LIVPAYVLS VTLKESG?GI L PS TLSLT CTFSGFSLST YGMGVGWIR [ 60] 
PSGKGLEWLA NI WWDDGK YY NPSLKNRLTI SKDTSNNQAF LKITNVDTVD TAAYYCFRIP [120] 
FYYHDADHWG GTLVTVSSA ETTAPSVYPL APGTALKSNS MVTLGCLVKG YFPEPVTVTW [180] 
NSGALSSGVH TFPAVLQ GL YTLTS SVTV P SSTWPSETV [21 J 
Figure 3.lt: Alignment of the aminoacid sequence of the variable region of 503 
mAb obtained by 5'RACE and the AA equence as predicted by Q-TOF analysis. 
This diagram shows the protein sequence of the clones carrying the heavy (C) and two 
light chains (A and 8), amplified from the RNA extracted from 503 hybridoma u ing 
5'RA E. Peptides ident ified by Q-TOF analy is of heavy and light chai n of the mAb 
503 are highlighted in grey. Variable region is show n in blue; green text indicates the 
complementary detem1ining regions within the variable regions; the red and black 
texts represent the constant regions of the heavy and light chains 503 mAb. The text 
highlighted with grey shade indicates the peptide identified by Q-TOF. (A) Sequence 
of variable region of 5D3 kappa chain; (C) sequence of 50 3 heavy chain ; (8) 
sequence of hybridoma partner present in the 503 hyb ridoma (Crowe et aI. , 1989). 
3.3.4 Characterization of DEC20S-HEL Ab and isotype control 
IgGL-HEL 
DEC205-HEL was used as the backbone to generate the 5D3-HEL chimeric 
Ab. As the sequence of the vector encoding DEC205-HEL was unknown, it 
was thus decided to either sequence the complete DEC205-HEL vector, or to 
clone the sequence encoding DEC205-HEL into another vector with a known 
nucleotide equence uch as pcDNA 3. 1 +. Results towards both aim have 
78 
Chapter 3 Generation of chimeric anti-MR antibodies 
been obtained which will be helpful in pnmcr designing and cloning. 
Endotoxin-free OEC205-HEL and IgG I-HEL pl asmids were transfected into 
the 293T-cells in order to con film the integrity of the plasmids and the 
specificity of the expres ed antibodies. The original protocol wa et up for the 
transfection of a ingle plasmid, but two plasm ids were required to be 
tran fected at a time. To optimise the transfection the HEK293T-cell were 
transfected with di fferent 0 A concentrations (Figure 3.12). Supelllatant 
were collected and analysed by Westelll Blotting using anti-mouse IgG -H RP . 
Con istent expression wa observed when usi ng ON concentration a in the 
original protocol, ee lane -A in figure 3.12. 
A 
2S0KDa ... _ ~ ~
160 KDa 
105 KDa 
75 KDa 
B c o 
Figure 3.12: Transfection assay to caliberate the amount of DNA in order to 
attain maximum transfection. Different amounts of DNA from each pIa mid wcre 
transfected: A (I.OO/lg) , B ( 1.5 /lg) , C (2 .00 ~ l g g , , D (negative control). 
After the optimisation of th transfection procedure, OEC205-HEL and IgG 1-
HEL were expres ed in HEK 293T-cells and puritled from the upematant by 
affinity chromatography; 4-5 days po t transfection . The concentrations of 
OEC205-HEL and IgG I HEL were mea ured by BCA protein quantification 
assay were found to be 3 0 1 ~ g / m l l and 9 1 ~ g / m l l rc pective1y. Purified antibodies 
were analysed by reducing SOS polyacrylamide gel elctrophoresis. Two bands 
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of molecular weight 52K and 24K were observed which correspond to to the 
molecular weights of the heavy and light chains of the IgO (Figure 3.13 A). 
In order to analyse the specificity of the DEC205-HEL antibody Western 
Blotting was perfonned using thymus lysate as it contains a large amount of 
DEC205 (Witmer-Pack et aI., 1995). DEC205-HEL and IgO I-HEL were used 
as primary antibody and peroxidase-conjugated donkey anti-mouse Ab was 
used as a secondary antibody. The western blot yielded bands for both [gO 1-
HEL and DEC205-HEL. IgG 1 did not bind the DEC205 receptor appeared to 
recognised a band that was also recognised by the secondary antibody 
(peroxidase-conjugated donkey anti-mouse Ab and could correspond to mouse 
IgO present in the thymus lysate. A band clearly corresponding to DEC205 
was observed with DEC205-HEL that was distinct from the band obtained by 
the binding of secondary antibody (Figure 3.13 C). 
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Figure 3.13: SOS-PAGE and Western blot analys is of purified IgGI -HEL and 
DEC205-HEL. 
Antibodies were separated in 12% and 6% acrylamide gels under reducing (A) and 
non-reducing (B) conditions, re pectively, and stained with Simp ly Blue safe stain. 
(C) Western Blot of thymus Iysates with DEC20S-HEL and IgG I-HEL to determine 
the ir specific ity. Thymus lysate was loaded as sample on 6% SDS-PAGE and 
DEC20S-HEL and IgG I-HEL were used as primary ant ibodies, and peroxidase-
conjugated donkey anti-mou e IgG as secondary antibody. 
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3.3.5 Construction of the light and heavy chains of the anti-MR 
ch imeric Ab S03-HEL 
The variable regions of 503 were inserted in the place of the vaIiable regions 
of OEC205-HEL ( ppendix 1&2) by re hiction cloning to generate 50 3-HEL 
(Appendix3&4). Compari on of the protein sequence of the heavy and light 
chain of the 50 3 and OEC205 ant ibodie is shown in Figure 3. 16. The 
variab le region of the 50 3 heavy and light chai ns were PCR- amplifi ed, with 
primers containing uitabl rest ri ction ites. PCR products were gel purified 
and digested with Eco RI and Hpal (Light chain) and with Eco RI and Apal 
(Heavy chain). OEC205-HEL containing vectors were also digested with the 
same et of restriction enzyme and li gated into the double digested 503 chain 
(F igure 3.12). Ligation mixtures were used to tran fOlm competenT-cells and 
screened by co lony PCR by using product specifi c primer (Figure 3.14). 
Almo tall of the clones were found po itive. 
M 1 2 3 <4 5 6 7 8 9 10 I I 
A 
f.OObp 
250bp 
f.OObp -? 
250bp -? 
M I 2 3 • 5 6 7 8 9 10 11 12 13 
1. 15 16 17 18 19 20 21 
B 
Fioure 3.1 4: Screening of clones carrying the heavy and light chain of 50 3 by 
colony PC R. PCR-amplified product was separated on 1 % Aga rose. 
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Michel's vectors carrying the VH and VL 
of anti-DEC205 Antibody respectively. 
1 
Restriction digestion 
EcoRI+Hpal and 
EcoRI+Apal 
EeoRI 
EeoRI 
Hpal Nhel 
Apa l Nhel 
Ligation 1 Expression vector 
EeoRI Apal 
Expression vector 
Nhel 
CJ CMV Promoter 
_ Leader peptide 
_ VH and Vl of 5D3 
Constant region 
CJ HEL epitope 
Figure 3.15: Schematic diagram showing the ge neration chimeric antibody: 503-
HEL from OEC205-HEL antibody. 
3.3.6 The anti-MR chimeric antibody 5D3-HEL binds the man nose 
receptor 
Once the plasmid encoding for SD3-HEL wa generated, it was transfected into 
HEK293 T-cells for its expression. Antibodies produced were purified from the 
media by affinity chromatography (Figure 3. L 6 8). The effect of genetic 
manipulation on the binding of chimeric antibody SD3-HEL to CTLD4-7-Fc 
was assessed u ing ELISA. Figure 3.16 A demon trates the binding of 503 , 
IgG2a, SD3-HEL and IgG L-HEL to CTLD4-7-Fc. Isotype control IgG I-HEL 
howed no binding compared to the anti -MR chimelic Ab SD3-HEL. Similarly, 
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the isotype control fgG 2a showed negligible binding compared to 5D3 mAb. 
CR-FNll-CTLD 1-3-Fc is used as negative control. 
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Figure 3.16: SOS-PAGE binding analysis anti-MR chimeric Ab (S03-HEL) and 
anti-MR mAb S03 with mannose receptor domain CTL04-7. 
(A) The maxisorp EUSA plate was coated with 5/-lg/ml of CTLD 4-7-Fc and CR-
FNlI-CTLO 1-3-Fc, followed by the addition of I ~ l l / m l l of primary antibodies. Anti-
rat-AP antibody was use as secondary antibody for 503 and IgG2a mAb and anti-
mouse-AP was used for the chimeric 503-HEL and [gG l -HEL. The extent of binding 
was measured by taking absorbance at 405nm after the addition of I mg/mt of p-
nitrophenyl phosphate substrate. The graph shows 00 of the samlples at 405nm and 
standard deviation (S D). (8) 3/-lg of the antibodies was loaded on 6% S OS-PAG E and 
molecular weight (MW) is shown on the left. 
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3.4 Discussion 
Cloning of the VH and VL of the 503 mAb is described in this study. An 
antibody molecule is composed of two (disulfide bond interconnected) heavy 
chains, each one linked to a light chain by disulfide bonds. It contains a 
constant region at the C-terminus and an antigen (or complementarity)-
determining region (CDR) at the N-terminus, fonned by the association of VH 
and VL. The variable region is futher composed of three hypervariable regions 
and three frameworks in between them, which are relatively conserved (Ellen 
Hsu and Lisa A. Steiner, 1992). Cloning of the variable domains of 
immunogloulins is often carried out by designing 5' degenerate primers: either 
against frame work-1 (FR-l) sequence or against conservative leader peptide 
sequences (Gavilondo-Cowley et aI., 1990). However, due to the presence of 
different types of leader peptides and the homology of FR-I with COR-3 
portions, the use of degenerate primers can result in mispriming and lead to a 
failure in the cloning of variable regions in 15 to 35% of cases (Ooenecke et 
aI., 1997). In order to avoid mispriming the variable region of 503 was cloned 
by designing highly specific primers binding to the highly conserved constant 
region of rat IgG; the po1y-C primer was used against the poly-G tail added at 
3' end by 5' RACE PCR in order to obtain a full length V-gene with their 
native leader peptide. After PCR amplification the VH and VL of 503 Ab were 
cloned into PCR 2.1 vector and sequenced. One of VH was identified on the 
basis of sequence analysis, with two types of VL clones being identified. 2-0 
Gel electrophoresis was carried out to detect the presence of different heavy 
and light chains in the 503 mAb molecule; two bands for the light chain were 
observed similar to the sequencing results wherein two types of VL clones 
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were identitied. Cloning of the V-gene from total RNA isolated from the 
hybridoma can become complex due to the amplitication of irrelevant VH or 
VK derived from the myeloma fusion partner (Carroll et at., 1988). Q-TOF 
sequence analysis and DNA sequence blast was performed in order to 
distinguish between the irrelevant and relevant VL. One VL clone was found to 
be similar to the hybridoma partner kappa chain (Crowe et at., 1989) and the 
other VL clone was considered as the VL of 503, being further used to 
generate the chimeric antibody. 
The variable region of an antibody (lgG) is assembled by integration of 
variable (V), diversity (D) and joining (1) segments which is then diversified 
by somatic hypermuataion (SHM). SHM introduce single nucleotide 
substituition more frequently in the CDR regions of the IgG to increase the 
affinity of antibodies for antigen (Oi Noia and Neuberger, 2007). VL and VH 
of 503 were analysed by IMGT/V -Quest, a sequence alignment software for 
IgG (Lefranc et aI., 1999), to assess the frequency of SHM in 503. In VH of 
503, V segment indicated 98.63% (2871291 nt) and J segment showed 80.39% 
(41/51 nt) similarity. While V segement of503-VL indicated 75.27% (210/279 
nt) and J-segment had 92.11 % (35/38 nt) similarity. The frequency of SHM 
was more in 5D3-VL as compared to 503-VH. 
In order to generate 5D3-HEL chimeric antibody, the anti-OEC205-HEL 
antibody was used as a backbone (Hawiger et aI., 2001). OEC205-HEL 
antibody is a mouse anti-mouse IgG 1 and possesses EcoRI and Not! restriction 
sites at the 5' and 3' ends of both its heavy and light chains. The DNA 
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sequence ofVH and VL of both OEC205-HEL (Appendix-l&2) and 503-HEL 
(Appendix-6&7) was analysed and appropriate restriction sites selected. VL 
and VH of 503 were reamplified by the primers having ApaI for VH and HpaI 
tor VL, which are also present in anti-OEC205-HEL near the variable region. 
After amplification 503 VH and VL were digested with appropriate enzymes 
and VH and VL of OEC205-HEL were also digested with the same set of 
enzymes. The variable region of OEC-205-HEL was then replaced with the 
variable region of 503 by DNA ligation (Scharf et aI., 1986). The heavy and 
light chain clones of 503-HEL were analysed by colony PCR and DNA 
sequencing. A stop codon was observed in the heavy chain clones due to a 
single nucleotide deletion, which was detected as the missing nucleotide in the 
reverse primer that was used in PCR amplification of VH for restriction 
cloning (data not shown). This problem was resolved using a new set of 
primers and clones carrying the heavy and light chains of 503-HEL were co-
transfected into HEK-293T for protein expression. Unfortunately, we failed to 
clone variable region of anti-MR mAb, 6C3 by 5' ARCE. However, the 
techniques learned during the generation of 503-HEL chimeric antibody can 
be employed to mutate the variable region of 503 to obtain chimeric antibodies 
of different binding affinities. 
Proteins or antibodies are usually well expressed in bacterial cells as they give 
good yield (Buchner and Rudolph, 1991). However, such bacterial proteins are 
not endotoxin-free nor are they properly glycosylated due to the lack of 
appropriate glycosylation machinery. For this study, therefore, HEK-293T 
were selected for protein expression. HEK-293T resembles myeloma cells 
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wherein machinery IS maintained intact for antibody synthesis, post-
translational moditication and secretion. Moreover, proteins expressed in 
mammalian cells are secreted in the supernatant in a proper folded form 
(Colcher et ai., 1989). The effect of genetic manipulation on the binding of 
chimeric antibody was assessed by ELISA, and Ag-binding was not affected as 
reported by Jones et al. that replacement of the variable region of one antibody 
by one from another does not affect its binding properties (Jones et ai., 1986). 
Although the ELISA result is indicative of conservation of speciticity after 
genetic manipulation, conservation of binding properties will need to be 
determined using SPR. 
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4 Investigation of the capacity of chimeric anti-MR Ab 
to target Ag to antigen presenting cells and induceT-
cell immunity 
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4.1 Introduction 
DCs internalize exogenous antigens through different mechanisms such as 
pincocytosis or receptor-mediated endocytosis, which results in the targeting of 
soluble Ag to distinct intracellular compartments and antigen presentation to 
CD4+ T-cells (Burgdorf et aI., 2007). Recent studies have shown that the 
antigen presenting cells, in particular DCs, have the ability to process 
exogenous antigen and present them on MHC-I molecules. This mechanism is 
known as cross-presentation and is important for the induction of the immune 
response against viruses and tumours that are not infecting APC (Heath and 
Carbone, 2001). DCs located in lymphoid tissues are divided in two subsets: 
CD8+ and C8- DCs. Among the differences between these cell subsets is that 
CDS+ DCs preferentially cross-present the exogenous Ag on MHC-I 
molecules, while CDS- Des do so on MHC-II molecules (Dudziak et aI., 
2007). 
Following innate stimulation DCs undergo a maturation process that results in 
the expression of high levels of MHC-peptide complexes and co-stimulatory 
molecules at the cell surface. Ags loaded on the MHC-peptide complexes are 
recognised specifically by the T-cell receptor, and co-stimulatory molecules 
interact with counter-receptors present in the T -cells. These, together with the 
range of cytokines produced by the DC, int1uence the outcome of T-cell 
activation. Therefore, DCs hold the key to the code-controlling the behaviour 
of the T-cell following interaction (Banchereau and Steinman, 1998). 
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Once being activated, T -cells perform its cytotoxic role by killing only those 
tumour or infected cells which display the same antigenic peptide presented by 
MHC class I molecules (Brodsky and Guagliardi, 1991). Different approaches 
have been used to target DCs and cross present the exogenous Ags to induce T-
cell immunity and antibody mediated targeting of the Ag is the most specitic 
and effective method as described in the general introduction section 1.7.2. Ags 
can be conjugated to Abs specific to the receptors expressed on the DC by 
either chemical coupling using cross linkers or by using genetic engineering (as 
described in Chapter 3). 
(A) Chemical conjugation: In this method purified Abs are linked with 
the antigenic peptide by using cross linker molecules such as SMCC 
(Sancho et aI., 2008). This method have been employed in our study as 
described in chapter number 5 of thesis in which a melanoma Ag, TRP-
2 was conjugated chemically to the anti-MR mAbs SD3 and 6C3 and 
used to target DCs through MR in order to induce TRP-2 specific T-cell 
activation. 
(8) Genetic engineering: Due to possible xenogenic problems DNA 
encoding the model Ag HEL and OVA Ag have been incorporated into 
the C-tenninus of the constant region of the heavy chain of anti-MR 
chimeric Ab using genetic engineering (Pudney et aI., 20 I 0). DEC20S-
HEL, 5D3-HEL (Chapter 3) and S03-0VA (Chapter 4) along with their 
isotypes controls have been generated by using this method. 
The potential of the novel reagents generated in this study to target DEC20S 
and MR specifically and to activate T-cells in vitro has been investigated. It has 
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been reported that antigen targeted through MR leads to antigen delivery into 
EER, a specialised compartment of the cell involved in the cross presentation 
of the antigens (Burgdorf et aI., 2007). Several reports have shown that murine 
CD8u + DCs are dedicated to cross prime antigen found in multiple viruses and 
tumours as well as in tolerogenic immunity (Segura et aI., 2009, Villadangos 
and Schnorrer, 2007). Burgdorf et al showed that CD8u + DCs express MR and 
that antigen uptake through MR in BM-DC transported to EER for cross 
presentation. DEC20S is another receptor expressed by CD8u + Des which 
delivers Ag into EER and leads to cross presentation. But it differs from MR as 
major part of the antigen delivered through DEC205 was transported to the 
MHC-II presentation pathway and co-localized with lysosome (Burgdorf et aI., 
2007). 
In vitro Ag presentation assays using HEL and OVA as model antigens were 
set up in this study. Novel reagents such as SD3-HEL (chapter 3) and 503-
OVA (this chapter) have been generated from DEC205-HEL and the potential 
of these antigen delivery reagents to activate T -cells was assessed, in vitro 
using these assays. DNA plasmids encoding SD3-0VA and IgOI-OVA have 
been used to immunise animals to test their potential to generate OVA-specific 
T-cells. 
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4.2 Materials and Methods 
4.2.1 Replacement of HEL with OVA antigen in SD3-HEL chimeric 
antibody to generate S03-0V A 
pBlueRIP vector carrying the tTf-OVA gene was kindly provided by Prof 
Christian Kurts, Bonn University, Germany. Plamid D A was recovered and 
transformed into TOP-10 chemically competent E.coli. QIAGEN miniprep kit 
was used for plasmid isolation aand purified plasm ids were characterized by 
restriction with HindrrI. The plasmid included the whole gene of the OVA. A 
fragment corresponding to a OVA mini-gene wa subcloned by using pecific 
primers capable of amplifying a portion of OVA and appropriate restriction 
sites as shown in table table 4.1. Nhel and Not[ restriction sites were 
incorporated into OVA insert using forward primer and revers primers 
respectively. 
The OV A-minigene was PCR amplified using Phusion enzyme (New England 
Biolabs) and following peR programme: 
95°C 1 min. (Denaturation) 
35 cycles: 95°C 30sec, 68°C 1 min, 68°C 2min. 
ov A-FP (Nhe!) TCAT AGCT AGCATGTTGGTGCTGTTGCCTGA T 46.9 68 .2 
OVA-RP (Not!) TGACAGCGGCCGCTTATGCAGCATCCACTCC 62.9 75 
AGCC 
Table 4.1: Primers designed to subclone OVA mini-gene which include regions 
complementary to the OV A-minigene and appropriate restriction sites such as 
Nhel and NotI. 
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PCR products were analysed by agarose gel electrophoresis (l %w/v) and were 
extracted from the gel by the gel extraction kit Gel extraction kit (QAIGEN) 
according to manufacturer instructions. This extracted DNA and the 5D3-HEL 
and IgG I-HEL was digested by using NheI and NotI restriction enzymes 
according to the manufacturer's instructions. Reactions were incubated at 3TC 
for 2-4 hours. After restriction digestion the relevant bands were cut and DNA 
was purified. The digested OVA-mini gene was ligated into the 5D3-HEL and 
IgGI-HEL vector with the help of T4 DNA ligase (Roche). The ligated 
plasmids were transformed into the One Shot E. coli cells. The transformed 
cells were incubated overnight at 37°C on LB agar paltes containing lOOJ.lglml 
ampicilln, O.lmM IPTG and 40J.lglml X-Gal. White colonies were selected and 
screened colony by PCR using same set of primer used for the amplification of 
the OVA-minigene and the following PCR programme: 
95°C 15 min. (Cell lysis and denaturation) 
35 cycles: 94°C 45 sec, 55°C 45 sec, noc 1.5 min. 
noc 10 min. (Final extension) 
Positive clones were sequenced at Biopolymer Synthesis and Analysis Unit, 
Nottingham University using the vector specific primers shown in table 3.4. 
4.2.2 Expression of SD3-0V A and its analysis 
Vectors carrying the heavy chain and light chains of 5D3-0VA (Apendix 5&4) 
and IgGI-OVA (Appendix 7&8) were co-transfected into HEK-293T and the 
chimeric antibodies were expressed and purified by following the protocol 
described in section 2.2.1 Purified SD3-0A and IgG I-OVA were analysed by 
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SDS-PAGE and western blotting and their binding to mannose receptor was 
assessed by ELISA as described in section 2.2.4.2. 
4.2.3 Characterization of endotoxin free commercial OVA. 
4.2.3.1 Lectin ELISA to analyse the binding of commercial OVA to 
MR 
Lectin ELISA and inhibition ELISA were perfonned as described in sections 
2.2.4.2 and 2.2.4.3. 
4.2.3.2 Endocytosis assay of commercial OVA 
Endotoxin free commercial OVA was labelled with FITC using the Fluoro-
Trap flourescein labelling kit (lnnovaBiosciences) following manufacturer's 
instructions. FITC-Iabelled OVA along with other endocytic tracers ( 5 ~ g l m l ) )
were used in edocytosis assays following the protocol described in section 
2.2.5. 
4.2.4 Generation of bone marrow derived dendritic cells. 
Bone marrow was collected from C57BLl6 and BALB/C mice according to the 
protocol described in section and dendritic cells were cultured in RIO medium 
supplemented with GM-CSF, following protocol described in section 2.3.1. 
Phenotype of BMDCs was analysed by tlowcytometry according to the method 
described in section 2.2.7. 
4.2.5 Maitenance of T-cell hybridoma cell lines 
The B3Z hybridoma cell line (Karttunen et aI., 1992), a kind gif from Dr. 
Andrew Jackson, University of Nottingham was maintained in RIO medium. 
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The suspension cell line was maintained by passaging 1 :25 every second day in 
T75 tissue culture tlasks at 3TC in 5% CO2. The MF2 hybridoma cell line was 
maintained in RIO medium by passaging every second day while the cells are 
still subcontluent in T75 tissue culture tlasks at at 3TC in 5% CO2• 
The IC5.1 hybridoma cell line was cultured in RIO medium at 3TC in 5% 
CO2• The cell suspension was passaged 1:4 every second day in T75 tlasks 
trying to keep the cells subcontluent. 
4.2.6 Antigen presentation assays 
4.2.6.1 Antigen presentation assay using 83Z T-cell hybridoma 
B3Z cells were harvested while still subconfluent and viable cells counted 
using Trypan blue (SIGMA) exclusion. Cells were resuspended to a density of 
5x105 per ml in RIO media and 1 0 0 ~ . t l l were added into the wells of a 96 well 
tlat-bottomed plate (i.e. 5xlO4 cells per well). Live APC (BMDCs) were 
resuspended to a density of of 5x I 05 per ml in RIO media and 1 O O ~ 1 1 were 
added into the wells of flat-bottomed plate (Le. 5x I 04 cells per well) or 106 per 
ml and 5 0 ~ 1 1 were added into each well (giving APC: T-cell ratio 1:1). 5 0 ~ 1 1 of 
serial 2- fold dilution series (6-dilutions) from a stock solution of endotoxin 
free ovalbumin (OVA, Prof os; Cat: 321000) at Img/ml was added per well in 
quadruplicate, thereby giving a titration of antigen from a top dose of 0.5 
mg/ml. The cultures were incubated for 18 hr at 37°C, centrifuged for 5 min at 
296 g and 7 5 ~ 1 1 of supernatant were collected and transferred to a fresh 96 well 
flat-bottomed plate. The plates were stored at 4°C or frozen at -20°C until 
required for quantification of IL-2. 
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An alternative procedure for MHC class I-restricted presentation was 
perfonned by following a method used by Burgdorf et ai, 2006 for 
investigation of the cross presentation of soluble OVA to naive T -cells. Live 
APC (BMDCs) were re-suspended to a density of 5x I 05 per ml in RIO and 
plated 100111 into the wells of a 96 well flat-bottomed plate (i.e. 5x 1 04 cells per 
well). BMDC were incubated with 100111 of media containing 10 j..I.glml LPS or 
21lglml MPLA for 2 hours at 37°C, 5% C02. A series of 2- fold dilution (6-
dilutions) of OVA (Profos; Cat: 321000) from 2.5mglml stock solution or the 
peptide SIINFEKL (a kind gift from Dr Andrew Jackson) at a final 
concentration of 200 nM were added into each wells. After 3-4 hours 
incubation, the cells were washed with PBS, and fixed with 0.008% 
glutaraldehyde for 3 minutes. The cells were washed again with PBS and co-
incubated with 5xl04 B3Z T-cell hybridoma in a 96-well flat-bottom plate at 
37°C. After 18 hours, the plates were centrifuged for 5 min at 296 g and 
supernatants were collected, and transferred to a fresh 96 well flat-bottomed 
plate. 
The antigen presentation of different OVA molecules and subsequent B3Z T-
cell proliferation was assessed by measuring the amount of murine IL2 
secreted by B3Z in the supernatant of co-cultures by following protocol 
reported in section 2.2.4.4 
4.2.6.2 Antigen presentation assay using MF2-T-cell hybridoma 
MF2 T -cells were harvested while still sub-confluent and viable cells counted 
using Trypan blue (SIGMA) exclusion. Cells were resuspended to a density of 
106 per ml in RIO media and 50111 were added into the wells of a 96 well flat-
bottomed plate (i.e. 5x104 cells per well). Similarly, live APCs (BMDCs) were 
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resuspended to a density of 106 per ml in RIO media and SO!!1 were added into 
the wells of flat-bottomed plate (i.e. Sx 104 cells per well) giving a APC: T-cell 
ratio 1: 1. Stock solution of commercial endotoxin-free OVA (Prof os; Hyglos) 
and purified SD3-0V A and IgO I-OVA was prepared and 100111 of serial 2-
fold dilution from the stock solution was added per well in duplicates, thereby 
giving a titration of relevant OVA antigen from a top dose of 40Ilg/ml to 
O.0781lg/rnl. The co-cultures were incubated for 18hr at 37°C, centrifuged for S 
min at 1200rprn and 75111 of supernatant were collected and transferred to a 
fresh 96 well flat-bottomed plate. The antigen presentation of different OVA 
molecules and subsequent MF2 T-cell proliferation was assessed by measuring 
the amount of murine IL2 secreted by MF2 in the supernatant of co-cultures by 
following protocol reported in section 2.2.4.4. 
4.2.6.3 Antigen presentation assay using the leS.l T-cell hybridoma 
The antigen presentaion assay was performed as described in section 2.3.S.2 
except that BMDC were derived from BALB/C mice and pulsed with Hen Egg 
Lysozyme (HEL)-related antigens from a top dose of 20Ilg/ml to O.0390Ilg/ml. 
The APCs were then co-cultured with 1 CS.l: MHC-II restricted HEL specific 
T-cell hybridoma as described above. 
4.2.7 Dectection of murine IL-2 from 83Z, MF2 and le5.1 by 
ELISA 
IL-2 produced in the co-culture was assessed by IL-2 ELISA as described in 
section 2.2.4.4. 
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4.2.8 DNA immunisation with plasmids encoding 5D3-0VA and 
IgGI-OVA 
Mice were divided into three groups. Each group was immunised with the 
plasmid DNA encoding SD3-OVA or IgGI-OVA using gene gun method. One 
group was immunised with IB-DNA-OV A (Metheringham et al., 2009, Pudney 
et al., 2010) plasmid using gene gun method as a positive control. Plasmid 
DNA encoding antibodies carrying the OVA-mini gene was coated on the 1.0 
~ m m gold particles by following the manufacturer's instructions (Biorad, Hemel 
Hempstead). DNA particles were administered intradermally into the shaved 
abdomen of the mice using Helios Gene Gun (Biorad) and each mouse was 
immunised with 1 . 0 ~ g g of DNA per immunisation. After this primary 
immunisation, secondary and tertiary immunisations were done one week apart 
as booster doses. One day after the third immunisation, mice were sacrifice and 
their blood, lymph nodes and spleens were collected in order to analyse the 
immune response against OV A. 
4.2.9 ELISPOT to detect OVA specific T-cells producing IFNy. 
ELISPOT assay was used to determine the frequency of peptide-specific 
interferon-gamma (IFNy)-secreting T-cells in murine splenocytes. The Mouse 
IFNy ELISPOT kit (Mabtech) was used as follows. 
Coating of plates with capture antibody 
On day one MAIP multi screen ELiSPOT plates were sterilized with 15 ~ l l of 
70% ethanol per well followed by 4 times washing with 200 ~ l l of sterile 
distilled water per well. The plates were coated with 1 0 ~ g l m l l anti-IFNy 
capture antibody and incubated at 4°C overnight. 
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Blocking plates 
Next day the capture antibody solution was flicked off and plates were washed 
4 times with 200 I • .tl of sterile PBS per well. Plates were blocked by adding 
I 00 ~ l l of complete medium to wells and incubation at room temperature for at 
least I hour. 
Preparation of effector cells from spleens 
Mice were killed by cervical dislocation. After killing the anilmals were 
sprayed with 70% ethanol and all further procedures were carried out in a 
laminar flow hood in order to maintain the sterility. 
The mouse was laid on its right side, on a paper towel, in the hood. The skin of 
the left side of the mouse was picked with large forceps and cut with large 
scissors. The peritoneum cavity was opened and spleen was collected. The 
spleen was transferred to a petri dish containing 10 ml RIO medium, warmed to 
37°C. The outer capsule of the spleen was punctured with 21 G needles and the 
splenocytes were flushed out of the spleen using syringe filled with complete 
medium. The spleen capsule was gently squeezed with forceps to remove 
remaining splenocytes. The clumps of splenocytes were allowed to settle for 
5 minutes then the cell suspension was decanted into a fresh 25 ml conical 
universal tube followed by centrifugation at 233 g for 10 minutes in a benchtop 
centrifuge. The cells pellet was resuspended in 10 ml complete medium 
containing 2-mercaptoethanol and trypan blue was used to count viable cells 
using a FastRead disposable haemocytometer. After counting the cells were 
resuspended at a concentration of 5 x 10 6 cells/ml in complete medium 
containing 2-mercaptoethanol and 5x 105 cells were added per well. SSINFEKL 
peptide diluted appropriately in complete media plus mercaptoethanol (1 ~ g l m l l
100 
Chapter 4 Ab-Mediated MR Targeting to APCs 
to 0.000001 Ilglml range) were added to ELISPOT plate and incubate at 3rc 
for 40hrs. 
Development of ELISPOT 
On day four the development of the ELISPOT plate was carried out on the 
bench in non-sterile conditions. 
ELISPOT plates were washed 5 times with PBS-0.05% Tween. Biotinylated 
detection antibody (monoclonal antibody R4-6A2 - provided with ELlS POT 
kit) diluted 1: 1000 in PBS was added to the ELISPOT plate and incubated at 
room temp for 2.5 hrs (2-4hrs). 
Next the plates were washed five times with PBS 0.05% Tween tollowed by 
the incubation with streptavidin alkaline phosphatase-cojugate (diluted 111000 
in PBS) for 1.5 hr (1-2 hrs) at room temperature. The plates were washed again 
six times with PBS 0.05% Tween-20 and was developed by adding 50 III per 
well of the development solution and leaving the plate in dark at room 
temperature for 35 mins (20-45 mins). Once the spots are visible, the plates 
were washed under tap to stop the reaction. Then, they were dried by keeping 
the plates at room temperature and the spots were counted. 
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4.3 Results 
4.3.1 Antigen targeting through MR leads to antigen specific CD4+ 
and CDS+ T-cell activation. 
4.3.1.1 Endotoxin free commercial OVA binds MR and shows MR 
mediated endocytosis. 
OV A is commercially available in an endotoxin free form and used as a model 
antigen in our study. Before we analyse MHC-II specific and cross presentation 
of OVA through MR in DCs, we assessed first whether OVA bound to MR by 
lectin ELISA. The plates were coated with either OVA or control sugars of 
which we used mannan, S04-3 Oal-PAA and Oal-PAA. Two different 
recombinant MR proteins were used with CTLD4-7-Fc preserving the mannose 
binding properties while CR-FNII-CTLDI-3-Fc was used as negative control. 
Anti-human IgO Fc-specific, alkaline phosphatase conjugate were used to 
detect binding. From figure 4.1A, can be observed that OVA bound the MR-
construct (CTLD4-7Fc) as mannan did, but not the other MR construct which 
interacted with the sulphated sugar. As expected none of the proteins 
recognised galactose. 
In order to investigate whether the binding of CTLD4-7-Fc to OVA is 
mannose-dependent we performed an inhibition lectin ELISA. The MR 
construct (CTLD4-7Fc) 2J.lglml was incubated with or without competing 
sugars. Results showed that binding of OVA to CTLD4-7-Fc is mannose 
dependent, as shown in figure 4.1 B. 
102 
Chapter 4 
~ ~
01 
o 
A 
Ab-Mediated MR Targeting to APCs 
lEI CTLD 4-1 Fe 1.0 Em OVA 
m CRFNII-CTLD 1-3 Fe 0.8 m Mannan 
E 
c: 
:g 0.6 ..... 
... ~ ~~ ~ 0.4 
C 
0 
02 
0.0 
.. 
B 
Figure 4.1: Lectin EUSA (A) and Inhibition ELISA (B) showed that OVA is a 
good ligand for MR. 
OV A as well as mannan, a polymer of mannose showed the strongest recognition by 
the mannose receptor. OVA did not bind to CR-FNII-CTLDI-3Fc as this protein is 
specific for sulphated sugars galactose was not recognised by CTLD4-7-Fc or CR-
FN[[-CTLDI-3 -Fc . rnhibition Lectin ELISA was used to analyse if the binding of 
OVA was sugar dependent. The binding of OVA to CTLD4-7 is mannose dependent 
as CTLD4-7 -Fc incubated with 50 mM mannose showed the least binding to OVA 
(B). 
Endocytosis assay was carried out using CHO cells expressing MR. These cells 
displayed specific uptake of OV A and ETC-labelled Mann-PAA compared to 
the control CHO cells (Figure 4_2). Thus, we can conclude that OVA is a good 
ligand for MR and its interaction is man nose dependent. 
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Figure 4.2: Assessment of MR mediated endocytosis by using CHO-MR cells. 
CHO cells expressing MR were used to see whether OV A is being endocytosed or not 
through MR. Mannose-PAA-FlTC was used as pos itive control and represented by 
light blue histogram while ga lactose represented by red histogram was u ed as a 
negati ve control. OVA was labelled with FlTC by using Fluoro-Trap fluorescein 
labelling kit ( lnnova Biosciences) by following manufacturer's instructions and it is 
represented by dark blue histogram. Res idual uptake by CHO cells was observed 
indicating the presence of another receptor capable of OV A uptake. 
4.3.1.2 Generation of murine BMDCs expressing MR 
As mentioned in the methods section, DCs were cultured from the bone 
marrow obtained fi·om both WT and MR-deficient mice using RIO media 
supplemented with mouse GM-CSF. DCs were cultured for one week and 
media was refreshed at day-3 and day-6. After a week, DCs were ready to use 
and could be seen floating in the form of clusters and loosely attached to 
macro phages in the TC plates (Figure 4.3A). Moreover, the expression of MR 
on BMDCs was confirmed by western blot analysis and flowcytom etry. 
Western blot analysis shown in figure 4.3B, implies that MR was expressed by 
DCs derived from BM of WT C57BLl6 mice but not in the knock out mice. 
We examined the phenotype of BMDCs cultured in the presence and absence 
of LPS by investigating the expression of different markers using flow 
cytometry analysis. We can see the differences between wild type and 
knockout mice were only at the extent of MR expression as Burgdorf et al. had 
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demon trated that MR is highly expressed in BMDCs grown with GM-CSF 
(Burgdorf et aI., 2006). fnterestingly, both populations disp layed similar 
expression of CO II c which is a marker of conventional DCs, indicating that 
both had the expected phenotype. Moreover, the expre sion of the maturation 
markers such as C080 and C086 wa increased dramatically in the presence of 
LPS in both wild type and MR-/- BMOCs as shown in figure 4.4. 
A 
MR+/+ MR-/-
B 
MR+/+ MR-/-
Figure 4.3: Pictures showing the appearance of 8MDC cultures from both 
WT and MR knockout mice (A) and western blot analys is to detect MR (8 ). 
(A) BMDCs were cultured in RPM [- 1640 upp lemented media with GM-CSF and 
picture were taken on day-7. Nice elu ters of BMDC expanding ov r a layer of 
fim1 1y adherent macrophages could be ob erved in both MR /+ and MR-/- culture. 
(8) [n order to detect M R expression in 8M Des, Sx I O ~ ~ cel l of both M R+/+ and MR-
/- were lysed and loaded on 6% PAGE. MR was dectected by using 503 mAb a a 
primary antibody and anti-rat [gG labelled peroxidase enzyme a a econday Ab by 
using the protocol de cribed in ection 2.2.3. 
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Figure 4.4 : Flow cytometry analys is showed the upregulation of different 
markers on BMOC surface during maturation. 
8M deri ved fro m C857fB L6 mi ce was cultured on RPMI 1640 upplemented with 
GMCSF and co llectcd o n day 7. 8MOC were cultured in the presence and absence of 
LPS ( I O)J.g/m l) for fo ur hours. Expre io n of CO Il c, COSO, CD 6 and MR wa 
analy ed by F CS. Ln each box, the grey hi togra m pi tted fo r cells o nly, the red ne 
repre ents the background tai ning with isotype matched antibodies, while the the blue 
hi togram indicate the markers used fo r ta ining. 
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4.3.1.3 Murine BMDCs present OVA to the OVA-specific MHC-I-
restricted B3Z T-cell hybridoma 
After analysing that murine BMDCs express MR and that the model Ag OVA 
binds MR, we examined whether Ag targeted to BMDCs through MR leads to 
Ag prersentation and activation of Tcells. In order to assess T-cell activation an 
antigen presentaion assay was performed in which 8MDCs fed with endotoxin-
free OVA were co-cultured with the 83Z cells, OVA-specific CD8+ T-cell 
hybridoma at a 1: 1 ratio. Antigen specific T-cell activation or proliferation 
was quantified by measuring IL-2 cytokine produced in the supernatants from 
the co-culture assay. LPS, a TLR-4 agonists was used in this study to aid the 
maturation of DCs and promote the CD8+ T-cell priming. 
In this assay, OVA peptide SIINFEKL was used to contirm that DCs were 
capable of presenting this peptide to the B3Z cells and that the B3Z cells were 
able to produce IL-2 in response to the peptide. The peptide used is an octamer 
derived from OVA and can be presented by the class I MHC molecule, H-2Kb 
(Carbone and Bevan, 1989). When loaded with SIINFEKL, we can see the 
BMDCs from MR deficient mice promoted similar activation of the 83Z 
hybridoma to the one seen with WT cells (Figure 4.5) consistent with results 
shown in a previous study (Burgdorf et at., 2006). This indicates our BMDCs 
could still activate the T -cells even without having the MR and from here also 
we can confirm that our B3Z cell line was working well. 
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Figure 4.5: (A) SIINFEKL a C08 epitope of OVA induces T-cell activation 
measured as IL-2 secretion by the OVA-specific CD8 T-cell bybridoma (83Z). 
Graph B shows 00 readings wbich represent different IL-2 cytokine productions 
induced in response to commercial OVA. 
BMDCs from MR+/+ and MR-/- mice were loaded with SrrNFEKL at different 
concentrat ions from a top dose of 200 nM to 0.625 nM (A) and commercial OVA 
from 2.5mg/ml to t.25mg/ml (B). LPS ( I O ~ L L / m l ) ) was used to induce DC maturation. 
BMDCs were fixed after 3 hours and co-cul tured with B3Z Tcells overnight at 37'C 
and 5% CO2. The level of OVA specific T-cel l proliferation was estimated by 
measuring the IL-2 cytokine in the supernatant of the co-cu lture. The error bar on each 
co lumn indicates SEM. 
Cross presentation assay was perfo rmed in w hich BMDCs were treated with 
1O/lg/ml LPS before addi ng OVA and OVA peptide SlfNFEKL following the 
procedure described in 4.2.6.1. After 3 hours, Des were fixed with 0.008% of 
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glutaraldehyde. Then the B3Z cells were added at a I: I ratio and the IL-2 in the 
supernatants was measured after 18 hours. 
Although we found a very poor OVA cross presentation in the assay (Figure 
4.5 B), it is quite interesting to see all the readings from MR deficient BMOCs 
seemed to have an identical B3Z activation (00=0.15), but increasing levels of 
IL-2 production with increasing dosage of OVA was observed when using 
WT-cells. This might indicate that MR-dependent antigen cross- presentation 
by BMOCs was taking place although MR-I- also induced less IL-2 production 
when using the peptide (Figure 4.5 A). 
Therefore, from what we have seen in the cross presentation assay, we could 
not get the B3Z hybridoma activated sufficiently when BMOCs were incubated 
with OVA and even in the presnce of a TLR-4 agonist. 
4.3.2 Generation of anti-MR chimeric antibody carrying the model 
antigen OVA (5D3-0V A) 
The HEL-derived peptide from 503-HEL and IgG l-HEL was replaced with a 
OVA mini gene using the primers and strategy described in section 4.2.1 to 
generate S03-0V A and IgG I-OVA. Both proteins were expressed in HEK 
293T-cells and after 3-4 days the supernatants were collected and purified by 
affinity chromatography. The concentration of 503-0V A and IgG I-OV A was 
measured by BCA protein quantification assay. Purified antibodies were 
analysed by reducing and non-reducing SOS-PAGE. Two bands of molecular 
weight 52K and 24K were observed which are similar to molecular the weight 
of heavy and light chain of the IgG (Figure 4.6C). 
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In order to confinn the replacement of HEL with OVA western blotting was 
perfonned using anti-OVA polyclonal Ab. Both S03-0V A and IgO l-OV A 
were detected by this Ab which indicated that these chimeric antibodies 
included the OVA antigen. As expected, both chimeric antibodies were also 
detected by a peroxidase-conjugated donkey anti-mouse Ab as S03 is a rat 
mAb while the chimeric Ab is mouse Ab and a band observed indicated these 
chimeric Abs are of mouse origin (Figure 4.6B). 
The effect of genetic manipulation on the binding of S03-0V A to CTL04-7-
Fc was assessed by using ELISA. Figure 4.6A demonstrates the binding of 
503, Ig02a, 5D3-0VA and IgOI-OVA to CTLD4-7-Fc. Isotype control IgOI-
OVA showed no binding compared to the anti-MR chimeric Ab S03-0V A. 
Similarly, isotype control Ig02a showed very negligible binding as compared 
to SD3 mAb. 
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Figure 4_6: Binding properties, SDS-PAGE and Western blot analys is of purified 
chimeric antibodies IgG I-OVA and SD3-0V A. 
(A) The maxisorp ELISA plate was coated with 5 ~ l l / m l l ofCTLO 4-7Fc and CR-FNIl-
CTLO 1-3Fc fo llowed by the addition of I ~ ~ / m l l of chimeric ant i-M R antibodies. 
Anti-rat-AP antibody was use as secondary antibody fo r 50 3 rnAb and anti-mouse-A P 
was used fo r the chimeric 50 3-0V A. The extent of binding was measured by tak ing 
absorbance at 405 nm after the addition of I mg/ml of p-ni trophenyl phosphate 
substrate. The graph shows 0 0 of the samlples at 405 nm and standard deviation (S O). 
(B) Western blot ana lysis in which chimeric Abs were loaded as sample on 6% 
acrylamide ge l and later detected by using anti-OVA and anti-mouse IgG. (C) 
Chimeric Abs were separated in 12% and 6% acrylam ide gels under reducing and non 
reduc ing conditions respective ly and sta ined with Simply Blue safe stai n. 
4.3.3 Chimeric antibody SD3-0VA induce activation of the MF2 T-
cell hybridoma 
Commercial OVA is mannosylated and shows binding to MR: due to these 
reasons it has been used as model antigen in vaccination studies involving MR-
mediated Ag targeting and the acti vation immunity. Due to broader binding 
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range of mannosylated Ags, anti-MR Ab carrying the OVA minigene (503-
OVA) has been generated for specific delivery of Ag through MR in order tod 
assess its potential to promote T-cell activation. In vitro antigen presentation 
assay (n= 1) was perfonned to assess the ability of 503-0V A to activate MF2 
hybridoma a MHC-lI-restricted OVA specific T-cell hybridoma, by co-
culturing ofBMOCs and MF2 in the presence of503-0VA and IgOI-OVA as 
control. Murine BMDCs were mixed with MF2 T-cell hybridoma at a 1: 1 ratio 
and cultured in the presence of commercial OVA, 5D3-0VA and IgO l-OV A 
titrated using two fold dilutions from a top dose of 40J.tg/ml to 0.0781 J.tg/ml. 
MF2 T -cells and DCs alone were considered as negative controls and the plates 
were incubated at 37°C with 5% C02. Supernatants were collected after 18 
hours of incubation and the amount of IL-2 produced was assessed by ELISA. 
IL-2 is a T-cell proliferation marker and negative controls such BMDCs only, 
MF2 cells only did not show any IL-2 production. No IL-2 production was 
observed in the absence of antigen while in the presence of commercial OVA, 
5D3-0V A and IgG I-OVA BMDCs induced IL-2 production in a dose 
dependent manner as shown in figure 4.7. 
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Figure 4.7: T-cell proliferation assay by co-cultures of BMDC and MF2: OVA 
pecific CD4+ T-cell hybridoma in response to commercial OVA, SD3-0V A and 
[gG I-OVA. 
BMDCs obtained from 57BLl6 tTIlce were fed with 503-0V , IgG l-OV A and 
commercial OV at different concentration from top do e of 40llg/ml to 
O.078IIlg/ml and co-cultured with MF2 Tcells ovemight at 37"C and 5% CO2, The 
level of OV pecific T-cell proliferation was estimated by measuring the IL-2 
cytokine in the supematant of the co-culture. The error bar on each column indicate 
SEM (n=2). 
Surprisingly T-cell produced the same IL-2 levels when incubated with DC 
in the presence of [gG I-OVA and SD3-0VA indicating that MR binding by 
SD3-0VA does not lead to enhanced T-cell acti vation which wa also simi lar 
to that obtained with OVA. To confinn that the IgG I portion of [gG I-OVA 
had not been modified during the cloning process, we tested the Ag 
pre entation capability of the proteins encoded by the original plasmid 
upplied by the laboratory of Prof. Michel u senzwelg. 
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4.3.4 Activation of the HEL-specific 1 CS.l T-cell hybridoma in the 
presence of DEC20S-HEL and IgGI-HEL 
Similarly as with OVA-derived antigens, antigen presentation assay has been 
performed with HEL. In vitro antigen presentation assay was performed to 
assess the ability of DEC-HEL, 5D3-HEL (chapter 3) and IgOI-HEL to 
activate the MHC-II restricted HEL specific T-cell hybridoma IC5.1. Balb/c 
BMDCs were mixed with 1 C5.1 T-cell hybridoma at a I: 1 ratio and cultured in 
the presence of low endotoxin HEL, DEC205-HEL, 5D3-HEL and IgO I-HEL 
titrated using two fold dilutions from a top dose of 20Ilg/ml to O.0391lg/ml, at 
37°C with 5% CO2• 1 C5.1 T -cells alone, DCs alone and DCs with T -cells in 
the absence of antigen were cultured as the negative controls. Supernatants 
were collected after 18 hours of incubation and the amount of IL-2 produced 
was assessed by ELISA. IL-2 is a T-cell proliferation marker and negative 
controls such BMDCs only, MF2 cells only did not show any IL-2 production. 
BMDCs did not induce any T-cell proliferation i.e IL-2 production in the 
absence of antigen while in the presence of HEL, 5D3-HEL and IgO I-HEL 
BMDCs induced IL-2 production in dose dependent manner as shown in figure 
4.8. 
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Fioure 4.8: Contribution of antibody-mediated targeting of the model Ag I-fEL to 
T-cell proliferation assay. 
DC (Sx I O ~ ~ c lis) obtained from the bone malTOWS of BALB/C mice were fed with 
DEC20S-HEL, 5D3-HEL (MR-HEL), IgG I-HEL and low endotoxin HEL at different 
concentrations from top do e of 40,ug/ml to 0.0781 ~ ~ g g m l l and co-cultured with Sx 104 
ICS .1 T-cell overnight at 3TC and 5% CO2. The level of HEL pecific T-cell 
proli ferat ion was estimated by measuring the IL-2 cytokine in the supernatant of the 
co-culture. The error bar on each column indicates SEM (n= I). 
The e result how that when using BMDC, the [gG I-HEL control was capable 
of promoting T-cell proliferation to levels imilar to tho e obtained with 
DEC205-HEL. MR-HEL induced very low T-cell activation most likely caused 
by the low levels of MR expre ion we observed in these BMDC cultures (data 
not shown). 
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4.3.5 In vivo immunisation of plasmid constructs encoding 5D3-
OVA by using gene gun method and quantification of OVA-specific 
CDS+ T -cells 
C578L16 mice were immunised with DNA plasmids encoding heavy and light 
chain of SD3-0VA and IgOI-OVA by Dr. Ian Spendlove. Moreover DNA 
plasmid encoding human IgO I in which a CDS epitope of OVA (SIINFEKL) 
was incorporated into CDRH2 region was also used for immunisation and used 
as positive control provided by my co-supervisior, Dr. Lindy Durrant (School 
of Molecular Medical Sciences, Nottignham University). Splenocytes from the 
immunised mice were collected and cultured in the presence of SIINFEKL 
titrated using ten fold dilutions. IFN-y secreting SIINFEKL specific CDS+ T-
cells were counted by ELlS POT. Mice immunized with SD3-0V A showed 
higher frequency of activated OVA specific T-cells (Figure 4.98) compared to 
mice immunised with plasmid DNA encoding human IgG I containing a CDS 
epitope of OVA (Positive control). Mice immunised with IgO l-OV A (Figure 
4.9C) showed highest frequency ofIFN-y secreting OVA specific CDS+ T-cells 
even more than the positive control and SD3-0V A (Figure 4.98). When the 
splenocytes were cultured in the absence of SIINFEKL peptide, no activated T-
cells were observed which indicated that the T-cell activation was OVA 
specific (Figure 4.9D). 
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Figure 4.9: Immunisation of C57BIJ6 mice with DNA encoding the SD3-0V A and 
IgG I-OVA and the assessment of T-cell activation. 
After three vaccinations, splenocytes were collected from the different groups of mice 
immunised with plasmid DNA encoding SD3-0V A, [gG I-OVA and human [gG I 
containing SIINFEKL in its CDRH2 region. Splenocytes were cu ltured in the presence 
of different concentrations of S[fNFEKL peptide which is a CD8 epitope of the model 
Ag OVA. The number of IT -"I ecreting OVA specific T-ce ll s were counted from the 
culture by using EUSPOT assay in which each spot indicated the [F -"I secreting 
OVA specific T-cell. (A) mice immunised with plasmid DNA encoding human [gG 1 
containing SlINFEKL in its CDR.H2 region (positive control) by using gene gun 
method, (B) mice immunised with plasmid D A encoding SD3-0VA, (C) mice 
immunised with [gG I-OVA and (D) Splenocytes cultured in the presence and absence 
of S[INFEKL. Graph shows mean spots/million splenocytes plus standard deviation 
(SD). 
117 
Chapter 4 Ab-Mediated MR Targeting to APCs 
4.4 Discussion 
4.4.1 Generation of MR specific chimeric Abs, their expression and 
purification 
Anti-MR chimeric antibodies were engineered by usmg an anti-DEC205 
chimeric Ab as starting material. Anti-DEC-20S Ab consists of the variable 
region of rat anti-DEC-20S variable region and a mutated form of the constant 
region of mouse IgG 1 that reduces binding to FcyRlIB and FcyRIll (Clynes et 
aI., 2000). In order to generate anti-MR chimeric Abs the variable region of 
anti-DEC-205 Ab was replaced with the variable region of anti-MR mAb 
thereby minimizing the possibility of these anti-MR chimeric Abs to engage 
FcyRs. After genetic manipulation, MR specific chimeric Abs retained their 
ability to bind MR as assessed by ELISA. MR specific chimeric Abs were 
expressed using HEK-293T however we consistently obtained low level of 
expression. To circumvent this issue chimeric Abs were expressed at a larger 
scale. Purified chimeric Abs were analysed by SOS-PAGE and the 
preparations of chimeric Abs such as SD3-0V A and S03-HEL contained a 140 
KDa product that could correspond to a degradation product (indicated by the 
red arrows in figure 4.10). The protein expression protocol was revised in order 
to reduce the degradation of chimeric Abs. Firstly, the time of expression was 
reduced from 4-5 days to 3 days to reduce the cell death and release of cellular 
proteolytic enzymes. Secondly, protesase inhibitors were used during storage 
and lastly the whole protein purification was performed in cold room at 4°C. 
After these series of optimization steps we were successful in geting 
undegraded MR-specific chimeric Abs as shown in figure 4.6 but still these 
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Abs were fo und highly prone to degradation when exposed to room 
temperature as discussed in chapter 7. Moreover, mouse 19G is difficult to 
puti fyas it has poor ab ility to interact with protein G or protein A compared to 
human and rabbit 19G. The exchange of threonine 256 residue in the mouse 
19G Fc region to methionine can enhance the binding of mouse 19G to protein 
A to facilitate the efficient purification of mouse 19G, so the purification of our 
chimeric Abs (lgG I) could be improved by these modifications in their Fc 
region ( agaoka and Akaike, 2003). 
~ ~
~ ~ ~ ~ ~ ~ ~ ~ '{, ~ ~ ~ ~ ~ ~ \).> ~ ~ ~ ~ ~ ~ 0 0 ~ ~ ~ ~ ~ ~ z. z. 
-y -y 
250 KDa 
130 KDa 
Figure 4.10: SOS-PAGE to tes t the integrity of the panel of antibodies used in 
this project. 3 ~ l g g of antibodies were separated in 6% acrylamide gels and stained with 
Simply Blue safe stain. Red arrows indicate the position of degraded product of 503-
OV A and 503-HEL Abs. Molecular weight (MW) markers are shown on left. 
Once the chimeric Abs were purified, their cellular binding and uptake should 
have been investigated by using stable transductants expressing fu ll length MR 
such as CHO-MR cells (Martinez-Pomares et a!., 2003) or using DCs and 
macro phages derived fro m the bone marrows of WT and MR-/- mice. 
Moreover, we could have injected MR-specific chimeric Abs into the fore limbs 
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of mice in order to analyse the potential of these Abs to target MR+ DCs in the 
secondary lymphoid organs. The presence of the chimeric antibodies could 
have been be detected in peripheral lymph nodes by immunohistochemical 
analysis as described by Mckenzie et al. (McKenzie et aI., 2007). But due to 
the lack of time (the optimization of Abs expression and elimination of the 
degradation product took a long time) we focussed on antigen presentaion 
assays to investigate the capacity of chimeric Abs to deliver Ag to APCs and 
promote T -cells proliferation using T -cells hybridoma such as MF2, B3Z and 
lCS.l. 
4.4.2 Cross presentation of commercial OVA and proliferation of 
B3Z T-cell hybridoma. 
Functional studies were initiated by testing the ability of BMDC to promote 
CD8+ T-cell activation when fed with a commercial preparation of OVA using 
in vitro antigen presentation assays with the OVA-specific MHC-I restricted T-
cell hybridoma, B3Z. We also demonstrated that OVA acts as a MR ligand 
(Figure 4.1). Burgdorf et al. (2006) demonstrated that MR is required for OVA 
cross presentation but they did not show that OVA bound MR. These authors 
also showed that in both in vivo and in vitro systems, soluble OVA requires 
MR for its uptake by DCs and cross presentation (Burgdorf et ai., 2006). OUf 
endocytosis assay using CHO cells expressing full length MR, confirmed that 
the internalisation of OVA by BMDCs (in vitro) is likely mediated by MR 
(Figure 4.2). Thus, we can conclude that OVA binds to MR and its uptake is 
MR-dependent. BMDCs were generated in our lab by using both wild type and 
MR deficient knockout mice. Consistent with the earlier study (Burgdorf et ai., 
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2006) MR was highly expressed by BMDCs generated with GM-CSF (Figure 
4.4). 
Burgdort: Scholz et at. (2008) proposed a cross presentation pathway! 
mechanism in which MR mediated uptake of soluble model Ag such as OVA 
by DCs leads to its accumulation in the stable early endosome compartment 
and facilitates cross-presentation. They demonstrated that endotoxin a common 
contaminant in OVA preparations is very important to recruit transporter 
associated with antigen processing (TAP) in the early endosomes. TAP 
transports Ag to the cytoplasm for its proteolytic digestion into peptides and 
reimports peptides into the same early endosome compartment for cross 
presentation (Burgdorf et at., 2008). However, Segura et at. (2010) repoted that 
MR mediated endocytosis of soluble Ag by DCs leads to cross presentation 
only in inflammatory conditions but not in steady-state conditions (Segura et 
at., 2009). 
The ability of OVA to be cross-presented was analysed by co-culturing 
BMDCs and B3Z and measuring IL-2 produced in the supernantant. When 
MR+!+ BMDC were fed with SIINFEKL peptide (MHC-I epitope) induced the 
same T-cell proliferation as MR-deficient BMDCs which indicated that the 
general ability of BMDCs to activate B3Z T-cell hyridoma is not affected by 
the absence of MR. In our cross-presentation model, very poor activation of 
B3Z T-cell hybridoma was observed compared to previous studies (Burgdorf et 
at., 2006, Burgdorf et at., 2007) but still, a minor effect of MR could be 
observed as shown in figure 4.5. 
121 
Chapter 4 Ab-Mediated MR Targeting to APCs 
Several possible reasons could be suggested for the lack of IL-2 productions in 
our cross presentation model. First, we know that the uptake of soluble OVA is 
likely mediated by the MR. We could test if in our BMDCs, OVA is also 
internalised and if this internalisation is MR-dependent. Second, the lack of 
antigen processing ability of DCs might be the cause of the failure of cross 
presentation. In order to address this question, BMDCs were co-cultured with 
MF2 (OVA-specific CD4+ T-cell hybridoma) in the presence of commercial 
OVA, to investigate whether OVA is being internalised, processed through the 
MHC class II pathway by the BMDCs used in our co-culture assays. IL2 
production by MF2 indicated that BMDC were capable of OVA uptake and 
processing. Another cause might be the lack of sensitivity of the B3Z T-cell 
hybridoma. So, the possibility of using naive T -cells isolated from transgenic 
OT-I cells instead of the B3Z cells might be considered, as it had been shown 
to be very sensitive to cross-present OVA in vitro (Burgdorf et aI., 2006). 
4.4.3 In vitro presentation of OVA and HEL containing reagents to 
CD4+T-cells, MF2 and lCS.l T-cells bybridomas 
Antibodies are more sophisticated and specific tool to target antigen to APCs 
(Keler et aI., 2007). Anti-MR chimeric Ab carrying the model Ag HEL (5D3-
HEL) was generated to deliver Ag specifically through MR as glycosylated 
proteins such as OVA could bind more than one receptor which leads to Ag 
delivery through several receptors and potentially, a different immune 
outcome. HEL Ag was replaced with the OVA-minigene in order to generate 
the chimeric antibodies, 5D3-0V A and IgG I-OVA due to the following 
reasons. Firstly, OVA has been widely used in MR-mediated Ag presentation 
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studies, so it would more appropriate to use OVA to compare results obtained 
in this study with earlier findings in which OVA has been used as a model Ag. 
Secondly, we had access to OVA specific CD4+ and CDS+ T-cell hybridoma in 
order to perform Ag presentation studies in vitro. Moreover, cancer cells 
expressing OVA Ag are available to assess the potential ofthese novel reagents 
to treat cancer. 
The response of the OVA-specific CD4+ T-cells (MF2) was examined in the 
presence of commercial OVA, SD3-0V A and IgO 1-0V A by using co-cultures 
of BMDC and MF2. In this assay, as described in results section figure 4.7, we 
used different doses of commercial OVA and chimeric antibodies carrying 
OVA but lacked the MR-/- control. Commercial OVA induced antigen specific 
CD4+ T-cells in a dose-dependent manner similar to SD3-0VA and IgO 1-
OVA. CD4+ T-cell proliferation was not enhanced by using SD3-0VA. In a 
previous assay we used BMDCs derived from both WT and MR-I- mice and 
CD4+ T -cells proliferation was found to be independent of MR (Figure 4.11), 
this is in agreement with studies reported earlier (Burgdorf et aI., 2007). 
Burgorf et aI. (2007) demonstrated that OVA-specific CD4+ T-cells (OTII) 
proliferation is completely independent from MR and that Ag uptake through 
MR targets OVA into early endosomes and result in OVA-specific CDS+ T-cell 
activation. These authors demonstrated that APC use distinct Ag uptake 
mechanisms and target the Ag to different intracellular compartment 
specialised for Ag presentation to CD4+ and CDS+ T-cells as shown in figure 
4.12. 
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They proved that OVA-specific CD4+ T-cells proliferation is dependent on the 
pinocytosed OVA using dimethylamiloride (DMA); an inhibitor of pinocytosis 
that keeps receptor mediated endocytosis intact. OVA-specific CD4+ T-cells 
proliferation was abrogated in the presence of DMA indicating the importance 
of pinocytosis in CD4+ T-cells proliferation. DCs uptake Ag contitutively 
through pinocytosis (independent of MR), which justifies CD4+ T-cells 
responses obtained by 5D3-0VA and IgG-OVA. However, the same isotype 
control did not induce CD4+ T-cells proliferation in vitro when used with anti-
DEC205 Ab to deliver Ag to DCs as reported by Bonifaz et al. and Hawiger et 
al. (Bonifaz et ai., 2002, Hawiger et ai., 2001). Tsuji et ai. reported that in vivo 
immunisations of anti-MR Abs fused to a tumour Ag can induce tumour 
specific CD4+ and CD8+ T-cells immunity but not the isotype control (Tsuji et 
al., 2010). So, either 5D3-0VA Ab lost its ability to bind cellular MR due to 
degradation as mentioned in section 4.4.1 or genetic manipulation, or the 
isotype control binds to some endocytic receptor expressed on DCs. In order to 
address this question a positive control such as DEC205-0VA (Anti DEC205 
Ab fused with OVA) should be generated to compare in parallel the effect of 
antigen targeting through MR (5D3-0V A) and DEC205 (DEC205-0V A) to 
Ag presentation and T-cells activation. 
Moreover, when analysing these results it should be considered that the tools 
used for Ag targeting through MR in most of the above mentioned studies are 
mannosylated proteins and MR is not the only receptor specific for 
mannosylated proteins. Other receptors such as SIGNR 1 in mouse and DC-
SIGN in humans recognise and are involved in the uptake of high mannose 
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oligosaccharides (Mitchell et aI., 2001). Ags targeted through DC-SIGN are 
directed to the late endosome or lysosome and are efficiently processed and 
presented to CD4+ T-cells (Engering et aI., 2002). 
HEL-specitic CD4+ T-cell hybridoma (1 C5.1) and BMDCs derived from 
BALB/C were co-cultured to analyse the capacity of 5D3-HEL, DEC205-HEL 
and [gGI-HEL to activate Ag specitic T-cells. HEL induced a much reduced 
T-cell proliferation while DEC205-HEL greatly enhanced Ag presentation and 
CD4+ T-cells activation. This is consistent with the studies performend by 
Bonifaz et aI, who demonstrated that OVA presentation and T-cell proliferation 
was increased 300 fold when targeted through DEC205 (DEC205-0V A) as 
compared to unconjugated OVA (Bonifaz et aI., 2002). Compared to DEC205-
HEL, Ag targeting using 5D3-HEL did not induce T-cells proliferation 
possibly due to the lack of MR expression by the BMDCs used in this 
occasion. Moreover, DEC205 differs from MR in Ag presentation as Ag 
targeted through DEC205 delivers the Ag to both early endosomal 
compartment and Iysosomes for MHC-I and MHC-II restricted Ag presentation 
respectively (Gurer et aI., 2008). On the other hand, MR delivers Ag to early 
endosomal compartment only for MHC-I restricted presentation. Therefore, the 
limited T-cells activation observed in response to 5D3-HEL could be 
independent from MR and might rely on the uptake of 5D3-HEL through 
pinocytosis (Burgdorf et aI., 2007). 
Results obtained with the isotype control IgG I-HEL and EgG I-OVA were not 
consistent with the published data (Bonifaz et aI., 2002, Hawiger et aI., 200 I). 
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In our hands the isotype control always induced T-cell activation even when 
used for in vivo DNA immunisation (see 4.4.5). We were concerned whether 
we got the right clones and this was verified by comparing the sequence of the 
isotype control in our lab with that original sequence obtained by Prof Michel 
Nussenweig laboratory (Hawiger et aI., 2001). So, the data obtained using 
chimeric antibodies needs further investigation to clarify these discrepancies. 
Moreover, it should be taken into consideration that the Fc portion of these Abs 
although mutated, can still bind to FcyRI and we need to consider the 
possibility of FeR-mediated uptake/presentation which is dicussed in detail in 
5.4.1. FcrRI is high affinity receptor for IgO, it is widely expressed on DCs, 
macro phages and monocytes (Deo et aI., 1997) and antigen uptake through this 
receptor results in Ag presentation via MHC-I and MHC-II pathway in vitro 
(Wallace et aI., 2001, Tacken et aI., 2006) 
In order to avoid FeR-mediated Ag uptake and presentation single chain Abs 
carrying OVA (ScFv-OV A) or Fab fragments fused with OVA (Fab-OV A) can 
be generated. ScFv comprised of the variable region of heavy (V H) and light 
chain (V d connected by a 15 amino acid linker (Huston et aI., 1988). Fab 
fragments consist of the variable domains and the corresponding tirst constant 
domain: VH-CHI and VL-CL. 
4.4.4 Limitations of in vitro CD4+ T -cells proliferation assay used to 
test anti-MR chimeric Abs 
Anti-MR chimeric Abs generated in this study have been tested by in vitro Ag 
presentation or co-culture assay which is not a very feasible method to test 
reagents involved in MR-targeted vaccines due to the following limitations: 
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Firslty, Anti-MR chimeric Abs such SD3-0VA and SD3-HEL are not stable 
and are highly prone to degradation at room temperature as described in section 
4.4.1 and in chapter 7. During Ag presentation assay (in vitro) BMDCs and T-
cell hybridoma have been co-cultured at 37°C for 18 hours. Therefore, during 
the Ag presentation assay anti-MR Abs could degrade rapidly while the isotype 
control being stable may persist longer to induce T -cells proli feration. In order 
to circumvent this issue the time of incubation can be reduced to 4-hours as 
reported by Singh et aI. (Singh et aI., 20 II). Secondly, Jordens et aI. have 
repoted that up to 20% of the newly synthesized MR is secreted into the culture 
medium in the form of soluble MR (sMR). sMR maintains it binding properties 
and the high amount of sMR released by DCs can bind directly to 5D3-0VA 
and 5D3-HEL and therefore could block or reduce their binding to DCs 
associated MR (Jordens et aI., 1999). Moreover, sMR have also been reported 
by Umut Gazi to be present in FBS used in the culture medium during Ag 
presentation personal (Gazi et aI., personal communication) Moreover, 
collagen fragments might be present in serum. Martinez et ai. reported that 
collagen fragments are MR ligands (Martinez-Pomares et aI., 2006) and 
therefore they could block MR. This was further contirmed by an endocytosis 
assay in which MR-mediated endocytosis by BMDCs was abrogated in the 
presence of collagen (Burgdorf et aI., 2010). 
Due to these limitations of the in vitro Ag presentation assay it will be more 
appropriate to test anti-MR Abs in vivo as reported in the following studies. 
He et ai. described that human anti-MR Ab (B 11) fused with OVA (B II-OVA) 
can induce OVA specific CD4 + and CD8+ T-cell responses when immunized in 
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vivo along with the appropriate adjuvants (He et aI., 2007). Similarly, Tsuji et 
al. demonstrated that B 11 fused with a tumour Ag when injected in vivo induce 
anti-tumour CD4+ and CDS+T-cell responses (Tsuji et aI., 2010). 
4.4.5 In vivo immunisation with DNA plasmids encoding 5D3-0VA 
and IgGI-OVA 
In vivo immiunisations with DNA encoding MR-OV A and [gG I-OVA were 
performed to assess their capacity to activate IFNy producing antigen specitic 
CD8+ T -cells. Mice immunized with plasmid DNA encoding an OVA peptide 
(Immunobody) were used as positive control. Immunobody was generated by 
incorporating the SIINFEKL epitope into the CDRH2 or by direct replacement 
ofCDRH3 of human [gGI. When administered, immunobody targets the Ag to 
APCs through high affinity FcyRs and induce 100 told higher CTL responses 
compared to the peptide only (Pudney et al., 2010). DNA immunisations of 
chimeric Ab were found more effective in inducing T-cell immunity as 
compared to their protein form as shown in figure 4.9 and 5.10. Enhanced T-
cells responses achieved by DNA immunisation (5D3-0VA) as compared to 
Ab (5D3-TRP-2) could be due to its ability to exploit two pathways of antigen 
presentation. Firstly, due to the direct Ag presentation through MHC-[ when 
DNA is transfected into local DCs. Secondly, DNA taken up by the somatic 
cells could be translated and secreted chimeric Abs out of the cells at the site of 
immunisation and taken up by the local DC through either MR or FcyRI and 
result in cross presentation of Ag to induce Ag specific CD8+ T-cell responses 
(Pudney et al., 2010). 
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However, [gO I-OV A induced OVA specific CD8+ Tcell activation similar to 
that induced by 5D3-0V A as in the in vitro assays and it is possible that this 
could be caused by low expression of 5D3-0VA and/or effective targeting 
through FcyR 1. 
4.4.6 Conclusion 
5D3-0V A and [gO I-OVA have been generated and tested tested for their 
binding to MR. In vitro Ag presentation assays using co-cultures of BMDCs 
and T-cell hybridoma such as 83Z, MF2 and lC5.I, were performed to 
investigate the capacity of chimeric Abs to deliver Ags to APCs and activate T-
cells. Plasmid DNA encoding 5D3-0VA and IgO-OVA were also immunised 
in vivo and found effective to induce OVA specific CD8+T-cells. However the 
data obtained by these assays raised questions regarding (i) the validity of 
results obtained with SD3-HEL and SD3-0V A due to their labile nature, (ii) 
the use of in vitro assays when testing MR-mediated Ag presenatation 
presentation because of the presence of sMR in the supernatant, (iii) the 
suitability of leaving the Ag throughout the in vitro co-culturing assay (iv) the 
possibility of FcyR-mediated antigen presentation. 
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5 Antibody-mediated targeting of TRP-2 Ag through 
MR to induce T-cell immunity 
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5.1 Introduction: 
Conventional methods of cancer treatment involves surgery, radiotherapy and 
chemotherapy which adversely atTect the normal tissues: In order to address 
this issue many alternate approaches of cancer immunotherapy are being 
evaluated (Pardoll, 1998). Immunotherapeutic strategies leading to the 
induction of CTL immunity against the relevant Ag is required to treat cancers 
(Zeh et aI., 1999). Many preclinical studies to develope vaccines against cancer 
have been performed. Vaccination studies are complicated as it involves the 
selection of appropriate tumour Ags which are highly immunogenic, 
vaccination strategies (Ag delivery) as the peptide Ags are unstable when 
injected in vivo, adjuvants and cytokines. 
B 16 is a murine melanoma, which spreads spontaneously into the host and it is 
poorly immunogenic but tumour regression could be triggered by 
immunotherapy with the antigens expressed by the melanoma (Moerch et a1., 
2000). Xenoenic Ags such as chicken-OVA and bacterial p-Galactosidase are 
transfected into tumour cells and used often as experimental models in 
preclinical tumour therapeutic studies (Paglia et ai., 1996). These model 
antigens leads to vigorous immune responses as these are non-self antigens and 
lack tolerance, while tumour associated Ags are self and the immune responses 
against them were relatively low due to the presence of tolerance against them. 
So, in order to develop a real model for immunotherapeutic studies the antigens 
used should be self and expressed by both the experimental organism and 
humans, as at the end these studies are going to be translated in humans. 
Melanocyte differentiation Ags (MDAs) is a group of Ags recognised by T-
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cells of melanoma patients associated with MHC-l molecules and includes 
gpI00/pmel-17, tyrosinase, Tyrosinase-related protein I (TRP-l)/gp75, 
Tyrosinase-related protein 2 (TRP-2) and MART -IIMelan-A (Bronte et aI., 
2000). To break tolerance and induce active immunity against these different 
tumour-associated self antigens, different vaccination strategies have been 
adapted which include immunisation with: antigen (peptide)-pulsed DC, naked 
DNA using gene gun method, purified antigens mixed with endotoxins and 
antibodies fused with Ag to target DC receptors (Bellone et ai., 2000). 
TRP-lIgp75 Ag expressed in insecT-cells or when trasfected as DNA led to 
induction of immunity and the eradication of the melanoma but it also caused 
depigmentation of the skin (Vitiligo) due to autoimmune response and 
destruction of some normal melanocytes sharing TRP-lIgp75 Ag expression 
(Overwijk et aI., 1999). TRP-2 antigen is expressed by normal and malignant 
melanocytes in both mouse and human (Wang et aI., 1996, Bloom et aI., 1997) 
and is ideal for vaccination as TRP-2 specific T-cells have been identitied in 
melanoma patients which show that it is an immunogenic Ag. lmmunisation 
with plasmid encoding murine TRP-2 antigen induced CTL responses in mice 
which led to the eradication of 8-16 melanoma cells but did not cause vitiligo 
which makes this Ag a good candidate for vaccination (Wang et aI., 1996). 
MR-specific antibodies fused to cancer antigen NY -ESO-l have been used to 
target dendritic cells specifically and result in the induction of antigen-specitic 
CD8+ and CD4+ T-cells which makes it a promising approach to develop 
strong immunity in cancer. DCs targeting through MR in the presence of an 
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appropriate ajuvant leads to cross presentation and the induction of powerful 
CTL immunity required for the immunotherapy of cancer (Tsuji et ai., 2010). 
In this study, MR specitic mAb (503 and 6C3) and isotype control Ig02a 
(Martinez-Pomares et aI., 2003) have been conjugated covalently with TRP-2, 
a MHC-I restricted melanoma Ag. Binding of antibodies to MR before and 
after conjugation have been analysed by ELISA in order to assess the effect of 
chemical coupling on the binding, moreover MR-mediated internalization have 
also been assessed by using CHO cells expressing MR. TRP-2 conjugates were 
injected subcutaneously into mice in the presence of MPLA and CpO as 
adjuvants. After two booster doses mice were sacrificed and spleens were 
collected and TRP-2 specific T -cells secreting IFNy were counted by 
ELISPOT. 
5.2 Materials and methods: 
5.2.1 Mice 
C57BLl6 mice were bred at BMSU as described in section 2.1.1. 
5.2.2 Synthesis ofTrp-2 peptide and its deprotection 
Tyrosinase related protein 2 (TRP-2) (SVYOFFVWL) (Bloom et aI., 1997), 
was synthesized at The Biopolymer Synthesis and Analysis unit, Nottingham 
University with an added cysteine at the C-terminus of the petide to generate a 
free sulfhydryl group to facilitate the chemical coupling to the anti-MR 
monoclonal antibodies and isotype control. A biotin molecule was added at the 
C-terminus of the peptide using a PEO (Polyethylene glycol) spacer (Pierce 
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Biotechnology) to track the labelling. The crude TRP-2 peptide was 
deprotected by overnight mild acid treatment. After deprotection the TRP-2 
peptide was purified by high performance liquid chromatography (HPLC) and 
analysed by Q-TOF mass spectrum. 
5.2.3 Chemical coupling of TRP-2 peptide to anti-MR and isotype-
matched control monoclonal antibodies (mAbs) 
Dr. Weng Chan helped in the chemical coupling of TRP-2 peptide with anti-
MR mASs (School of Pharmacy). Sulfosuccinimidyl-4-(N-maleimidomethyl) 
cyclohexane-l-carboxylate (Sulfo-SMCC) (Pierce Biotechnology) was used to 
activate the monoclonal anti-MR antibodies 503 and 6C3 and their isotype 
control IgG2a (Martinez-Pomares et al., 2003). The mAbs were treated with 
Sulfo-SMCC at a 10:1 molar ratio for 30 minutes to generate sulfo-reactive 
groups. The activated mAbs were purified by size exclusion chromatography, 
using O-salt dextran desalting column (Pierce Biotechnology) following the 
manfacturere's instructions. The mAbs were eluted in PBS and quantified by 
BCA protein quantification assay (Pierce Biotechnology). 
The TRP-2 peptide containing the sultbydryl group was freshly prepared by 
dissolving it in 20% OMSO-H20 at concentration of I mg/ml. The solution 
containing TRP-2 peptide was mixed with the monoclonal antibodies at a 5: I 
molar ratio and incubated at 3TC for I hour. The mix was further incubated 
overnight at 4°C for better coupling (Figure 5.1). Antibody-peptide conjugate 
was purified by protein G chromatography following the protocol described in 
section 2.2.1. Purified conjugates were dialysed against PBS using Dialysis 
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cassettes (Pierce Biotechnology). The dialysed conjugates were quantified by 
BCA protein quantification assay and the extent of biotinylation (number of 
peptide coupled to mAb) was determined by using the Fluoreporter kit 
(Invitrogen) following the instructions provided by manufacturer. 
S.2.4ln vitro TRP-2 specific antigen presentation assay 
5.2.4.1 Harvesting the bone marrow and generation of BMDCs 
GM-CSF induced bone marrow derived DCs were generated tollowing the 
protocol described in section 2.3.1. 
5.2.4.2 Generation of TRP-2 specific T -cells 
TRP-2 specific T -cells were generated by Dr. Victoria at City Hospital, 
Department of Clinical Oncology, University of Nottingham. 
5.2.4.3 Co-culture assay 
DCs were incubated with 50/-lg of conjugates overnight and then co-cultured 
with TRP-2 specific CTLs at City Hospital, Clinical Oncology department. 
ELISPOT assay was performed in order to look at the ability of TRP2-specific 
CTLs to recognize TRP-2 presented by these DCs and their activation 
measured by ELISPOT. 
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Figure 5.1: Schematic diadram showing the mechanism of chemical coupling of TRP-2 peptide to SD3 and other JgG molecules. 
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5.2.5 Immunisation studies 
Mice were divided into four groups for vaccination experiments. Each mouse 
was injected subcutaneously at the base of the tail with 1 Ollg of anti-MR mAbs 
or their isotype-matched control covalently coupled with TRP-2 along with 
61lg of MPLA as an adjuvant. One group was immunised with IB DNA-TRP-2 
plasmid by gene gun method and it was used as a positive control 
(Metheringham et at., 2009). Plasmid DNA carrying the TRP-2 gene fragment 
was coated on 1.0 11m gold particles following the manufacturer's instructions 
(Biorad, Hemel Hempstead). DNA particles were administered intardermally 
into the shaved abdomen of the mice by using Helios Gene Gun (Biorad) and 
each mouse was immunised with 1.01lg of DNA per immunisation. After this 
primary immunisation, secondary and tertiary immunisations were done one 
week apart to act as booster doses. One day after the tertiary immunisation, 
mice were sacrifice and their blood, lymph nodes and spleens were collected in 
order to analyse the immune response against TRP-2 antigen and ratIgG. 
In-vivo immunisations were repeated by following the same parameters except 
MPLA (3Ilg) and CpG (3Ilg) were used as adjuvants instead of using only 
MPLA, during second immunisation. 
5.2.6 ELISA to detect humoral response against rat-IgG 
Serum was collected from the blood of immunised mice and analysed for 
humoral response in the form of anti-rat IgO which was detected by using 
ELISA. MAXISORP 96 well flat bottomed plates (Nunc Cat no 439454) were 
coated with 10 Ilglml of rat IgG. The coated plates were incubated overnight at 
4°C. The next day the plate was washed three times with PBS and blocked with 
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3% BSA in PBS for an hour at 3TC. Then, it was washed 3X with PBS-O.l % 
(v/v) Tween 20 and incubated with appropriate dilutions of sera for an hour at 
room temperature. Then the plate was incubated with donkey anti-mouse IgO-
AP diluted 1 :2000 (Jackson Immunoresearch laboratories) tor one hour. The 
plate was again washed 3 times with PBS 0.1 % (V/V) Tween20, tollowed by 2 
times with AP developing butTer (100 mM Tris-HCl, lOO mM NaCl, 1 mM 
MgCI2.6H20 pH 9.5), before being incubated with 1 mg/ml of p-nitrophenyl 
phosphate substrate (SIGMA). The 00 absorbance was measured at 405nm on 
a 96-well plate reader (MultiskanEX; Labsystem). 
5.2.7 ELISPOT to detect TRP-2 specific T-cells producing IFNy 
ELISPOT assay was used to determine the frequency of peptide-specitic IFNy-
secreting T-cells in murine splenocytes and in in vtro assay, using mouse IFNy 
ELISPOT kit (Mabtech) and following the protocol described in section 4.2.9. 
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5.3 Results 
5.3.1 Preparation of Anti-MR-TRP-2 conjugates and their 
characterization 
The TRP-2 peptide was synthesized and purified by high perfonnance liquid 
chromatography (HPLC). The purity of the molecule was found more than 
70% as shown in the Figure 5.2. The main HPLC peak was analysed using Q-
TOF mass spectrum and two molecules of molecular weight 1704.829 Dalton 
and 1750.815 Dalton were observed respectively. The increase in mass in the 
1750.815 peak was found due to the addition of tert-Butyloxycarbobnyl (SOC) 
molecule which is used to protect reactive amines during the synthesis of 
peptides (Figure 5.3). The TRP-2 peptide was then deprotected by overnight 
treatment with mild acid. After deprotection the peptide was Iyophilised again 
and analysed by Q-TOF. A single peak of mass 1706.81 was observed after 
deprotection (Figure 5.4). Oeprotected TRP-2 peptide was then chemically 
coupled to the anti-MR mAbs and their isotype control by covalent bond. 
After, chemical coupling the conjugates were purified by affinity 
chromatography and their degree of labelling was calculated by using a 
tluoreporter kit. The degree of labelling of 503-TRP2, 6C3-TRP2 and [g02a-
TRP2 was found to be 1.2, 1.5 and 1.7 peptides per molecule of [gO 
respectively. 
The purified conjugates were analysed by SDS-PAOE and a shift in the size of 
mAbs was observed as shown in Fig.5.5.A. In order to continn the presence of 
biotinylated peptides western blotting using streptavidin-peroxidase conjugate 
was performed and clear bands showed the successful conjugation. On the 
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basi of band intensity the degree of labelling was contl11l1ed as calcul ated by 
fluoreporter kit. [gG2a-TRP2 showed highest intensity then 6C3 -TRP-2 and 
5D3-T RP-2 show d the least intense band on western blot Fig.5.6. 
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Figure 5.2 : Reverse-phase chromatogram of TRP-2 peptide synthesized at the 
Biopolymer Synthesis and Analys is Unit, Nottingham University. 
1< igure 5.3: Chromatogram obtained by the Q-TOF mass spectrum analys is of 
main HPLC peak shown in figure 5.1. 
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Figure 5.4: Q-TO F mass spectrum a nalysis of the T RP-2 peptide after its 
deprotection. 
The crude TRP-2 peptide was deprotected by overnight treatment with mild acid and 
purified using HPLC by the p ptide synthesis facility . Q-TOF mas pectrum analysis 
was perfornled to confirm the deprotection ofTRP-2 peptide. 
250 KOa 
130 KOa 
Figure 5.5: SOS-PAG E analys is of anti-MR monoclonal 503 and 6C3 and IgG2a 
before and after chemical coupling. 
l.5,ug of the mAbs wa loaded on a 6% SDS-P GE and proteins were vi uali ed by 
gel staining with blue afe for one hour and destained with distilled water overnight. 
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Figure 5.6: Western Blot to confirm chemical coupling of biotinylated T RP-2 
peptide to the monoclonal antibodie . 
150 ng of c njugates were electrophoresed on 6% SDS-PAG E and transfetTed to the 
nitrocellulo e membra ne. The nitroce ll ulo e membrane was blockcd with 4% BS 111 
PBS and the biotin molecule in TRP-2 peptide coupled to the m b " a detected 
u ing streptavid in-HRP. 
5.3.2 Analysis of the binding of anti-MR conjugates to recombinant 
MR-constructs 
The bi nding abil ity of the m bs after chemical coupling was determi ned by 
ELISA using the MR-con truct CTL0 4-7-Fc as Ag. After chemical coupl ing 
anti-MR conj ugates showed binding to MR domain CTL0 4-7Fc. The chemical 
coupling eemed to reduce the bind ing ability of both anti-MR mAb uch S0 3 
and 6C3 but its affect was more on the binding of 6C3 a hown in Figure S.7. 
The iso type-matched contro l of the anti -MR mAbs did not howed any binding 
before and after chemi cal coupling. 
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E Before chemical coupling 
em After chemcal coupling 
Figure 5.7: Binding of anti-MR monoclonal antibodies to CTLD4-7-Fc before 
and after chemical couplino of TRP-2 peptide. 
The plate wa coated with S ~ l g l m l l of CTLD4-7Fc, which i recognised by anti-MR 
mAbs, followed by the addition of 1 ~ ~ / m l l anti-MR mAb and anti-rat-AP conjugated 
antibody a a econdary antibody and the level of binding \Va measured by taking 
ab orbance at 405nm after the addition of I mglml of p-nitrophenyl phosphate 
sub trate. 
5.3.3 iVlR-mediated endocytosis of different TRP-2 conjugates 
[n order to analyze the MR mediated internali zation of anti-MR conjugates 
CHO cell line expressing MR (CHO-MR) wa used and WT CHO was u ed a 
a negative control. CHO and CHO-MR were incubated with anti-MR mAbs 
and the level of internalization was a essed by usi ng lexa4 8-1abelled anti-
rat fgG a econclary Ab and flow cytometric analy is. Anti-MR mAb 6C3-
TRP2 showed better internalization as compared to 5D3-TRP2 (both shown in 
blue histograms) as hown. The isotype control (shown in red histogram) did 
not how any endocytosi as shown in Figure 5.8. 
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Figure 5.8: Histograms showing MR-mediated internaliza tion of different anti-
MR mAbs conjugates. 
CHO and CHO-MR cell were incubated with 20).lg/ml of anti-MR-TRP2 conjugates 
for 30 minutes fo llowed by permeabilization of the cells and incubat ion with 
Alexa4 8 labelled anti-rat IgG. 
5.3.4 Analysis of the ability of anti-MR conjugates to deliver TRP-2 
to Des and activate TRP-2 specific T -cells in vitro. 
The abili ty of conjugates to activate TRP-2 pecific T-cell re pon e wa 
a se sed by co-culture of BMDC fed with anti-MR-TRP-2 conj ugates with 
TRP-2 specific T-cells cultured by Dr. Victoria Pudney (City Hospital, Clinical 
Oncology depaltment). Activation of, IF -y secreti ng TRP-2 specific T-cel l 
was assessed by using ELIS POT. T RP-2 pecitic CTLs and DCs alone were 
con idered as the negative control and howed a negligible number of cells 
xpressing IF -y a hown in Figure 5.9 . In the absence of TRP-2 peptide 
RMAS cell s (A non profes ional antigen presenting cell line which i u ed as a 
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positi ve control 111 the presence of TRP-2 peptide) did not show any T-cell 
activation capacity, but it howed v ry good T-cell activation in the presence of 
T RP-2 peptide which indicates that T-cell activation in thi as ay i TRP-2 
specific (Figure 5.9). Generally, conj ugat s did not howed very good CTL 
activation potential except 6C3-TRP2 which showed marginally a better 
re pon e a hown in the Figure 5.9. 
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Figure 5.9: EL[SPOT a ay showing the number of IFN-y secreting Tltr-2 
specific T-cells when cocultured with BMDCs in re pon e to anti-MR conjugates 
ilt vitro. 
Mouse BMDCs fed wi th anti-M R conjugates (IgGs) were co-cu ltured with a T RP-2 
sp cific T-cell line ovemight. The numb r of [F -y secreting TRP-2 pecific T-cell 
wa counted fro m the culture by using ELISPOT. Rl\1AS is a non prote s iona l antigen 
presenti ng ce ll line wh ich i used as a po itive contr I in the pre nce of TRP-2 
peptide. Graph hows mean pot Imillion plenocytes plus tandard deviation (SO). 
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5.3.5 Immunisation with anti-MR conjugates using MPLA only and 
mix of MPLA and CpG as adjuvants. 
5.3.5.1 Analysis of TRP-2-specific T -cells activation 
TRP-2 was synthesized and conjugated to anti-MR mAbs in order to target 
TRP-2 to APCs and induce TRP-2 specific CD8+ Tcells. DNA plasmid 
encoding TRP-2 Ag delivered using a gene gun method was used as positive 
control. Initially, immunisations were pertormed by using MPLA only as an 
adjuvant but it didn't show promising results as the number of activated TRP-2 
specific T -cells was found to be less than in the case of DNA immunisation 
which was used as a positive control (Data not shown). Immunisations were 
repeated using MPLA and CpG as adjuvants to achieve innate activation 
through TRIF and MyD88 signalling. CpG motifs helps to recruit TAP to the 
early endosome and to cross-present Ag and induce cell mediated immunity 
(Burgdorf et aI., 2008). Moreover, MHC-II loading organelles require 
TLR4/MyD88 signalling to load phagocytosed Ag to MHC-II molecules and to 
induce humoral immunity (Blander and Medzhitov, 2006). 
Splenocytes from the immunised mice were collected and IFN-y secreting 
TRP-2 specific T-cells were counted using ELISPOT. Mice immunized with 
5D3-TRP-2 conjugate showed highest frequency of activated TRP-2 specific 
T-cells (Figure 5.10 B) as compared to mice immunised with plasmid DNA 
encoding TRP-2 peptide (Positive control). Mice immunised with IgG2a-TRP-
2 (Figure 5.10 C) showed relatively less frequency when cultured in low 
peptide concentration but at higher peptide concentration the frequency was 
even more than positive control (Figure 5.10 A). 
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Figure 5.10: Analysis of TRP-2 specific T-cell responses in mice immunised with 
anti-MR conjugates along with MPLA and CpG as an adjuvant. 
After three vacc inations, splenocytes were collected from the different groups of mice 
immunised with the TRP-2-conjugates and cultured in the presence of di ffe rent 
concentrations of the TRP peptide. The number of IF -y secret ing TRP-2 specific T-
cells was counted from the culture by us ing ELlS POT assay in which each spot 
indicated the presence of [F -y secreting TRP-2 specific T-cell (A) Mice immunised 
with the TRP-2 encoding 0 A (8) Mice immunised with SD3-T RP-2-conjugate and 
(C) Mice immunised with [gG2a -TRP-2 conjugate. Graphs show mean spots/million 
splenocytes plus standard devi at ion (SO). 
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5.3.5.2 Anti-rat IgG Ab response in animals immunised with Rat-lgG-
TRP-2 conjugates. 
The antibody response against anti-MR conjugates was measured by ELISA in 
the sera from mice immunised with TRP-2-mAb conjugates using MPLA as 
adjuvant (Data not shown) or using a mixture of MPLA and CpG (Figure 
5.11). A good anti-rat antibody response was observed in the mice immunised 
with 5D3-TRP-2, 6C3-TRP-2 and IgG2a-TRP-2 proved that these conjugates 
could induce 8-cell immunityin the presence of adjuvants. The tourth hTfOUP 
immunised with plasmid DNA did not showed any anti-rat antibody (anti-rat 
IgG) response which showed that the antibody response was specific against 
rat IgG. Second time mice were immunised with TRP-2 conjugates in the 
presence of MPLA and CpG as adjuvants similar pattern of anti-rat antibody 
response was observed. 
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Figure 5.11: Measurement of anti-rat IgG humoral responses in mice immunised 
with rat-lgG using ELISA. 
Serum was collected from the blood of mice immunised with TRP-2 plasmid (A), 
5D3-TRP-2 (8), and 19G2a-TRP-2 (C) and di luted I: 100 to I :24300 using PBS. The 
ELlSA plate was coated with IO,ug/m l of rat IgG and the amount of ant i-rat antibodie 
in different d ilutions of the serum was measured by measuring 00 at 405 nm after 
add ing the alkaline phosphatase substrate to the plates coated with alkaline 
pho phatase conjugated anti-mou e antibody. 
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5.4 Discussion: 
In this study we conjugated the peptide TRP-2, a melanoma-associated CDS 
epitope (SVYDFFVWL) (Bloom et ai., 1997) to MR-specitic mAbs and an 
isotype control rat-IgG2a to investigate the potential of these conjugates to 
target APCs through MR and activate TRP-2 specific CDS+ T-cells which are 
required to treat cancer. McKenzie et ai. reported immunisation with these 
MR-specific mAbs in combination with endotoxin can target MR+ DCs in T-
cell areas of draining LNs and induce enhanced humoral reponses in vivo. The 
humoral responses were completely abrogated in MR-/- mice indicating the 
role of MR to promote B cell responses (McKenzie et ai., 2007). 
A cysteine residue and a biotin molecule were added at the C-terminus of the 
peptide to generate a free sulfhydryl group to facilitate the chemical coupling 
and to track the labelling respectively. Antibody-peptide conjugates were 
successfully generated. The purified conjugates were analysed by SDS-PAGE 
and a shift in the size of TRP-2 conjugated mAbs was observed which 
indicated that the conjugation was successful and this was further confirmed by 
westerb blotting using streptavidin-peroxidase (Figure 5.5 and 5.6). The 
amount of TRP-2 peptide conjugated to each IgG molecule was calculated by 
using a fluoreporter kit. The degree of labelling of 5D3-TRP2, 6C3-TRP2 and 
IgG2a-TRP2 was found to be 1.2, 1.5 and 1.7 peptides per molecule of IgG 
respectively. The same chemical coupling method has been employed in a 
study in which a CD8 epitope of OVA was covalently linked to anti-DNGR-I 
Ab (Sancho et ai., 2008). DNGR-l is a DC-restricted C-type lectin. It is an 
endocytic receptor and antigen targeting using a mAb-Ag conjugate together 
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with adjuvant induced tumour-specific immunity and protected mice 
challenged with tumour cells (816-0VA-GFP melanoma cells) (Sancho et aI., 
2008). 
After chemical coupling the binding properties of anti-MR mAbs to the MR 
domains CTL04-7 was analysed, and reduced binding was observed. Stable 
transductants expressing full length MR (CHO-MR) were employed to assess 
the endocytosis of anti-MR mAbs after chemical coupling of TRP-2 peptide. 
6C3-TRP2 was endocytosed more efficiently as compared to 503-TRP-2 in 
agreement with previous studies in which it was shown that 6C3 mAb has 
more internalization capacity than 503 (Martinez-Pomares et aI., 2003). 
Changes in endocytosis could be due to the chemical coupling or differential 
binding capacity of these mAbs to MR. MR is a recycling endocytic receptor 
and during recycling it releases its ligands inside the endosome, a process 
likely dependent on the quality of the interaction between MR and its ligands. 
As 503 binds more efficiently to CTL04-7 than 6C3 and the release rate of 
503 is also low as compared to 6C3 (see figure 3.4 and 3.5), 6C3 could be 
released into the endosome more efficiently than 503 which would facilitate 
receptor recycling and increase the level of internalization. 
S.4.l/n vivo immunisation with anti-MR-TRP2 conjugates activates 
TRP-2 specific INFy secreting T -cells 
Antigen delivered to APCs through MR using MR-specific Ab along with 
appropriate adjuvants leads to the cross presentation and activation of C08+ T-
cells(Tsuji et aI., 20 I 0, Ramakrishna et aI., 2004, He et aI., 2007). In order to 
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assess the potential ofTRP-2 conjugates to deliver antigen and activate CD8+ 
T -cells, mice were immunized subcutaneously with these conjugates together 
with adjuvant. In the presence of only MPLA no significant T-cell activation 
was achieved. MPLA binds TLR-4 and signals through the TRIF mediated 
pathway (Mata-Haro et aI., 2007). TLR-4 engagement by LPS that signals 
through TRIF and MyD88 is essential for the maturation and migration of local 
DCs loaded with anti-MR Ab to local lymph nodes (McKenzie et aI., 2007). 
Moreover MyD88 signalling recruits TAP to early endosomes which is 
believed to be involved in the transfer of peptide and allows loading on the 
MHC-I molecule in the early endosome leading to cross presentation (Burgdorf 
et aI., 2008). Therefore, the immunisations were repeated using both MPLA 
and CpG as adjuvants as CpG signals through MyD88. 
Mice immunized with plasmid DNA encoding TRP-2 peptide (Immunobody) 
were used as positive control. Immunobody was generated by incorporating the 
TRP-2 epitope into the CDRH2 of human IgG 1. When immunized, 
immunobody targets the Ag to APCs through high atlinity FcyRs and induce 
100 fold higher CTL responses compared to the peptide (Pudney et aI., 20 I 0). 
In our study, Abs-TRP2 conjugates were not as good as the immunobody to 
induce TRP-2 specific CD8+ T -cells. Enhanced T -cells responses achieved by 
immunobody are due to to its ability to exploit two pathways of antigen 
presentation. Firstly, due to direct TRP-2 presentation through MHC-I when 
the immunobody is transfected into local DC present in the skin resulting in the 
activation of CD8+ T-cells. Secondly, DNNimmunobody taken up by the 
somatic cells could be translated and secreted out of the cells at the site of 
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immunisation and taken up by the local DC through FcyR and result in cross 
presentation (Pudney et ai., 2010) however, the comparision would be difficult 
because effective doses of DNA and its protein counterpart might be very 
different. Chimeric Abs induced relatively low T-cells activation as they rely 
only on one pathway of Ag presentaion by Ag targeting to APCs, however 
DNA immunisations exploit both APC and non-APC for Ag expression and 
presentation. Cho et al. analysed the contribution of APC and non APC in 
DNA immunisations by using tissue and cell (APC) specific promoters. They 
demostrated that DNA immunised into non APC induced more rapid and 
vigorous CDS+ T-cells proliferation as compared to APC. Firstly, due to 
relatively more numbers of non APC and secondly, due to prolonged 
expression of DNA in non APC as compared to APC (Cho et aI., 2001). 
In this particular study, the mice immunized with 5D3-TRP-2 induced higher 
frequency of TRP-2 specific CDS+ T-cells activation at relatively lower 
concentration of the peptide as compared to the isotype control (lgG2a-TRP-2) 
which indicated that rat IgG2a could also improve antigen uptake and 
activation of CDS+ T-cells (Figure 5.10). One possible explanation for this is 
the targeting of FcyR by rat IgG2a. The receptors specific for the Fc region of 
IgG (FcyRs) are expressed by many immune cells and are critical for the 
promotion and regulation of immune responses. These molecules were first 
described on macro phages followed by B cells and dendritic cells. Murine DCs 
predominantly express FcrRI, FcyRIIB and FcyRIIl (Nimmerjahn and Ravetch, 
200S). FcyRs can be activating receptors and these include high affinity 
receptor such as FcyRI and low affinity recetor such as FcyRlI1. However, 
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FcyRlIB is an inhibitory receptor (Smith and Clatworthy, 20 I 0). IgO molecules 
complexed with Ag, immune-complexes (IC) have been employed to target 
Ags to DC through FcyRs and to induce Ag specific immune responses. 
ICs can either promote or suppress immune response depending on their 
interaction with FcyRs. ICs engagement through activating FcyRs with an 
immunereceptor-tyrosine based activation motif (ITAM) leads to cellular 
activation. On the otherhand ICs engaged through the inhibitory FcyRIIB 
signal through immunereceptor-tyrosine based inhibition motif (ITIM) that 
inhibit ITAM mediated activation signals (Kalergis and Ravetch, 2002). 
Regnault et ai. reported that Ag uptake by DCs through FcyRs is 100 times 
more efficient as compared to the soluble Ags and uptake through FcyRs 
induce DCs maturation effectively (Regnault et aI., 1999). FcyRs-mediated 
rcs intaemalization results in MHC-lI as well as MHC-I restricted Ag 
presentation or cross presentation of Ags therefore priming both CD4+ and 
CD8+ T-cell responses (Regnault et aI., 1999). 
Akiyana et ai. demonstrated that mouse IgO 1 ang Ig02a molecules complexed 
with OVA are able to target DCs through FcyRs and results in MHC-I and 
MHC-II specific Ag presentation in vivo (Akiyama et aI., 2003). The mAbs-
TRP-2 conjugates are rat-Ig02a which are known to have a very strong affinity 
for activating Fc receptor (Getahun et aI., 2004) and it would be expected that 
antigen delivery through this receptor might lead to cross-presentation and 
activation of antigen specitic CD8+ T-cells. Murai et ai. reported that the 
engagement of MR with its ligand activates or enhances FcyR-mediated 
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phagocytosis of mouse IgO potentially by increasing the number of FcyRs or 
by the enhancement of FcyR function (Murai et aI., 1995, Chavelc et aI., 20 I 0). 
Therefore, the enhanced adaptive immune response obtained in terms ofTRP-2 
specitic CD8+ T-cells activation by mice immunized with 5D3-TRP-2 could 
be caused by Ag delivery through MR and FcyR and by the additive effect of 
MR enhancing FcyR function. 
5.4.2 In vivo immunisation of anti-MR-TRP2 conjugates induces 
humoral immunity 
MR is an endocytic receptor and Ab-mediated Ag targeting through this 
receptor is known to induce Ag-specific humoral immunity (McKenzie et aI., 
2007). In order to analyse whether MR-specific rat IgOs-TRP2 can induce anti-
rat IgO humoral responses, sera from the mice immunized with anti-mAbs 
together with MPLA and CpO as adjuvants were assessed for antibodies 
against rat IgO. Mice immunized with DNA-TRP-2 plasmid were used as a 
negative control and their sera did not contain any significant anti-rat IgO 
compared to mice immunized with 503-TRP-2 and the isotype control mAb 
Ig02a-TRP-2. Relatively lower anti-rat IgO production was induced by Ig02a 
compared to 5D3-TRP2 in agreement with published results using LPS as 
adjuvant (McKenzie et aI., 2007). Both 503 and 6C3 bind to CTL04-7 domain 
of MR but 503 mAb bind more efficiently as compared to 6C3 while the 
isotype control does not show any binding. It was originally concluded that 
differential adaptive immune response in terms of anti-rat IgO production 
could be due different binding efficiencies of anti-MR mAb (McKenzie et aI., 
2007). The adaptive immune response obtained in terms of anti-rat IgO could 
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be due to Ab uptake by APCs through activating Fc receptors which are known 
to have strong affinity for Ig02a antibodies (Oetahun et ai., 2004) promoting 
T-activation and Ag specific Ab production discussed above (Akiyama et al., 
2003). Moreover, CpO used as an adjuvant in this study enhances loading of 
phagocytosed Ag on MHC-II which would activate anti-rat IgO Ab production 
(Blander and Medzhitov, 2006). 
5.4.3 Limitations of the approach and Summary 
In conclusion, Immunisation of anti-MR conjugates along with appropriate 
adjuvants indicated that there is a scope for MR ligands to induce adaptive 
immune responses, resulting in Ab production and antigen-specific T-cell 
activation. These findings will benefit the development of novel antigen 
delivery methods through MR suitable for robust T-cells activation and the 
development of vaccines against cancer other infectious diseases. 
Chemical coupling is an inefficient method of linking Ags with IgO molecules 
as the degree of conjugation is variable even between IgO molecules 
conjugated side by side (Sancho et al., 2008). Therefore, anti-MR chimeric 
antibodies in which Ag was incorporated at the constant region of their heavy 
chains as described in chapter 3 and 4 were the prefered option. These reagents 
have several advantages over chemically linked conjugates. Firstly, each IgO 
molecule contains same amount of Ag. Secondly, the variable region of anti-
MR mAb was incorporated into the constant region of mouse IgO I containing 
mutations in its Fc region and thereby eliminating the possibility of FcR 
engagement and lastly, the contstant region chimeric Abs is mouse IgO 1, so 
157 
Chapter 5 MR-Mediated Targeting ofTRP-2 Ag 
the xenogenic responses can be avoided when immunized in mice. On the 
otherhand, these reagents would not benefit from the potential beneficial effect 
of engaging MR and FeR simultaneously and the use of a non mutated Fe 
portion might need to be re-considered. 
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6 Use of Glycopolymers for Antigen Targeting to 
dendritic cells potentially through MR 
159 
Chapter 6 Use of glycopolymers to target Ag 
6.1 Introduction 
Antigen targeting through different receptors results into different immune 
outcome (Keler et aI., 2007) and even targeting through a single receptor by 
using antibodies of different affinity induced different immune responses as 
suggested by the study conducted by Mckenzie et al (McKenzie et aI., 2007). 
Generation of antibodies against different receptors is expensive, difficult, time 
consuming process. Furthermore it is not easy to generate different antibodies 
of different affinity against a single receptor. Due to these limitations, a more 
robust and convenient alternative method was required for antigen delivery to 
Des in vivo. 
In this study glycopolyrners have been used to target DC through MR as an 
alternative to Ab mediated targeting. MR is an endocytic receptor and the 
binding of ligands is calcium dependent. The CTLD4-7 region of MR has 
affinity for mannose and mannosylated proteins (East and Isacke, 2002). 
Antigen targeting through MR leads to cross presentation and the development 
T-cell immunity which is essential to treat chronic infectious disease and 
cancer (Burgdorf et aI., 2008). 
In biology, carbohydrates are involved in a number of crucial events spanning 
from signal transduction to cellular recognition and can be used as ligands to 
improve the distribution of drugs and Ag to develop vaccines and other 
therapeutic agents to treat human diseases (Seeberger and Werz, 2007). 
Carbohydrates ligands bind to leetins, with C-type leetins being present on the 
cell surface of APC that can act as receptors with a strong affinity and can be 
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used to deliver Ag (Lee and Lee, 2000). In nonnal circumstances, 
monosaccharides interact weakly with their binding proteins, glycan-binding 
receptors. To achieve strong interaction for Ag targeting through C-type lectins 
multivalent interactions are required. These could be achieved by chemical 
modification of the carbohydrate ligands. Therefore, to get a stronger 
interaction, carbohydrate molecules are often placed along a polymer backbone 
and the observed increase in binding efficiency is known as 'the glycoc1uster 
effect' (Ting et aI., 2010). 
Polymers carrying carbohydrate functional groups are known as 
glycopolymers. Glycopolyrners include linear glycopolymers, glycodendrimers 
and spherical glycopolymers in the fonn of nanoparticles and vesicles (Pieters, 
2009). In 2001, Sharpless and co-workers introduced the concept of "click 
chemistry", which defines a modular synthetic approach to generate new 
moieties by joining small units together in order to achieve high yield, as well 
as generating fewer by-products (Kolb et aI., 2001). 
Click chemistry has wide applications in the production of glycopolymers for 
biomedical applications. Potential toxicity due to contamination by residual 
metal catalysts must be taken into account when traditionally synthesised 
products are to be used in biological applications (Wang et aI., 2003). In 
copper-catalysed azide-alkyne cyc1oadditions, a ppm amount of copper 
remains in the product even after the purification. Therefore, an alternative to 
such traditional click reactions had to be developed. Chemists are working to 
develop new "Click" reactions, which can work without the presence of any 
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metal catalyst and thus avoiding associated metal toxicity to living organisms. 
Bertozzi first carried out alkyne-azide cycloadditions at room temperature for 
dynamic in vivo imaging without the use of any copper catalyst (Baskin and 
Bertozzi, 2007, Baskin et aI., 2007). Subsequently, in 2008, Lutz presented an 
alternative idea to perform azide-alkyne cycloaddition without any copper 
catalyst (Lutz, 2008). Post-polymerisation modifications, curing reactions and 
certain polymerisation reactions are widely performed by free-radical addition 
of thiol to a double bond, to facilitae the coupling of peptides with the 
glycpolymers (David and Kornfield, 2008, Nilsson et aI., 2008, Dondoni, 2008, 
Willcock and O'Reilly, 20 I 0). 
This study is a part of a wider project which has the ultimate goal to develop an 
Ag delivery system and vaccine against cancer. In this study functionalisable 
('clickable') polymers were prepared by Atom transfer radical polymerisation 
(ATRP) starting from an initiator which presented a reactive unit able to react 
selectively with free cystein protein sulphidryl units. The polymer alkyne 
repeating units were then clicked with different sugar azides in different 
relative concentration to generate a library of glycopolymers with different 
relative amount of sugar units. Binding of different glycopolymers to MR and 
MR-mediated endocytosis was analysed. In future, glycopolymers will be 
conjugated with recombinant OVA mini-protein: a protein of molecular weight 
of 15 kDa and 136 aminoacid residues containing major CD4+ and CD8+ 
epitopes. Glyco-conjugates will be tested for their potential to induce T-cell-
immunity. 
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6.2 Materials and Methods 
6.2.1 Synthesis of glycopolymers 
Four different glycopolymers containing 100% mannose, 66% mannose/34% 
galacose, 34% mannose, 66 % galactose and 100% galactose were synthesised 
as a part of collaborative project with Dr O. Mantovani (Pharmacy Department, 
Nottingham University) using click methodology. Oregon green was 
incorporated into the glycopolymer molecule to facilitate its tracking within the 
cells as shown in figure 6.1. 
6.2.1 Endocytosis assay of glycopolymers by using flowcytometry 
Endocytosis assays were performed to test the ability of MR to intemalise the 
different glycopolymers using the protocol as described in section 2.2.5 using 
mouse bone derived-macrophages, CHO cells, CHO-MR cells and monocyte 
derived human DC. These cells were generated by following the protocols as 
given below. 
6.2.2 Growing CHO and CHO-MR cells lines 
CHO and CHO-MR cell lines were cultured by following the protocol 
described in section 2.2.6. 
6.2.3 Generation of bone marrow derived Macrophages. 
Bone marrow was collected form C57Bl/6 mice according to the protocol 
described in section 2.3.1 and cultured by following protocol described in 
section 2.3.2. Macrophages were resuspended in RPMI complete media 
defined in 2.1.2 section and used for endocytosis assays of glycopolymers. 
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Figure 6.1: Schematic diagram showing the synthesis of glycopolymer. 
6.2.4 Generation of monocyte derived human dendritic cells 
Monocyte derived human dendritic cell s were cultured according to the 
protocol reported in section 2 .3.3 of thesis. Dendriti c cel ls were used at day 6 
fo r the endocytosis assays of glycopolymers. 
6.2.5 Analysis of endocytosis by confocal microscopy 
Cover s lips were steril ised with concentrated sulphuri c acid and washed several 
times with media to remove the traces of acid . 5x 105 CHO-MR cells were 
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seeded on the cover slip of each well in 12 well tissue culture plates. Bubbles 
under the cover slips were removed to stop cells from sticking to the bottom of 
the cover slip. CHO-MR cells were cultured overnight and washed with PBS 
followed by the incubation of the cells with different glycopolymers for 5 min, 
15 min and 30 min at room temperature. The cells were washed with PBS and 
incubated with ice-cooled 2% paraformaldehyde hepes buffered saline for 10 
minutes at 4°C. Cells were washed again with PBS and incubated with 4',6-
diamidino-2-phenylindole (DAPI) for 3-5 minutes at room temperature. DAPI 
is a fluorescent dye which has a strong binding affinity to A-T rich region of 
DNA. After fixing, the coverslips were mounted onto the slides by using 
fluorescent mounting media and the coverslips were sealed on the slide by 
using nail polish on the edges. 
6.2.6 Lectin ELISA to analyse the binding of glycopolymers with 
mannose receptor 
Lectin ELISA was perfonned to analyse the binding of different glycopolymers 
to different MR-constructs according to the protocol decribed in section 
2.2.4.2. Inhibition ELISA was performed to analyse if the binding of 
glycopolymer to MR is mannose dependent. It was performed as a 
modification of the technique as described in section 2.2.4.3 in which MR 
constructs were prepared in TBS-IM NaCI with with glycopolymers ranging 
from 13mM to O . 1 3 ~ M . .
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6.2.7 Generation of the expression vector encoding OVA mini-
protein 
pBlueRIP vector carrying the full OVA gene was kindly provided by Prof 
Christian Kurts. It was recovered and transfonned into TOP-10 chemically 
competent E.coli and plasmid isolation was done using QIAGEN miniprep kit. 
Purified plasmids were characterized by restriction digestion with HindIII. 
Fragment encoding the OVA mini-gene was amplified using a forward primer 
containing a region complementary to the OVA-minigene, an EcoRI restriction 
site and a leader peptide (MGWSCIILFLV ATA TGVHS). A Cystein residue 
was incorporated at the carboxy tenninus of the OVA-mini protein to facilitate 
its chemical coupling to the glycopolymer. The leader peptide was inserted to 
assist the extracellular localisation of the OV A-miniprotein. The reverse primer 
included the NotI restriction site to facilitate cloning and a His-tag to facilitate 
purification by affinity chromatography as shown in figure using commercially 
available nickel columns as described in section 2.2.1.2. 
The OV A-minigene was PCR amplified by using Phusion enzyme using the 
following PCR programme: 
98°C 40 sec. (Denaturation) 
45 cycles: 98°C 8sec, 58°C 20 sec, noc 30sec. 
72°C 5min. 
PCR products were analysed by agarose gel electrophoresis (1 % w/v) and were 
extracted from the gel using a Gel extraction kit (QIAGEN) according to 
manufacturer's instructions. This extracted DNA and the expression vector 
provided with the DEC205-HEL construct was digested with EcoRI and Notl. 
Reactions were incubated at 3TC for 2-4 hours. After restriction digestion the 
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relevant bands were puritied by agarose electrophoresis and the DNA was 
puritied. The digested OVA-minigene was ligated into the expression vector 
with the help ofT4 DNA ligase (Roche) using a 1:3 molar ratio insert to vector 
The ligation mix was incubated at 4°C overnight in a tinal volume of 10 Ill. 
The ligated plasmids were used to transform One Shot E.coli cells (Invitrogen). 
The transformed cells were incubated overnight at 37°C on LB agar plates 
containing 1001lg/ml ampicillin. Same set of primers used for the amplitication 
of the OV A-minigene were used for the colony PCR screening and using the 
following PCR programme: 
95°C 15 min. (Cell lysis and denaturation) 
35 cycles: 94°C 45 sec, 55°C 45 sec, 72°C 1.5 min. 
72°C 10 min. (Final amplification) 
Positive clones were sequenced at the Biopolymer Synthesis and Analysis 
Unit, Nottingham University by using the vector specific primers as shown in 
table 3.4. 
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pBlue RIP 
trf'()VA OVA 
trf 
Forward Primer 
S'-ATITGAATTCGCCATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAA 
CTGCAACTGGAGTACATTCAATGTTGGTG l g TTGCCTGATGAAG -3' 
Reverse primer 
S'-AGCTGCGGCCGCTIAGTGATGGTGATGGTGATGTGCAGCATCCACTCCA 
GCCTC-3' 
Figure 6.2: pBlueRIP carries a full OVA insert of about 2Kb size and was 
generated by inserting the rat insulin promoter (RIP)/SV40 cassette into multiple 
cloning site (MCS) (SamHI) of pKs-Blue script vector (Stratagcne). 
6.2.8 Removal of the N-glycosylation sites from the OV A-minigene 
by point mutation. 
Two [ -glycosylation sites NLT and LS were identitied in the OVA-
miniprotein and removed by point mutation by designing the special ptimer 
II ing primer3 sftware as hown in table 6.1. Two glycosylation ites were 
removed in two step each step involved the PCR amplification of the whole 
vector catTying the gene of interest and Dpn degradation . The PCR programme 
used for the point mutation was as follow : 
98°C 2 min. (Denaturation) 
30 cycles: 98°C 10 ec, 55°C 15 sec, 72°C 6 min. 
72°C 10 min. (Final amplification) 
For Dpn degradation the PCR product was treated with Dpn enzyme for 4 hour 
at 3 TC to degrade the vector which wa used a a template. After Dpn 
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dige tion the PCR am pl ified vector was transfonned into One Shot E. coli cell s. 
T he transfonned cell were incubated overni ght at 37°C on LB agar plates 
containing 1 O O ~ ~ g g m l l ampicilln , 0 .1 mM IPTG and 4 0 ~ ~ g g m l l X-Gal when 
white/blue election was required . 
Positi ve clone were further screened by sequencll1g to confinn the point 
mutation. The same procedure wa repeated to remove the econd 
glycosylation site except the primers used a shown in table 6.1. 
Pr imer nClllle Primer sequence GC cOlllenl(%) Till ( C) 
Ponit- \ FP AT CAACCTCGCATCTGTCTTAATGGCTATGG 42.2 67 
Ponit- I RP ATTCTGTCTACGCTCCAACAT AAAAGGAGGTA 39.4 66.8 
Poni t-2 FP C GCCAATCTGGCTGGCATCTCCTC 60 67.9 
Ponit-2 RP CCTCTACGGTCGGTCT CCG CTT 56 66.3 
Table 6.1: Two set of primers designed using primer 3 software in order to 
remove two N-glycosylation sites from O VA-mini gene by point mutation. 
6.2.9 Expression and purification of OVA mini-proteins with and 
without glycosylation sites 
OVA mini-proteins with and without glyco ylation site were purified , 
analysed using SDS PAG E and Western as described in sections 2.2 . 1, 2.2.2 
and 2.2 .3. 
6.2.10 Lectin Blot 
O VA mini-proteins with and without glyco ylation si tes were analysed by 
electrophore is using 12% ovex Tris-Glycine precast gels fro m [nvitrogen. 
T ris Glycine running bu ffe r (TGS) was prepared (30.3g T ri s, 144g Gl ycine and 
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109 SDS made up to 1 L with water) and protein samples were run in XCell 
SureLock™ Mini-Cell from InVitrogen under reducing conditions for 1 hr 
30mins at 12SV. Samples were diluted with 4X sample buffer (0.2SM Tris-HCl 
pH 6.8, 8% SDS, 30% Glycerol, 0.02% Bromophenol Blue and 0.3M DTT) 
and heated to 9SoC for S mins prior to loading. Protein concentrations upon 
loading were S ~ g g per well; S ~ l l of a control pre-stained protein ladder 
(Fermentas) was added to track sample migration in the first lane ofthe gel. 
After gel electrophoresis, nitrocellulose membranes (Amersham, UK) were cut, 
soaked in Tris Glycine (TG blotting buffer (2SmM Tris pH8.5, 0.2M Glycine 
and 20% Methanol), gel and membrane were assembled in an Invitrogen XCell 
IITM Blot Module apparatus and soaked with 60 ml of TG blotting buffer. The 
gels were then transferred for 1 hr at 30V. When finished, the membranes were 
blocked overnight with 5% BSA in TSS (0.05 M Tris-HC1, O.IS M NaCI at pH 
7.S) at 4°C. In the glycan detection process, the DIG Glycan Differentiation Kit 
(from Roche Applied Sciences, Germany) was used. The membranes were 
washed twice with TBS and once with buffer I (TBS; 1 mM MgCh, 1 mM 
MnCh, 1 mM CaCh at pH 7.S). The required amount of lectin solution was 
added (for GNA, SNA and DSA 10 ~ l l each; for MAA 50 ~ l l and for PNA 100 
~ l ) ) to 10 ml of buffer 1. All these lectins that are Digoxigenin (DIG) labelled 
(Table 6.2) were incubated separately for 1 hr with the membranes and the 
membranes were then washed three times with TBS to remove any unbound 
antibodies. The secondary antibody was prepared (10 ~ l l of anti-DIG 
conjugated to Alkaline phosphatase (diluted in 10 ml of TBS) and the 
membranes were incubated with the antibody for one hour (Fig 2-1). The 
detection solution was prepared by using 10 ml Buffer 2 (0.1 M Tris-HCI, O.OS 
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M MgC2, 0. 1 M NaCI at pH 9.5) diluted in 200).11 BT/BCIP solution and the 
membranes were then incubated with the detection solution for 20 mins in the 
dark (Colorimetric detection). The reaction was stopped by washing with ultra 
pure H20. Membranes were scanned using BioRad GS800 Densitometer. 
Positive and negative controls are provided with the DIG Glycan detection kit 
and were used in the western blot experiments. 
Labeled lectin Detection 
GNA, Digoxigenin-Iabeled Recognizes tenninal man nose, (1-3), 
(Galanthus nivalis agglutinin) (1-6) or (1-2) linked to mannose 
SNA, Digoxigenin-labeled Recognizes sialic acid linked (2-6) to 
(Sambucus nigra agglutinin) galactose 
MAA, Digoxigenin-labeled (Maackia Recognizes sialic acid linked (2-3) to 
amurensis agglutinin) galactose 
PNA, Digoxigenin-Iabeled (Peanut Recognizes the core disaccharide 
agglutinin) galactose (1-3) N acetylgalactosamine 
PNA, Digoxigenin-labeled 
DSA, Digoxigenin-labeled ( Datura Recognizes Gal- (1-4) 
stamonium agglutinin) 
Table 6.2: The Lectins used to detect glycosylation in allergens. All lectins were 
purchased from Roche Applied Science, Germany. 
The detection of 1,3 fucose was done u ing anti-I ,3 fucose rabbit polyc\onal 
antibody (no. AS07 268, Agrisera, uk). This antibody cross-reacts with fucose 
residues bound to N-Glycans in alpha 1,3 in plants and insects. The 
concentration of antibody used was I ).1g11 Oml of TBS buffer; the reaction 
mixture was incubated for one hour then washed three times with TBS buffer. 
Anti-rabbit antibody conjugated with horseradish peroxidise (Sigma) was used 
as a secondary antibody, again incubated for one hour, washed and the reaction 
was detected using ECL chemiluminescent detection reagent (GE Healthcare 
Life Sciences) according to manufacturer' s protocol. Membranes were scanned 
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using BioRad OS800 Densitometer. Bromelain was used as a positive control 
and Cathepsin from mammalian origin was used as a negative control 
6.2.11 MHC-I1-restricted antigen presentation of purified 
OV A mini-proteins to the MF2 T-cell hybridoma 
MF2 T-cells were were added into APCs (BMDCs) giving an APC: T-cell ratio 
1: 1 as described in section 4.2.6.2. Stock solution of commercial OVA (Profos; 
Hyglos) and prufied OVA mini-proteins were prepared in RIO media and 
I 0 0 ~ 1 1 of serial 2- fold dilution from the stock solution was added per well in 
duplicates, there by giving a titration of relevant OV A antigen from a top dose 
of 2 0 ~ g l m l l to 0 . 6 2 5 2 0 ~ g l m l . . The amount of IL2 in the supernatants was 
quantified as described in section 2.2.4.4. 
6.2.12 Chemical coupling of the glycopolymers to OVA-mini 
protein 
The cysteine (Cys) residue incorporated into the OVA-mini proteins by genetic 
manipulation was used to facilitate chemical coupling to glycopolymers 
through a disulfide bond. Due to the presence of this Cys OVA-mini protein 
dimerized through disulfide bridges and it was reduced before conjugation. 
Tris(2-carboxyethyl)phosphine (TCEP), a commercially available reducing 
agent was used to reduce the OVA-mini protein dimers. Seq. ofTCEP prepared 
in water was added to 10 mM PBS solution carrying OVA-mini protein and the 
final solution was stirred at room temperature for 2 hours. 60eq. of the 
glycopolymers (10 mg) was prepared in 100 mM of PBS (pH 8.0) and mixed 
with the reduced OVA-miniprotein. The resulting solution was kept at room 
temperature for few minutes and left to stir overnight at 4°C. 
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6.2.13 Purification of Glycopolymers conjugates using 
Dynabeads (Invitrogen). 
After the conjugation of the OV A-miniprotein to the glycopolymers the 
conjugates were purified by using nickel-coated dynabeads. For the 
purification using dynabeads it is important that the solution should not contain 
ionic detergents, DTT, DTE, EDTA or any other chelators. TCEP from the 
conjugation mix was removed by diluting it in water or PBS and concentrating 
it using an Amicon filter of MWCO 3 KDa. After the removal of TCEP from 
the conjugation mix the conjugates were purified by using dynabeads 
according to the manufacturer's instructions. 
6.2.13.1 In vitro Ag presentation of glycopolymers-OV A conjugates 
to OVA specific MHC-I and MHC-II T-cell hybridomas. 
Antigen presentation of the glycopolymers-OV A conjugates was performed by 
co-culturing BMDCs and OVA specific T -cells hybridomas. Two types of T-
cell hybridomas were used: B3Z, an OVA specific CD8+ T-cell hybridoma, 
and MF2, a OVA-specific CD4+ T-cell hybridoma. 
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6.3 Results 
6.3.1 Binding of different glycopolymers to MR depends on their D-
mannose content. 
MR belongs to the class of C-type lectin molecules that binds carbohydrates in 
a calcium-dependent manner. We used CTLD4-7-Fc and CR-FNII-CTLDI-3-
Fc, MR constructs to test the binding ability of the glycopolymers MR by lectin 
ELISA. Different concentrations (2J.Lglml-O.252J.Lglml) of the glycopolymers 
were used according to the standard Lectin ELISA. The binding of the CTLD4-
7-Fc MR construct was observed to be dependent on the density of the 
mannose epitopes present in the glycopolymers and the concentration of the 
giycopolymers (Figure.6.3-A). There was no binding to the CR-FNII-CTLDI-3 
Fc-MR construct by any of the glycopolymers (Figure.6.3 B). 
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Figure 6.3: Recognition of different glycopolymers containing different 
percentage of mannose by CTLD4-7-Fc. 
Maxi-sorp EUSA plate was coa ted with g lycopo lymers conta ll1ll1g d ifferent 
percentages of mann ose dil uted in PBS fro m 2fJ.g/ml to 0.25fJ.g/ml fo llowed by the 
addition of 2fJ.g/ml of CTLD4-7Fc (A) or C R-FN[[ CTLD 1-3Fc (B). Anti-human [gG 
Fc- pecific conjugated to AP wa used as secondary Ab; the leve l of bi ndi ng of 
different g lycopo lymer mo lecul es with di ffe rent M R domains was assessed by 
measuring OD at 405nm after add itio n of I mg/ml of p-ni trophe nyl pho pha te 
substrate . Error bar o n each co lumn ind icates SEM. 
[nhibition EUSA was perfomled to confiml that binding of glycopolymer to 
CTLD4-7 Fe domain depends on their manno e content. everal dilutions of 
the glycopolymers (from 13mM to O. I3)..tM) were prepared and mixed with 2 
)..tglml of CT LD4-7- Fc MR. Since man nose has trong binding affinity to 
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CTLD4-7 Fc domain of MR, the glycopolymers containing more manno e 
cpitopc should how morc inhibition of CTLD4-7 Fc binding. Glycopolymer 
containing 66% manno e howed maximum inhibition at concentration of 
0.13m to 0.13 )lM. Other glycopolymer inhibited in the following order: 
100% manno e > "4% manno e. The glycopolymer containing 0% manno e 
did not how any inhibi tion except at higher concentration of 13mM, which 
wa li kely due to over aturation. The opti mal level of inhibit ion of differ nt 
glycopolymcr wa een at th concentration interval O. 13 m M to 0. 13).lM; at 
higher conc ntration complete inhi bition wa observed due to oversaturation 
of giycopo lymer (Figure 6.4). 
1.0 
~ ~ 100% Mannose 
0.8 66% Mannose 
E 34% Mannose c: 
~ ~ 0% Mannose 
-ns 
C 
o 
O.O-'-r---r---r--..,---....---.---
Concentration of Glycopolymers (mM) 
Figure 6.4: Inhibition ELI A to confirm that the binding to the CTLD4-7 region 
of M R depends on the content of ma n nose of the glycopolymers. 
EUSA plate was coated with mannan. Glycopolymers containing different 
percentage of mannose were di luted in TBS ranging from 13mM to 0 0 1 3 ~ l M M mixed 
with 2)lg/ml CTLD4-7 Fc MR. Anti-human IgG Fe-specific conjugated with AP was 
u ed as econdary antibody and the leve l of inhibi tion of CTLD4-7Fc by di fferent 
glycopolymer wa a e ed by taking OD at 405nm after additi n of I mg/ml p-
nitrophenyl phosphate sub trate. Error bar on each column indicates SEM. 
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6.3.2 Glycopolymers containing mannose are internalized by MR-
in differenT -cells. 
Glycopolymers containing terminal mannose binds to MR as shown in the 
lectin ELISA. The endocytosis potential of glycopolymers was assessed by 
endocytosis assay using monocyte-derived human DCs (moDCs) and bone 
marrow-derived macrophages (BM-macrophages). Both types of cells express 
MR as shown in figure 6.5. The level of endocytosis of different 
glycopolymers was assessed using flow cytometry and fluorescent microscopy 
by tracing the Oregon green fluorescent dye. Glycopolymers containing 100%, 
66% and 34% mannose showed similar endocytosis in moDes, but in BM-
macro phages endocytosis levels were as follows: 100% mannose=66% 
mannose>34% mannose. Additionally, glycopolymers containing 0% mannose 
was not endocytosised, which indicates that the endocytosis of the 
glycopolymers is mediated by a mannose-binding lectin. Endocytosis of the 
glycopolymers is dose-dependent as they were better endocytosed at 
concentrations of 10 J.l.glml relative to 5J.1.glml in the case ofmoDCs, while in 
BM-macrophages, a gradual decline in endocytosis from highest dose of 
10J.l.glml to 0.625J.1.glml was observed. After endocytosis for different time 
spans, CHO-MR cells were also analysed by confocal microscopy and similar 
endocytosis levels was observed in glycopolymers containing 100%, 66% and 
34% mannose; glycopolymers containing 0% mannose showed relatively less 
endocytosis (Data not shown). 
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Figure 6.5: Confirmation of MR (C D206) express ion on monocyte derived DCs 
and BM-macropbages by flow cytometry. 
Monocyte-derived human DCs (A) and macrophages derived from mice bone-ma rrow 
(8) were cultured and expres ion of CD206 (MR), CD209 and F4/80 was analy ed by 
FACS. 
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Figure 6.6: Flowcytometric analysis to assess endocytosis of different 
glycopolymers by human moDes. 
Monocyte-deri ved human DCs were cultured and on day 6 DCs were incubated (30 
minutes) with glycopolymers containing 100% mal1l10Se, 66% mannose, 34% 
mannose and 0% malll10se labelled with oregon green. After incubation cells were 
washed with PBS, fixed with 2% formaldehyde and endocytosis was assessed by Dow 
cytometly. 
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Figure 6.7: Flowcytometric analys is of the endocytosis of different glycopolymers 
by bone marrow derived macrophages. 
Macrophages derived from mice bone-marrow were incubated for 30 minutes with 
glycopolymers containing 100% manno e, 66% mannose, 34% man.nose and 0% 
mannose at concentration ranging from 10flg/ml to 0 . 6 2 5 ~ l g / m l . . After incubation 
cells were wa hed with PBS, fixed with 2% fonna ldehyde and endocytosis was 
assessed by flow cytometry. 
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6.3.3 Synthesis of recombinant OVA-mini proteins 
OV A-minigene was subcloned from full OVA gene using specific primers. The 
primers were designed in such a way that a leader peptide followed by cysteine 
residue was incorporated at 5' end and a His-tag was added at the 3' end of the 
OV A-minigene to facilitate protein purification (Figure 6.8A). OVA-mini 
protein was cloned into an expression vector and positive clones were screened 
by colony PCR and DNA sequencing. In order to generate an aglycosylated 
OV A-mini-protein, its two N-glycosylation sites were removed by point 
mutation using two sets of primers as described in Materials and Methods 
(Figure 6.8B). After removal of glycosylation sites the positive clones were 
screened by colony PCR and DNA sequencing. Both glycosylated and 
aglycosylated OVA-miniproteins were expressed in HEK-293T and purified by 
affinity chromatography as described in section 2.2.1.2. The purified OVA-
miniproteins were concentrated using amicon ultra column (Millipore) 
following the manufacturer instructions. The concentrated OVA-mini proteins 
were quantified by BeA protein quantification method and analysed by 
western blotting using polyc1onal anti-OVA antibody as shown in figure 6.9. 
Western blotting confirmed that the protein purified is the OVA-miniprotein. 
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A 
MGWSCIILFLVATATGVHSMLVCLPDEVSGLEQLESIINFEKLTEWTSS 
NVMEERKIKVYLPRMKMEEKYNLTSVLMAMGITDVFSSSANLSGISS 
AESLKISQAVHAAHAEINEAGREVVGSAEAGVDAAHHHHHHstop-
codon . 
B 
Figure 6.8. Schematic representa tion the express ion vector for the OV A-minigenc 
(A) and its protein sequence (B). 
Vector carrying OVA minigene ha a CMV promoter and EcoRl re triction ite at the 
5' end and Hi -tag and ot[ restriction ite at 3' end ( ) . Protein equenee of OV A-
miniprotein with leader equence at the tenninu hown in blue text, OV sequence 
in black and Hi -tag at C-tenninu shown in blue text. The OV A-minigene ha two 
-glycosylation sites NL T and NLS hown in red text which were removed by point 
mutation (8). 
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Figure 6.9: Western Blot analysis using polyclonal anti-OVA antibody to confirm 
the identity of purified OVA- mini proteins. 
200ng of commercial OVA, recombinant OVA-mini and aglyco ylated OVA-mini 
were run in a 12% polyacrylamide gel under non-reducing (A) and reducing 
condition (8). The gel was tran ferred to nitr cellulo e membrane and block d in 
blocking bu ffer. OV was identified u ing a rabbit polyclonal anti-OV antib dyand 
HRP-goat anti-rabbit antibody. 
6.3.4 Recombinant OVA-mini proteins do not bind to MR due to the 
lack of mannosylation. 
Binding of both glycosylated and aglyco ylated OVA-miniprotein to the MR 
domain CTLD4-7 was a sessed by lectin ELISA. Commercial OV howed 
binding (in agreement with data shown in Chapter 3) but OVA-miniprotein 
did not as shown in figure 6. 10. Binding of MR to proteins dep nd on their 
level of man no ylation. The glycosylation pattern of commercial OVA and 
recombinant OV -miniprotein wa asse sed by I cti n blot with the help of Dr. 
Abeer Al-Ghouleh and Dr. Ameer Ghaemmaghammi, by fo llowing the 
protocol as described in ection 6.2. 11 . Commercial OVA and recombinant 
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OVA-miniprotein are highly glycosylated with terminal galactose as compared 
to aglycosylated OVA-mini protein. Commercial OVA also howed terminal 
mannosylation , however neither glycosylated nor aglycosylated OV A-
miniprotein showed mannosylation. No ne of the OVA proteins howed 
tetminal ialic acid a hown in figu re 6.1 1. Glycosylation analys is proved that 
recombinant OVA-mini proteins did not show binding to MR probabl y due to 
the lack of manno ylation, while commercial OV binds to MR due to it 
tetminal manno ylat ion. 
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Figure 6.1 0: Binding analys is of commercial OVA and purified OVA- mini 
proteins to CTL 0 4-7-Fc. 
EUSA plate was coated with 5).lglml of commercial OVA and purified OVA-mini 
proteins and incubated overnight at 4"C, fo llow d by the addition of 5 ~ L g l m l l of 
CTL04-7-Fc and CR-FNlI-CTLOI-3- Fc. Anti-human [gG Fc pecific conjugated 
with AP was used as secondary antibody; the leve l of binding of different OVA 
molecules with different MR domain was assessed by taking 00 at 405nm after 
addition of 1 mg/ml of p-nitrophenyl phosphate sub trate. Error bar on each co lumn 
indicates SEM. 
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Figure 6.11 : Terminal carbohydrate analys is of commercial OVA and purified 
OVA-mini proteins using DIG glycan differentiation kit. 
Different OVA protein (3Ilg) were separated on 12% SDS polyacrylamidc gel and 
tran ferred to nitrocellulose membrane. fter immobilisation the membrane were 
blocked , followed by one hour incubation with different lectin labelled with 
Digoxigenin: (A) DSA recogni es terminal ga lacto e (8) G A recogni e terminal 
mannose (C) MPA recogni es sialic acid (D) P A recognise tCll11inai ga lac to e (E) 
SNA recognises sialic acid. The pre ence of different terminal sugar unit wa 
identified by anti-Digoxigenin-AP and taining so lution provided with the kit (Roche 
Applied Sciences, Germany). 
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6.3.5 DC pulsed with recombinant OV A-miniprotein are more 
efficient activators of T-cell proliferation than commercial OVA. 
T-cell activation potential of commercial OVA and recombinant OVA-
miniproteins were compared by culturing BMDCs (both (WT and MR-/-) 
together with the OVA-specific CD4+ T-cell hybridoma MF2 in the presence 
of different OVA and the amount of IL-2 in the supernatant was measured. 
Aglycosylated OVA-miniprotein was found less effective in inducing T-cell 
proliferation compared to recombinant-glycosylated OV A-miniprotein in both 
MR+/+ and MR-/- DCs. The degree ofT-cell proliferation was the same when 
DCs were fed with 20 ~ g l m l l of recombinant OV A-miniprotein and I O O ~ g l m l l
of commercial OVA. Apparently, glycosylated OVA-miniprotein appeared to 
be 5-fold more potent in inducing T-cell proliferation relative to commercial 
OV A as shown in figure 6.12. Since for the same amount of protein there will 
be more molecules of miniOV A than of commercial OVA, furher work is 
required to determine if mini-OVA could be better presented than unmodified 
OVA. The robust T-cell proliferation in response to OVA induced by MR-/-DC 
was surprising as MR has been shown to be involved in OVA uptake. Further 
dilutions of the Ag are required to address this issue. T-cell proliferation as 
assessed by IL-2 measurement was relatively low with OVA-miniprotein 
having no N-glycosylation sites, which was further reduced in MR-/- DCs 
(Figure 6.12B). 
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Use of glycopo lymers to target Ag 
Figure 6.12: CD4+ T-cell prolifaertion in response to commercial OVA, 
recombinant OVA and aglycosylated OVA protein using co-cultures of BMDC 
and MF2 T-cell hybridoma. 
DCs (5 x I 04 cells) obta ined from the bone marrows of MR+/+ (A) and MR-/- (8) mice 
were fed with different OV A protein at a range of concentrations from I O O ~ l l / m l l to 
0 . 6 2 2 ~ ~ g / m m , , and co-cultured with 5x 104 MF2 T-cells overnight at 37°C and 5% CO2, 
T he level of OV A-specific T-cel l pro li feration wa e timated by mea uring the lL-2 
cytokine in the supernatant of the co-culture. The error bar on each co lumn indicate 
SEM (n= I ) . 
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6.4 Discussion 
The aim of this study was to assess how antigen targeting using novel 
glycopolymers could affect the processing and presentation of the model 
antigen OVA. For this we tested their binding to MR a major C-type lectin 
receptor expressed by DCs. 
Four different types of glycopolymers containing 0%, 34%, 66% and 100% 
mannose were generated by click chemistry and a thiol (SH) group was 
incorporated into the polymer to facilitate efficient conjugation of these 
glycopolymers to model antigens through a disulfide bond. Similarly a 
fluorescent dye, Oregon green was included into the backbone of the 
glycopolymers in order to track these molecules inside the cells. 
Glycopolymers were tested for MR-binding and their ability to bind MR was 
found to be dependent on the amount of mannose monomers on the 
glycopolymer backbone. The glycopolymer containing 0% mannose and 100% 
galactose did not show any binding to MR. This is in agreement with other 
studies in which it has been reported that the amount of mannose in the 
polymer linearly correlated to their binding to ConA, a lectin specific for 
binding to a-D-mannosyl and a-D-glucosyl residues in terminal position (Cairo 
et aI., 2002, Gestwicki et aI., 2002). Endocytosis of the glycopolymers was 
investigated using monocyte-derived human DCs and bone-marrow derived 
macro phages expressing MR as shown in figure 6.6 and 6.7. The endocytosis 
was also found to be dependent on the presence of mannose monomers and 
MR is capable of intemalising mannose-containing glycopolymers. However, 
glycopolyrners containing 100% mannose and 66% mannose showed the same 
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level of binding to MR and endocytosis probably due to saturation or high 
density of mannose monomers on these glycopolymers. Interestingly the 
glycopolymers containing 345% mannose showed reduced MR binding in 
lectin ELISA but was endocytosed as efficiently as glycopolymers containing 
100% and 66% mannose, indicating that poor MR-binding does not have to 
translate into poor intemalisation. Glycopolymers have multivalent interaction 
with lectin receptor and during this interaction a significant amount of the 
sugar monomers is not involved in the binding process due to their high density 
on the glycopolymer backbone. In order to achieve good binding the distance 
between the two sugar monomer on the glycopolymer should be the same as 
distance between the two receptors, therefore flexible polymers with moderate 
sugar density show better binding (Teruaki Hasegawa, 1999). 
Different approaches used for antigen targeting through MR to induce 
immunity involves Ab-mediated targeting (He et aI., 2007) or using MR 
ligands as described in section 1.7. Ligand mediated Ag targeting has been 
successful, for example oxidized mannan linked with the MUC 1 antigen 
(highly expressed by adenocarcinoma) can target DCs through MR. It 
etfectively induces MUC I specific CTL immunity (Apostolopoulos et aI., 
2000); during phase I clinical trials of patients with advanced carcinoma, 
oxidized mannan linked with the MUC I antigen induced tumour specific 
humoral responses in 50% of the patients, but did not successfully induce 
tumour specifc CTL immunity (Karanikas et aI., 1997). However, in phase III 
clinical trials, patients with stage II breast cancer oxidized mannan-MUCI 
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conjugates showed promising results, and the patients receiving this 
immunotherapy were free of tumour recurrence (Apostolopoulos et aI., 2006). 
Glycopolymers bind are a better choice for antigen delivery and vaccme 
development as compared to other methods mentioned above as they can be 
easily manipulated to change the content of mannose residue which directly 
affects their binding properties to lecting receptors. Therefore, libraries of 
glycopolymers having different binding capacities can be generated and tested 
for their potential to deliver Ag and trigger T-cell activation. It has been 
established that glycopolymers or carbohydrates, having high off rate or 
dissociation rate are more potent for Ag delivery and cross presentation which 
is a critical mechanism involved in the development of vaccines against cancer 
and other infections which need CTL based immunity (Howland and Wittrup, 
2008). Synthesis of the glycopolymers employs simple click chemistry and is 
relatively easy and less inexpensive to synthesise glycopolymers on a large 
scale. Recently, Singh et ai. reported that OVA linked to glycans such as 3-
sulfo-LewisA or N-acetylglucosamine targets DCs specifically through MR and 
enhance its cross presentation. Therefore, to avoid binding of glycopolymers to 
multiple receptors the glycopolymers containing 3-sulfo-LewisA or N-
acetylglucosamine monomers could be prepared to target antigen specifically 
through MR. 
Commercial OVA is highly glycosylated with terminal mannose and binds 
MR; it has thus been used as model antigen in MR-related antigen targeting 
studies (Burgdorf et aI., 2007, Burgdorf et aI., 2008, Burgdorf et aI., 2010, 
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Burgdorf et al., 2006). In our study, we generated a shorter fonn of OVA 
(OVA-mini) containing MHC-I and MHC-II epitopes by genetic engineering 
as shown in figure 6.8. A leader peptide and a cysteine residue were added at 
the 5' end and a His-tag was added at 3' end. The leader peptide and His-tag 
were inserted to facilitate protein secretion and its purification while the 
cysteine residue will facilitate coupling to the glycopolymers designed for 
lectin-mediated targeting. N-glycosylation sites in the OVA-miniproteins were 
removed by point mutation to ensure that binding of the glycopolymer-OVA 
conjugates was not through OVA. After the generation of the OV A-
miniproteins their integrity was confirmed by western blotting using polyclonal 
anti-OVA Ab (Figure 6.9). The OVA mini-proteins (l4KDa) contain cysteine 
and form dimers (28KOa) through a disulfide bridge as seen by western blot. 
Additionally, lectin ELISA showed that commercial OVA binds to MR, unlike 
the OV A-miniproteins generated in our lab (Figure 6.10). In order to confirm 
that binding of commercial OVA to MR depends on its mannosylation, 
glycosylation of the commercial OVA and OV A-miniproteins was assessed by 
lectin blot. Only commercial OVA showed terminal mannosylation which 
correlated with its ability to bind MR. The OVA-mini proteins did not show 
terminal mannosylation however, they contain terminal galactose. 
Presentation of different OVA molecules to OVA-specific MHC-II restricted 
T-cell hybridoma (MF2) was assessed using co-culture of BMDCs and MF2, 
the T-cell hybridoma. The glycosylated OVA-mini protein appeared to induce 
CD4+ T-cell proliferation more effectively, while aglycosylated OVA 
miniprotein induced T-cell proliferation to a lesser extent. As indicated in the 
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lectin blot, the OVA mini-proteins contains only terminal galactose which was 
absent in the aglycosylated OVA-mini-protein. Macrophage galactose binding 
lectin (MOL) is expressed by macrophages and recognizes galactose or N-
acetylgalactosamine (Kawasaki et al., 1986, Higashi et aI., 2002). Sandar et al. 
reported that MOL-mediated uptake of soluble Ag results in efficient Ag 
presentaion to CD4+ T-cells. Therefore, the OVA-mini proteins could be 
targetd through MOL and higher CD4+ T-cell proliferation obtained by 
glycosylated OVA-mini could be due to its high terminal galactose content as 
compared to aglycosylated OVA-mini. Overall, the CD4+ T-cells proliferation 
was found to be independent from MR as T-cell proliferation was not affected 
by using BMDC derived from MR-/- mice, which is in agreement to the studies 
reported previously (Burgdorf et al., 2007). Ag presentation is affected by the 
rate of internalisation, cellular trafficking and processing rate. Additional work 
investigating the rate of uptake of all OVA preparations using equal number of 
molecules needs to be done. It needs to be considered that commercial OVA 
contains different glycoforms that will be internalised probably through 
different mechanisms (Burgdorf et al., 2010). 
Conjugation of the OVA-mini protein to the one of the glycopolymer was 
attempted by following the procedure described in section 6.2.13. OVA-mini 
protein has the property to form dimers due to the presence of a cysteine, 
included to facilitate the formation of disulfide bonds. In the first step of 
conjugation, an excess of TECP was used to break the disulphide bond 
between the monomers. A thiol group was inserted into the glycopolymers and 
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they were coupled to the OVA-mini by a di sultide bridge as shown in figure 
6. 13 (Jone ct aI., 2009). 
Glycopolymer Glvcopolymer OVA·minl 
protein conjugate 
Figure 6.13: General scheme for the conjugation of glycopolymers and OV A-
mini. 
SDS-P GE and We tern blotting was perfonned to analyse the conjugation of 
OVA-mini protein to the glycopolymer. SDS-PAGE results showed the 
formation of a smear with molecular weight between 72 KDa to 250 KD a 
indicate the fonnation of conjugates as shown in the figure 6.14. But the 
conjugation was not efficient (F igure 6.(4) probably due to incomplete 
reduction of the OVA-mini protein which makes the cysteine residue 
unavaiab le for the conjugation. Further optimization of the conjugation 
reaction i required in order to reduce dimers of OV A-mini by increasing the 
quantity of TCEP in the conjugation reaction or an alternate protocol for 
protein conjugation and monitoring could be followed as reported by Dirks et 
al. (Dirks et aI., 2009). 
fn the future the different glycopolymers synthesised and characterised in this 
study will be coupled to recombinant OVA-mini proteins, and their potential to 
target DC both in vitro and in vivo to induce OV A-specific CD4+ and CD8+ T-
cell proliferation will be assessed. [f glycopolymers-OV A conjugates 
demon trate improved T-cell activation then they could be used to target the 
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melanoma antigen TRP-2 to assess their potential to activate TRP-2-specitic 
[F -y secreting cells by EUSPOT assay and protect against tumours . 
Reducing Non-Reducing Reducing Non-Reducing 
.. 
A B 
Figure 6.14: Chemical conjugation of glycopolymers with OVA-mini protein and 
their analysis by (a) SOS-PAGE and (b) Western blotting. 
(A) OVA-mini protein only and in conjugated fonn were separated in 12% acrylamide 
gels under reducing and non-reducing cond itions, respectively, and tained with 
Simply Blue safe stai n. (8) OVA-mini protein in conjugated and unconjugat d form 
was loaded as sample on 12% SDS-PAGE under reducing and non reducing 
conditions and detected by using Rabbit anti-OV polyclonal antibody. 
In summary, a library of fluorescent glycopo lymers with different binding 
ability to MR was synthesised effectively by using ATRP and click chemistry. 
Attempts were made to conjugate OVA-mini protein to the glycopolymer but 
this needs further optimization. Glycopolymer have a natural affinity to CLR , 
and more specifically to MR expressed on DCs; thus they have a lot of scope in 
the development of vaccines by promoting Ag delivery to Des. 
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7 General discussion and future directions 
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7.1 Introduction 
A drastic development in the field of vaccine technology has occurred due to 
the better understanding of pathogenic antigens and the processes leading to 
the induction of immunity. These findings have paved the way for the rational 
design and production of safe and more effective vaccines against emerging 
infectious agents, tumours and autoimmune diseases. 
DCs have been used directly as an adjuvant 10 immunotherapy 
(Mohamadzadeh and Luftig, 2004) but with limited success as the 
methodology is very expensive, complex and time consuming. Additionally, 
antigen-loaded DCs accumulate at the site of injection and only 1-2% of the 
antigen pulsed DCs reach the local lymphoid organ. Due to these limitations 
alternative approaches have been developed to target DCs directly in vivo in 
the presence or absence of infectious signals (Shortman et aI., 2009, Tacken et 
aI., 2006). Selective Ag targeting to DCs through a specific pathway is critical 
for the development of vaccines. MR is an endocytic receptor; type-I protein of 
molecular weight 175 KDa that was the first discovered member of the MR-
family. It was found to be involved in the clearance of endogenous 
glycoproteins. Targeting of antigen through MR using anti-MR antibody 
(Ramakrishna et aI., 2004, He et aI., 2007, Tsuji et aI., 2010) or glycosylated 
Ags such as the model antigen ovalbumin (OVA) results in cross presentation 
and activation of cytotoxic T-cell responses. These fascinating finding makes 
MR a strong candidate for the development of therapeutic vaccines against 
viral infections and tumours. 
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The aim of this study was to develop tools to deliver Ag through MR and 
investigate how the interaction between MR and a MR ligand-Ag influences 
Ag processing and T-cell differentiation. Three different novel reagents were 
generated to verify the hypothesis. (i) Anti-MR mAbs: 5D3 and 6C3 
chemically linked to the melanoma epitope TRP-2 by a covalent bond; (ii) MR-
specific chimeric Abs fused to HEL and OVA Ags and (iii) novel 
glycopolymers having different mannose content that will be linked to OVA-
mini and tested in vitro and in vivo. 
7.2 Antibody-mediated Ag targeting through MR 
Targeting Ag through antibodies against DC receptors is the ideal technique for 
Ag delivery to DCs due to their specificity and higher affinity (Keler et aI., 
2007). Receptors used in Ag targeting mostly belong to the C-type lectin 
receptor (CLR) family, which are calcium-dependent lectins and share primary 
structural homology in their carbohydrate recognition domain (CRD). The 
common CLRs used in targeting studies are the mannose receptor (MR, 
CD206) (Ramakrishna et aI., 2004, He et aI., 2007, Tsuji et aI., 2010), DEC-
205 (Hawiger et aI., 2001, 80nifaz et aI., 2002, 80nifaz et aI., 2004, 80scardin 
et aI., 2006), and the DC-specific intercellular adhesion molecule-3 (ICAM3)-
grabbing non-integrins (DC-SIGN) (Tacken et aI., 2006). Ag targeting through 
different receptors might result in different immune outcomes due to different 
intracellular receptor routing, signalling pathways and expression patterns 
(Tacken et aI., 2007). Ramakrishna et al. first described MR targeting by using 
human anti-MR mAb (811) fused to the melanoma Ag, pmeIl7 (811-pmeIl7) 
that lead to Ag presentation in the context of MHC-I and MHC-II molecules, 
resulting in antigen specific CD4+ and CD8+ T-cell proliferation in vitro 
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(Ramakrishna et aI., 2004). In order to perform in vivo studies transgenic mice 
expressing hMR were generated and immunized with B II-OVA along with 
CpG that induced OVA specific tumour immunity, while WT mice failed to 
induce protective immunity (He et aI., 2007). Human anti-MR Ab was 
employed to target Ag in the studies mentioned above; it had a xenogenic 
response when immunized into the mice. We generated mouse anti-MR 
chimeric Abs to be tested in the mice in order to avoid the xenogenic etfect 
against the chimeric Abs. 
The study was started with the aim to generate anti-MR conjugates by chemical 
coupling of Ag to anti-MR mAb. In this study, MR specific mAb (503 and 
6C3), and isotype control IgG2a (Martinez-Pomares et aI., 2003) were 
conjugated covalently to TRP-2 and MHC-I restricted melanoma Ag as 
described in chapter 5. As previously established, MR is expressed by murine 
bone marrow-derived DCs and other subtypes of DC present in mice (Linehan 
et aI., 2001, McKenzie et aI., 2007). This study was performed to assess the 
potential of anti-MR-TRP-2 conjugates to target DC in vivo and activate CD8+ 
T -cells. Binding of antibodies to MR before and after conjugation and other in 
vitro assays such as coupling efficiency of TRP-2 to IgG molecules, MR-
mediated endocytosis and Ag presentation assay were performed before in vivo 
studies. 
Initial immunisations performed using MPLA induced no significant T-cell 
activation, as MPLA signals through TLR-4 in the TRIF-mediated pathway 
only. However, TLR-4 signalling through My088 is essential for the 
maturation and migration oflocal Des loaded with anti-MR conjugates to local 
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lymph nodes (McKenzie et ai., 2007) Therefore, the immunisations were 
repeated using both MPLA (TLR4-mediated TRlF pathway) and CpG (TLR9-
mediated MyD88 pathway) as adjuvants to activate TRP-2 specific, lFN-y 
secreting T -cells. 
Although this study indicated that targeting using 503 induces T-cell activation 
anti-MR mAbs-TRP-2 conjugates were not considered the ideal tools to test 
this question as chemical conjugation is an inefficient method of linking Ag. [n 
this way, anti-MR chimeric antibodies were engineered as described in chapter 
3 and 4. MR-specific chimeric Abs carry the constant region of mouse 19G in 
order to avoid xenogenic immune responses. Moreover, the Fc region of the 
chimeric Abs was mutated to prevent engagement with FcyRs. 
In vitro Ag presentation assays were performed using T-cell hybridomas such 
as MF2, B3Z and 1 C5.1, to investigate the capacity of anti-MR chimeric Abs 
to deliver Ag to APC and induce T-cell proliferation. In our antigen targeting 
srudies the isotype control always induced T-cell activation even when used for 
in vivo DNA immunisation, which is not consistent with the published data that 
used the same isotype controls such as IgG I-HEL and IgG I-OVA (Hawiger et 
ai., 2001, Bonifaz et ai., 2002).The DNA sequence of our clones encoding 
isotype control was verified by comparing it with the original sequence 
obtained from the laboratory of Prof. Michel Nussenweig (Hawiger et aI., 
2001). Although the Fc portions of the chimeric Abs are mutated they remain 
able to bind FcyRI and we need to consider the possibility of FcR-mediated 
uptake/presentation, which is dicussed in detail in section 5.4.2. Murine DCs 
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and macro phages predominantly express FerRI, FerRIIB and FerRIll 
(Nimmerjahn and Ravetch, 2008). Regnault et aI. reported that Ag uptake by 
DCs through FcyRs is 100 times more efficient than the soluble Ags. This 
results in MHC-II as well as MHC-I restricted Ag presentation, and priming of 
both CD4+ and CD8+ T-cell responses (Regnault et aI., 1999). 
The chimeric Abs used in this project were tested for their binding to FcyRs 
expressed on bone marrow-derived macrophages (BM-macrophages). BM-
macro phages derived from WT and MR-I- mice were cultured and were 
collected at day-7 by using 10 mM EDT A in PBS, washed in PBS. MR 
expression was confirmed by FACS analysis, as shown in figure 7.1. The 
binding of chimeric Abs to FcyRs expressed on BM-macrophages was tested 
by the following protocol. SD3-0V A, IgG l-OV A, SD3-HEL, IgG I-HEL and 
anti-DEC20S-HEL Abs were labelled with FITC by using Fluoro-Trap 
fluorescein conjugation kit (InnovaBiosciences) according to the 
manufacturer's instructions. 50 III aliquots containing 2x 1 OS macro phages 
derived from bone marrow of WT and MR-I- mice were distributed in 96 well 
tissue culture plates. Macrophages were incubated on ice for 30 minutes in 
F ACS buffer in the presence and absence of normal mouse serum (20 % final) 
and 2.4G2 (Anti-Fc receptor Ab, 20 Ilg/ml final) respectively. Then SOlll of of 
labelled antibodies (lOIlg/ml) were added into the wells containing 
macro phages and on ice for an hour. Cells were washed 3 times with F ACS 
wash and fixed by using 2% formaldehyde in PBS. Flow cytometry was 
performed to assess the binding of antibodies to FerR expressed on 
macrophages. 
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Anti-MR chimeric Abs did not show any binding to the macrophages under 
any condition, as shown in figure 7.2. This is in agreement with earlier studies 
by Clynes et aI. showing that the Fc portion of chimaeric Abs is mutated and 
therefore they lack the ability to bind FcyRs (Clynes et aI., 2000). Surprisingly, 
SD3-HEL and SD3-0V A did not show any binding to MR expressed by the 
WT macrophages. To determine the cause of this, purified Abs were analysed 
by SDS-PAGE to test their integrity. It was found that the MR-specific Abs 
5D3-HEL and 5D3-0V A (indicated by the red arrows) were degraded almost 
completely and a major cleaved product of of MW 140 KDa was detected as 
shown in the figure 7.3. Thus, the degradation of 5D3-HEL or SD3-0VA can 
render them unable to bind MR on WT macrophages. 
Therefore, it was concluded that T -cells proliferation in response to the isotype 
controls (IgO I-OVA and IgO I-HEL) was not likely due to FcyR mediated Ag 
targeting. Hence, the lack of enhanced T-cell proliferation in response to 503-
OV A and 5D3-HEL could be due to the nature of in vitro Ag presentaion 
assays, which involve the co-culturing of BMDCs and T-cell hybridoma at 37 
°C for 18 hours. The anti-MR Abs used in these Ag presentation assays could 
potentially rapidly degrade due to their labile nature, and the isotype control 
being stable may persist longer and induce T-ceU proliferation. So, the 
degradation of the 5D3-HEL or SD3-0VA may be the cause of reduced T-cell 
proliferation in our Ag targeting studies. The intemalisation ability of degraded 
anti-MR Abs could be further tested by performing an endocytosis assay in the 
presence of DMA, which inhibits pinocytosis-mediated endocytosis and allows 
only receptor mediated endocytosis. Moreover, to test the actual potential of 
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SD3-0VA, a po itive control such a DEC20S-0VA could be generated to 
compare in parallel the contribution of both SD3-0V A and D EC20S-0VA with 
[gG I-OVA to induce T-cell proliferation. 
MR 
CD11b 
Wild type MR-I-
Cells only 
Isotype control 
Marker 
Figure 7.1: Flowcytometric analysis to test M R (C0206) expression on the 
surface of macrophages derived from the bone marrow of WT and M R-I- mice. 
Macrophages derived from mice bone-marrow of WT and M R-I - mice were cultured 
and on day 7 expres ion ofCD206 (M R), COli b wa ana lysed by F S. 
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Figure 7.2: Binding a e sment of the panel of chimeric antibodies to FcyR 
expressed on bone-marrow derived macrophage . 
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Antibodie w re labelled with FrTC by u ing Fluoro-Trap fluore cein labelling kit 
(LnnovaBio cience) by following manufacturer' in tructions. 2x 1 05 macrophage 
derived from WT and MR -/- mice bone-marrow were incubated in the pre ence and 
ab ence of mou e erum or anti-FcRIV[[[ b (2.4 G2) followed by the incubation with 
the labelled antib die for an hour on ice. fter incubation cells \: ere wa hed with 
PBS, fixed with 2% formaldehyde and the binding to FcyR was asse sed by flow 
cytometry. 
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Figure 7.3: SDS-PAGE to check the integrity of panel of antibodies used in the 
project. 3 ~ ~ g g of antibodies were separated in 6% acrylamide gels and stained with 
Simply Blue safe stain. Red arrows indicate the position of intact 5D3-0V A and 5D3-
HEL Abs. 
In the future , anti-MR chimeric Abs would be used to prepare lower molecular 
weight antibody fragments in order to avoid Abs degradation and to enhance 
their distribution when immunised in vivo, in collaboration with Dr. lordi 
Ochando (Mount Sinai School of Medicine). Small engineered fragments of 
the Ab include single chain-Fv fragment (Sc-Fv), dimers of Sc-Fv (diabody) 
and minibodies which is a pair of Sc-FV fused to single constant domain CH3 
(ScFv-CH3)2 (Wu and Senter, 2005).The expression of low molecular weight 
antibody fragments Sc-Fv (25KDa) and dibodies (55KOa) is relatively low, 
and they are less soluble and highly prone to aggaregation compared to full 
length Abs and minibodies (Holliger and Hudson, 2005). Moreover, 
minibodies are more stable than Sc-Fv and some minibodies such as Her2 
(Pettersen et aI. , 2004) and CEA are in their preclinical stages for tumour 
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imaging and therapies. Therefore, mini bodies fused with the model Ag could 
be a better option for purposes of Ag targeting. 
7.3 Use of glycopolymers for Ag targeting to APe 
Different approaches used for antigen targeting through MR to induce 
immunity involve Ab-mediated targeting (He et aI., 2007) or natural ligands. 
Ligand mediated Ag targeting has been successful, for example oxidized 
mannan linked with the MUC 1 antigen is in phase III of clinical trials to treat 
patients with stage II breast cancer as discussed in section 6.4. 
We used glycopolymers containing different relative percentages of mannose 
and galactose. Glycopolymers bind MR and are a better choice for antigen 
delivery and vaccine development compared to other methods (as mentioned 
above) because they are easily manipulated to change the content of mannose 
monomers, which directly affects the binding properties of the glycopolymers 
to lectin receptors. Therefore, libraries of gJycopolymers having different 
bidning kinetics can be generated and tested. It has been established that 
glycopolymers or carbohydrates, having high off rate or dissociation rate are 
more potent for Ag delivery and cross-presentation, which is a critical 
mechanism involved in the development of vaccines against cancer and other 
infections requiring CTL-based immunity (Howland and Wittrup, 2008). 
Synthesis of the glycopolymers employs simple click chemistry and is 
relatively easy and less expensive in a large scale. Singh et a1. reported that 
OVA linked with the glycans 3-sulfo-LewisA or N-acetylglucosamine targets 
DCs specifically through MR and enhances cross-presentation of OVA (Singh 
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et al., 20 II). Therefore, to avoid binding of glycopolymers to multiple 
receptors the glycopolymers containing 3-sulfo-LewisA or N-
acetylglucosamine monomers could be prepared using the same methodology 
(click chemistry) to facilitate antigen delivery specifically through MR. 
7.4 Relevance of our antigen targeting studies 
Our MR-mediated Ag targeting studies help to understand the importance of 
adjuvants, type or mode of vaccination, and the use of glycopolymers in MR-
targeted vaccines, as described below in detail. 
7.4.1 Role of adjuvants 
Results obtained by the immunisation of 5D3-TP2 antibodies indicate the 
importance of MyD88 signaling in the activation of TRP-2 specitic T -cells. In 
this study, MPLA, which signals through TLR-4 via TRIF pathway alone did 
not induce T-cell activation. CpG (signalling through TLR-9 via Myd88 
pathway) in combination with MPLA, however, effectively induced TRP-2 
specific T-cell activation. Mckenzie et al. reported that TLR-4 mediated 
MyD88 signaling is essential for the maturation and migration of local DCs 
loaded with Anti-MR Ab to local lyph nodes (McKenzie et al., 2007), 
demonstrating its importance in the induction of Ag specific immunity. 
Moreover, MyD88 signaling recruits TAP to early endosomes, which is 
believed to be involved in the transfer of peptide and allows loading on the 
MHC-I molecule in the early endosome, leading to cross-presentation of OVA 
(Burgdorf et al., 2008). However, Singh et al. reported that OVA linked to 
glycans such as 3-sulto-LewisA and N-acetylglucosamine can target OVA to 
206 
Chapter 7 General Discussion 
MR and result III the cross-presentation of OVA without TLR-4 signaling 
through the MyD88 pathway (Singh et al., 2011). Obviously, the generation of 
highly specific MR-targeting tools will help in defining the potential of MR as 
a target for Ag delivery. 
7.4.2 Method of vaccination (Protein versus DNA) 
In our studies DNA vaccination was highly effective in activating Ag specific 
CD8+ T-cells. Enhanced T-cell responses achieved by DNA immunisation 
could be due to its ability to exploit two pathways of antigen presentation. 
Firstly, due to the direct Ag presentation through MHC-I when DNA is 
transfected into local DCs. Secondly, DNA taken up by the somatic cells could 
be translated and chimeric Abs secreted out of the cells at the site of 
immunisation, which could be taken up by local DCs through either MR or 
FerRI, resulting in cross-presentation of Ag (Pudney et al., 20 I 0). When 
immunized, chimeric Abs (protein) induce relatively low T-cell activation as 
they only target APCs, and excludes the possibility to exploit non APCs for Ag 
production. However, DNA immunisation exploits both APe and non APC for 
Ag expression and presentation. Cho et al. reported that DNA immunised into 
non APCs induced more rapid and vigorous CD8+ T-cells proliferation as 
compared to APC: first, due to relatively more numbers of non APes and, 
second, due to the relatively prolonged expression of DNA in non APe as 
compared to APC (Cho et al., 2001). 
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7.4.3 Effectivenes of the in vitro versus in vivo assays to test MR 
targeting tools 
According to our studies in vitro Ag presentations assay might not be an 
effective method to test MR-targeted vaccines due to the presence of sMR in 
the culture medium. sMR can bind directly to anti-MR antibodies or MR 
ligands. In this way, it could block or reduce the binding of Ag targeting 
reagents to DCs, thereby effecting Ag presentation (Jordens et a!., 1999). 
Moreover, collagen fragments could be present in the serum that can also block 
MR and inhibit Ag presentation. Due to these limitations, in vivo immunisation 
could be be more appropriate to test anti-MR Abs. He et a!. reported that in 
vivo immunisation of human anti-MR Ab (Bll) fused with OVA (BII-OVA) 
along with the appropriate adjuvants can induce OVA specific CD4+ and CD8+ 
T -cell responses (He et a!., 2007). Additionally, because of the restricted 
expression of MR in DCs in vivo could better predict the efficacy of MR-
targeting. 
7.4.4 Comaprision of the mAbs and glycpolymers for Ag delivery 
In our experience glycopolymers seem a better choice compared to mAbs for 
the targeting of Ag to APes and the induction of immunity, for the following 
reasons. First, generation of antibodies against different receptors is an 
expensive, difficult and time consuming process. Moreover, chimeric 
antibodies have low expreSSIon and sometimes they become labile due to 
genetic modification. Second, antibodies used for Ag targeting can induce 
adverse immune responses when immunised in humans due to xenogenic 
effect, while these etfects could be avoided using natural ligands or 
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glycopolymers for targeting. Due to these limitations, glycopolymers provide a 
more robust and convenient alternative method for antigen delivery to APCs. 
Synthesis of the glycopolymers employs simple click chemistry, making it 
relatively easy and less inexpensive to synthesise glycopolymers on a large 
scale. Moreover, glycopolymers can be easily manipulated to change the 
content of mannose monomers, which directly affects the binding properties of 
glycpolymers to lectin receptors. Therefore, libraries of glycopolymers having 
different binding kinetics can be generated using different quantities of 
mannose monomers; however. This methodology is highly novel and will be 
further investigated in the lab. 
7.5 Potential Applications of MR targeting tools 
Previous studies showed that antigens derived from common infectious 
diseases such as the circumsporozite protein of malaria parasite (Boscardin et 
aI., 2006), gig protein of HIV (Bozzacco et aI., 2007) and nuclear antigen of 
Epstein-Barr virus (Gurer et aI., 2008) can be targeted through DEC-205 in the 
presence of an adjuvant and result in strong antigen specific immunity. 
Recently Tsuji et aI., found that DCs targeting through MR in the presence of 
an appropriate adjuvant leads to cross-presentation and induction of powerful 
CTL immunity to facilitate immunotherapy of cancer. In his study, MR 
specific antibodies fused to cancer antigen NY-ESQ-l were used to target DC 
specifically through MR. This resulted in the induction of antigen specific 
CD8+ and CD4+ T -cells, which makes it a promising approach to develop 
strong immunity against cancer (Tsuji et aI., 2010). Anti-MR reagents 
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generated in this study could be used to target malarial, cancerous and viral 
Ags once their potential has been established using in vitro and in vivo assays. 
On the other hand, in the absence of an infectious signal, antigen targeting 
through DEC-205 may lead to antigen specific T-cell tolerance. In this respect, 
13 cell antigen targeting results in the deletion of autoreactive CD8+ T-cells, 
which causes Type 1 Diabetes Mellitus (Mukhopadhaya et aI., 2008). In 
previous studies the role of MR in homeostasis and allergy has been 
established. Recently Emara et aI., demonstrated the binding of major allergens 
such as Der p-l and Fel d 1 to MR and showed that MR binding promotes Th2 
responses indicating a role in allergy and in modulation of T-cell 
differentiation (Emara et aI., 2011, Royer et aI., 2010). Therefore, in future, the 
anti-MR reagents generated in this study could be used to target allergens and 
self-Ags to APC in an attempt to induce tolerance. 
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Appendix 1: DEC20S-HEL Heavy chain 
EcoRI . 5 ' tgggatggtcatgtatcatcctttttctagtagcaactgcaactggag 
tacattcaGAGGTGAAGCTGTTGGAATCTGGAGGAGGTTTGGTACAGCCGGGGGGT 
TCTCTGAGACTCTCCTGTGCAGCTTCTGGATTCACCTTCAATGATTTCTACATGAA 
CTGGATCCGCCAGCCTCCAGGGCAGGCACCTGAGTGGTTGGGTGTTATTAGAAACA 
AAGGTAATGGTTACACAACAGAGGTCAATACATCTGTGAAGGGGCGGTTCACCATC 
TCCAGAGATAATACCCAAAACATCCTCTATCTTCAAATGAACAGCCTGAGAGCTGA 
GGACACCGCCATTTACTACTGTGCAAGAGGCGGTCCTTATTACTACAGTGGTGACG 
ACGCCCCTTACTGGGGCCAAGGAGTCATGGTCACAGTCTCCTCAgccaccaccaa9 
ggcccatctgtctatccactggcccctggatctgctgcccaaactaactccatggt 
gaccctgggatgcctggtcaagggctatttccctgagccagtgacagtgacctgga 
actctggatccctgtccagcggtgtgcacaccttcccagctgtcctgcagtctgac 
ctctacactctgagcagctcagtgactgtcccctccagcacctggcccagcgagac 
cgtcacctgcaacgttgcccacccggccagcagcaccaaggtggacaagaaaattg 
tgcccagggattgtggttgtaagccttgcatatgtacagtcccagaagtatcatct 
gtcttcatcttccccccaaagcccaaggatgtgctcaccattactctgactcctaa 
ggtcacgtgtgttgtggtagcaatcagcaaggatgatcccgaggtccagttcagct 
ggtttgtagatgatgtggaggtgcacacagctcagacgcaaccccgggaggagcag 
ttcaacagcactttccgctcagtcagtgaacttcccatcatgcaccaggactggct 
caatggcaaggagttcaaatgcagggtcaacagtgcagctttccctgcccccatcg 
agaaaaccatctccaaaaccaaaggcagaccgaaggctccacaggtgtacaccatt 
ccacctcccaaggagcagatggccaaggataaagtcagtctgacctgcatgataac 
agacttcttccctgaagacattactgtggagtggcagtggaatgggcagccagcgg 
agaactacaagaacactcagcccatcatggacacagatggctcttacttcgtctac 
agcaagctcaatgtgcagaagagcaactgggaggcaggaaatactttcacctgctc 
tgtgttacatgagggcctgcacaaccaccatactgagaagagcctctcccactctc 
ctggtaaagctagcGACATGGCCAAGAAGGAGACAGTCTGGAGGCTCGAGGAGTTC 
GGTAGGTTCACAAACAGGAACACAGACGGTAGCACAGACTATGGTATTCTCCAGAT 
TAACAGCAGGTATTATGACGGTAGGACATGATAG 3 '-NotI 
i 
Appendix 2: DNA sequence of DEC20S-HEL Light chain 
EcoRI -
5 ' atgggatggtcatgtatcatcctttttctagtagcaactgcaactggagtacat 
tcaGACATCCAGATGACACAGTCTCCGTCATTTCTGTCTACATCTCTTGGAAACAG 
CATCACCATCACTTGCCATGCCAGTCAGAACATCAAGGGTTGGTTAGCCTGGTACC 
AACAAAAGTCAGGGAATGCTCCTCAACTGTTGATTTATAAGGCATCTAGCCTGCAA 
TCAGGGGTTCCATCAAGATTCAGTGGCAGTGGATCTGGAACAGATTATATTTTCAC 
TATCAGCAACCTACAGCCTGAAGATATTGCCACTTATTACTGTCAGCATTATCAAA 
GCTTTCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAATTGAAACGGgctgatgct 
gcaccaactgtatccatcttcccaccatccagtgagcagttaacatctggaggtgc 
ctcagtcgtgtgcttcttgaacaacttctaccccaaagacatcaatgtcaagtgga 
agattgatggcagtgaacgacaaaatggcgtcctgaacagttggactgatcaggac 
agcaaagacagcacctacagcatgagcagcaccctcacgttgaccaaggacgagta 
tgaacgacataacagctatacctgtgaggccactcacaagacatcaacttcaccca 
ttgtcaagagcttcaacaggaatgagtgttga - 3 ' NotI . 
ii 
Appendix-3 DNA sequence of SD3-HEL heavy chain . 
ATGGACAGGCTTACTTCCTCATTCCTACTGCTGATTGTCCCTGCATATGTCCTGTC 
TCAGGTTACTCTGAAAGAGTCTGGCCCTGGGATATTGCAGCCCTCCCAGACCCTCA 
GTCTGACTTGCACTTTCTCTGGGTTTTCACTGAGCACTTATGGTATGGGTGTGGGC 
TGGATTCGTCAGCCTTCAGGGAAGGGTCTGGAGTGGCTGGCAAACATTTGGTGGGA 
TGATGGTAAGTACTACAATCCATCTCTGAAAAAC CGGCTCACAATCTCCAAGGACA 
CCTCCAACAATCAAGCATTCCTCAAGATCACCAATGTGGACACTGTAGATACTGCC 
GC ATACTACTGTTTTCGGATTCCCTTTTATTATCATGATGCGGATCACTGGGGCCA 
AGGCACTCTGGTCACTGTCTCTTCAGCTGAAACAACGGGCCCATCTGTCTATCCAC 
TGGCCCCTGGATCTGCTGCCCAAACTAACTCCATGGTGACCCTGGGATGCCTGGTC 
AAGGGCTATTTCCCTGAGCCAGTGACAGTGACCTGGAACTCTGGATCCCTGTCCAG 
CGGTGTGCACACCTTCCCAGCTGTCCTGCAGTCTGACCTCTACACTCTGAGCAGCT 
CAGTGACTGTCCCCTCCAGCACCTGGCCCAGCGAGACCGTCACCTGCAACGTTGCC 
CACCCGGCCAGCAGCACCAAGGTGGACAAGAAAATTGTGCCCAGGGATTGTGGTTG 
TAAGCCTTGCATATGTACAGTCCCAGAAGTATCATCTGTCTTCATCTTCCCCCCAA 
AGC CCAAGGATGTGCTCACCATTACTCTGACTCCTAAGGTCACGTGTGTTGTGGTA 
GCAATCAGCAAGGATGATCCCGAGGT CCAGTTCAGCTGGTTTGTAGATGATGTGGA 
GGTGCACACAGCTCAGACGCAACCCCGGGAGGAGCAGTTCAACAGCACTTTCCGCT 
CAGTCAGTGAACTTCCCATCATGCACCAGGACTGGCTCAATGGCAAGGAGTTCAAA 
TGCAGGGTCAACAGTGCAGCTTTCCCTGCCCCCATCGAGAAAACCATCTCCAAAAC 
CAAAGGCAGACCGAAGGCTCCACAGGTGTACACCATTCCACCTCCCAAGGAGCAGA 
TGGCCAAGGATAAAGTCAGTCTGACCTGCATGATAACAGACTTCTTCCCTGAAGAC 
ATTACTGTGGAGTGGCAGTGGAATGGGCAGCCAGCGGAGAACTACAAGAACACTCA 
GCCCATCATGGACACAGATGGCTCTTACTTCGTCTACAGCAAGCTCAATGTGCAGA 
AGAGCAACTGGGAGGCAGGAAATACTTTCACCTGCTCTGTGTTACATGAGGGCCTG 
CACAACCACCATACTGAGAAGAGCCTCTCCCACTCTCCTGGTAAAGCTAGCGACAT 
GGCCAAGAAGGAGACAGTCTGGAGGCTCGAGGAGTTCGGTAGGTTCACAAACAGGA 
ACACAGACGGTAGCACAGACTATGGTATTCTCCAGATTAACAGCAGGTATTATGAC 
GGTAGGACATGATAG 
iii 
Appendix-4 DNA sequence of SD3-HEL light chain . 
ATGGCCATGAAGACGCCTGCCCAGGCATTGGCAATTTGGTTACTCTGGGTCTCAGG 
TGCCAGATGTGATATTCAAGTGACTCAATCTCCATCCTCCCTCTTGGCATCTCTAG 
GAGAGAGAGTCACTATCACATGCCAGACAAGTCAGACCATTAGCAAAAACCTAAAC 
TGGTATCAGCAGAAACCAGGACAAGTTCCTATACTCTTGATCTATTTTGCAACCAG 
TTTGCAGACTGGCATGCCATCAAGGTTCAGTGGCCAATATTCTGGGAGAAGTTTCA 
CTCTAACCATCACTAGCCTGGAACCAGAAGATATTGCAAATTATTTTTGTCTGCAG 
CATTACAATCCTCCGTGGACGTTCGGTGGAGGGACCAAGCTGGAATTGAAACGGGC 
TGATGCTGCACCAACTGTATCCATCTTCCCACCATCCAGTGAGCAGTTAACATATG 
GAGGTGCCTCAGTCGTGTGCTTCTTGAACAACTTCTACCCCAAAGACATCAATGTC 
AAGTGGAAGATTGATGGCAGTGAACGACAAAATGGCGTCCTGAACAGTTGGACTGA 
TCAGGACAGCAAAGACAGCACCTACAGCATGAGCAGCACCCTCACGTTGACCAAGG 
ACGAGTATGAACGACATAACAGCTATACCTGTGAGGCCACTCACAAGACATCAACT 
TCACCCATTGTCAAGAGCTTCAACAGGAATGAGTGTTGA 
iv 
Appendix-S DNA sequence of SD3-0VA heavy chain . 
ATGGACAGGCTTACTTCCTCATTCCTACTGCTGATTGTCCCTGCATATGTCCTGTC 
TCAGGTTACTCTGAAAGAGTCTGGCCCTGGGATATTGCAGCCCTCCCAGACCCTCA 
GTCTGACTTGCACTTTCTCTGGGTTTTCACTGAGCACTTATGGTATGGGTGTGGGC 
TGGATTCGTCAGCC TTCAGGGAAGGGT CTGGAGTGGCTGGCAAACATTTGGTGGGA 
TGATGGTAAGTACTACAATCCATCTCTGAAAAACCGGCTCAC AATCTCCAAGGACA 
CCT CCAACAATCAAGCATTCCTCAAGATCACCAATGTGGACACTGTAGATACTGCC 
GCATACTACTGTTTTCGGATTCCCTTTTATTATCATGATGCGGATCACTGGGGCCA 
AGGCACTCTGGTCACTGTCTCTTCAGCTGAAACAACGGGCCCATCTGTCTATCCAC 
TGGCCCCTGGATCTGCTGCCCAAACTAACTCCATGGTGACCCTGGGATGCCTGGTC 
AAGGGCTATTTCCCTGAGCCAGTGACAGTGACCTGGAACTCTGGATCCCTGTCCAG 
CGGTGTGCACACCTTCCCAGCTGTCCTGCAGTCTGACCTCTACACTCTGAGCAGCT 
CAGTGACTGTCCCCTCCAGCACCTGGCCCAGCGAGACCGTCACCTGCAACGTTGCC 
CACCCGGCCAGCAGCACCAAGGTGGACAAGAAAATTGTGCCCAGGGATTGTGGTTG 
TAAGCCTTGCATATGTACAGTCCCAGAAGTATCATCTGTCTTCATCTTCCCCCCAA 
AGCCCAAGGATGTGCTCACCATTACTCTGACTCCTAAGGTCACGTGTGTTGTGGTA 
GCAATCAGCAAGGATGATCCCGAGGTCCAGTTCAGCTGGTTTGTAGATGATGTGGA 
GGTGCACACAGCTCAGACGCAACCCCGGGAGGAGCAGTTCAACAGCACTTTCCGCT 
CAGTCAGTGAACTTCCCATCATGCACCAGGACTGGCTCAATGGCAAGGAGTTCAAA 
TGCAGGGTCAACAGTGCAGCTTTCCCTGCCCCCATCGAGAAAACCATCTCCAAAAC 
CAAAGGCAGACCGAAGGCTCCACAGGTGTACACCATTCCACCTCCCAAGGAGCAGA 
TGGCCAAGGATAAAGTCAGTCTGACCTGCATGATAACAGACTTCTTCCCTGAAGAC 
ATTACTGTGGAGTGGCAGTGGAATGGGCAGCCAGCGGAGAACTACAAGAACACTCA 
GCCCATCATGGACACAGATGGCTCTTACTTCGTCTACAGCAAGCTCAATGTGCAGA 
AGAGCAACTGGGAGGCAGGAAATACTTTCACCTGCTCTGTGTTACATGAGGGCCTG 
CACAACCACCATACTGAGAAGAGCCTCTCCCACTCTCCTGGTAAAGCTAGCATGTT 
GGTGCTGTTGCCTGATGAAGTCTCAGGCCTTGAGCAGCTTGAGAGTATAATCAACT 
TTGAAAAACTGACTGAATGGACCAGTTCTAATGTTATGGAAGAGAGGAAGATCAAA 
GTGTACTTACCTCGCATGAAGATGGAGGAAAAATACAACCTCACATCTGTCTTAAT 
GGCTATGGGCATTACTGACGTGTTTAGCTCTTCAGCCAATCTGTCTGGCATCTCCT 
CAGCAGAGAGCCTGAAGATATCTCAAGCTGTCCATGCAGCACATGCAGAAATCAAT 
GAAGCAGGCAGAGAGGTGGTAGGGTCAGCAGAGGCTGGAGTGGATGCTGCA 
v 
Appendix-6 DNA sequence of IgGl-HEL Heavy chain 
ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACTGGAGTACATTC 
ACAGGTGCAGCTGAAAGAGTCAGGACCTGGTCTGGTGCAGCCCTCACAGACCCTGT 
CTCTCACCTGCACTGTCTCTGGGTTCTCACTAATCAGCTATCATGTAACCTGGGTT 
CGCCAGCCTCCTGGAAAGAGTCTGGTGTGGATGGGAACAATATGGACTGGTGGAGG 
TAGAAATTATAATTCGGCTGAACAATCCCGACTGAGCATCAGCCGGGACACCTCCA 
AGAGCCAAGTTTTCTTAAAAATGAACAGTCTGCAACCTGAAGACACAGGCACTTAC 
TACTGTGCCAGACATCGAGGGGGGTATAACTACGGCTTTGATTACTGGGGCCAAGG 
AGTCATGGTCACAGTCTCCTCAGCCACCACCAAGGGCCCATCTGTCTATCCACTGG 
CCCCTGGATCTGCTGCCCAAACTAACTCCATGGTGACCCTGGGATGCCTGGTCAAG 
GGCTATTTCCCTGAGCCAGTGACAGTGACCTGGAACTCTGGATCCCTGTCCAGCGG 
TGTGCACACCTTCCCAGCTGTCCTGCAGTCTGACCTCTACACTCTGAGCAGCTCAG 
TGACTGTCCCCTCCAGCACCTGGCCCAGCGAGACCGTCACCTGCAACGTTGCCCAC 
CCGGCCAGCAGCACCAAGGTGGACAAGAAAATTGTGCCCAGGGATTGTGGTTGTAA 
GCCTTGCATATGTACAGTCCCAGAAGTATCATCTGTCTTCATCTTCCCCCCAAAGC 
CCAAGGATGTGCTCACCATTACTCTGACTCCTAAGGTCACGTGTGTTGTGGTAGCA 
ATCAGCAAGGATGATCCCGAGGTCCAGTTCAGCTGGTTTGTAGATGATGTGGAGGT 
GCACACAGCTCAGACGCAACCCCGGGAGGAGCAGTTCAACAGCACTTTCCGCTCAG 
TCAGTGAACTTCCCATCATGCACCAGGACTGGCTCAATGGCAAGGAGTTCAAATGC 
AGGGTCAACAGTGCAGCTTTCCCTGCCCCCATCGAGAAAACCATCTCCAAAACCAA 
AGGCAGACCGAAGGCTCCACAGGTGTACACCATTCCACCTCCCAAGGAGCAGATGG 
CCAAGGATAAAGTCAGTCTGACCTGCATGATAACAGACTTCTTCCCTGAAGACATT 
ACTGTGGAGTGGCAGTGGAATGGGCAGCCAGCGGAGAACTACAAGAACACTCAGCC 
CATCATGGACACAGATGGCTCTTACTTCGTCTACAGCAAGCTCAATGTGCAGAAGA 
GCAACTGGGAGGCAGGAAATACTTTCACCTGCTCTGTGTTACATGAGGGCCTGCAC 
AACCACCATACTGAGAAGAGCCTCTCCCACTCTCCTGGTAAAGCTAGCGACATGGC 
CAAGAAGGAGACAGTCTGGAGGCTCGAGGAGTTCGGTAGGTTCACAAACAGGAACA 
CAGACGGTAGCACAGACTATGGTATTCTCCAGATTAACAGCAGGTATTATGACGGT 
AGGACATGATAG 
vi 
Appendix-7 DNA sequence of IqGl-OVA Heavy chain 
ATGGGATGGTCATGTAT CATCCTTT TTCTAGTAGCAACTGCAACTGGAGTACAT TC 
ACAGGTGCAGCTGAAAGAGTCAGGACCTGGTCTGGTGCAGCCCTCACAGACCCTGT 
CTCTCACCTGCACTGTCTCTGGGTTCTCACTAATCAGCTATCAT GTAACCT GGGTT 
CGCCAGCCTCCTGGAAAGAGTCTGGTGTGGATGGGAACAATATGGACTGGTGGAGG 
TAGAAATTATAATTCGGCTGAACAATCCCGACTGAGCATCAGCCGGGACACCTCCA 
AGAGCCAAGTTTTCTTAAAAATGAACAGTCTGCAACCTGAAGACACAGGCACTTAC 
TACTGTGCCAGACATCGAGGGGGGTATAACTACGGCTTTGATTACTGGGGCCAAGG 
AGTCATGGTCACAGTCT CCTCAGCCACCACCAAGGGCCCATCTGTCTATCCACTGG 
CCCCTGGATCTGCTGCCCAAACTAACTCCATGGTGACCCTGGGATGCCTGGTCAAG 
GGCTATTTCCCTGAGCCAGTGACAGTGACCTGGAACTCTGGATCCCTGTCCAGCGG 
TGTGCACACCTTCCCAGCTGTCCTGCAGTCTGACCTCTACACTCTGAGCAGCTCAG 
TGACTGTCCCCTCCAGCACCTGGCCCAGCGAGACCGTCACCTGCAACGTTGCCCAC 
CCGGCCAGCAGCACCAAGGTGGACAAGAAAATTGTGCCCAGGGATTGTGGTTGTAA 
GCCTTGCATATGTACAGTCCCAGAAGTATCATCTGTCTTCATCTTCCCCCCAAAGC 
CCAAGGATGTGCTCACCATTACTCTGACTCCTAAGGTCACGTGTGTTGTGGTAGCA 
ATCAGCAAGGATGATCCCGAGGTCCAGTTCAGCTGGTTTGTAGATGATGTGGAGGT 
GCACACAGCTCAGACGCAACCCCGGGAGGAGCAGTTCAACAGCACTTTCCGCTCAG 
TCAGTGAACTTCCCATCATGCACCAGGACTGGCTCAATGGCAAGGAGTTCAAATGC 
AGGGTCAACAGTGCAGCTTTCCCTGCCCCCATCGAGAAAACCATCTCCAAAACCAA 
AGGCAGACCGAAGGCTCCACAGGTGTACACCATTCCACCTCCCAAGGAGCAGATGG 
CCAAGGATAAAGTCAGTCTGACCTGCATGATAACAGACTTCTTCCCTGAAGACATT 
ACTGTGGAGTGGCAGTGGAATGGGCAGCCAGCGGAGAACTACAAGAACACTCAGCC 
CATCATGGACACAGATGGCTCTTACTTCGTCTACAGCAAGCTCAATGTGCAGAAGA 
GCAACTGGGAGGCAGGAAATACTTTCACCTGCTCTGTGTTACATGAGGGCCTGCAC 
AACCACCATACTGAGAAGAGCCTCTCCCACTCTCCTGGTAAAGCTAGCATGTTGGT 
GCTGTTGCCTGATGAAGTCTCAGGCCTTGAGCAGCTTGAGAGTATAATCAACTTTG 
AAAAACTGACTGAATGGACCAGTTCTAATGTTATGGAAGAGAGGAAGATCAAAGTG 
TACTTACCTCGCATGAAGATGGAGGAAAAATACAACCTCACATCTGTCTTAATGGC 
TATGGGCATTACTGACGTGTTTAGCTCTTCAGCCAATCTGTCTGGCATCTCCTCAG 
CAGAGAGCCTGAAGATATCTCAAGCTGTCCATGCAGCACATGCAGAAATCAATGAA 
GCAGGCAGAGAGGTGGTAGGGTCAGCAGAGGCTGGAGTGGATGCTGCATAA 
vii 
Appendix-8 DNA sequence of IgGl-HEL Light chain 
ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACTGGAGTACATTC 
AGACATCCAGATGACC CAGTCTCCTTCACTCCTGTCTGCATCTGTGGGAGACAGAG 
TCACTCTCAACTGCAAAGCAAGTCAGAATATTAATAAGAACT TAGACTGGTATCAG 
CAAAAGCTTGGAGAAGCGCCAAAAGTCCTGATATATTATACAGACAATTTGCAAAC 
GGGCTTCTCATCAAGGTTCAGTGGCAGTGGATCTGGTACAGATTACACACTCACCA 
TCAGCAGCCTGCAGCCTGAAGATGTTGCCACATATTACTGCTATCAGTATAACAGT 
GGGCCCACGTTTGGACCTGGGACCAAGCTGGAACTGAAACGGGCTGATGCTGCACC 
AACTGTATCCATCTTC CCACCATCCAGTGAGCAGTTAACATCTGGAGGTGCCTCAG 
TCGTGTGCTTCTTGAACAACTTCTACCCCAAAGACATCAATGTCAAGTGGAAGATT 
GATGGCAGTGAACGACAAAATGGCGTCCTGAACAGTTGGACTGATCAGGACAGCAA 
AGACAGCACCTACAGCATGAGCAGCACCCTCACGTTGACCAAGGACGAGTATGAAC 
GACATAACAGCTATACCTGTGAGGCCACTCACAAGACATCAACTTCACCCATTGTC 
AAGAGCTTCAACAGGAATGAGTGTTGA 
vi ii 
